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Abstract 
 
A new paradigm for the treatment of infectious disease is through the modulation 
of innate immune responses.  In this capacity, host defense peptides (HDPs) and 
synthetic Toll-like receptor 9 (TLR9) ligands have the greatest demonstrated potentials.  
The work presented here considers mechanisms for the improvement of these treatments 
through optimization, or in the case of HDPs the minimization, of the interactions of 
these ligands with sensory receptors. 
Toll-like Receptor 9 activates the innate immune system in response to microbial 
DNA or immune-modulating oligodeoxynucleotides.  While cell stimulation 
experiments demonstrate the preferential activating ability of CpG-containing nucleic 
acids, direct binding investigations have reached contradictory conclusions regarding the 
sequence-specificity of TLR9 ligand binding.  To address this discrepancy the 
characterization of human TLR9 ligand binding properties is reported. TLR9 has a high 
degree of ligand specificity in being able to discriminate not only CpG dinucleotides, but 
also higher order six nucleotide motifs that mediate species-specific activation.  
However, TLR9 ligand binding is also functionally influenced by nucleic acids in a 
sequence-independent manner both in vitro and in cell proliferation experiments.  A 
model is proposed in which TLR9 activation is mediated specifically by CpG-containing 
ligands while sensitivity of the receptor is modulated by the absolute concentration of 
nucleic acids in a sequence-independent fashion.  
Host defense peptides are among the leading candidates to combat antibiotic 
resistant bacterial strains.  Recently, HDPs have been demonstrated to function as 
ligands for the bacterial sensory kinase PhoQ resulting in the induction of virulence and 
 ii
adaptive responses.  Thus, concerns have been raised regarding therapeutic applications 
of HDPs.  Here a methodology is described that permits discrimination and 
quantification of the distinct, but related, peptide behaviors of direct antimicrobial 
activity and PhoQ ligand potential.  Utilizing peptide derivatives of the model HDP 
Bac2A it is demonstrated that antimicrobial efficiency is significantly, and inversely, 
related to PhoQ ligand efficacy.  This provides a rational basis for HDP selection with 
greater therapeutic potential and minimized potential for initiation of bacterial 
resistance. 
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1.0 Introduction 
 For millions of years, hosts and pathogens have been in constant contact with 
one another.  As a result, both organisms have undergone a dynamic co-evolutionary 
process resulting from significant selective pressures exerted by one upon the other.  
These pressures have resulted in the development of offensive and defensive strategies 
centered on mutual inhibition, evasion and adaptive strategies (Peschel 2006).   
 Central to the offensive and defensive strategies of these organisms are sensory 
systems that constantly monitor both the internal and external cellular environments.  
Host organisms rely on the innate immune system, and in particular the Toll-like 
receptor system, for early detection of microbial invasion and for the initiation of an 
appropriate response to limit pathogen colonization.  Microbial organisms rely on 
similar sensory systems for the initiation of adaptive responses – the two-component 
sensory system.  Although much less complex than the Toll-like receptor system of the 
host, two-component sensory systems increase the ability of the microbe to resist the 
antimicrobial arsenal of the innate immune system.   
 
1.1 The Innate Immune System 
 The innate immune system is a universal and ancient form of host defense 
against infectious organisms.   The central role of this system is the recognition of 
microbial invasion and the initiation of responses that limit the spread of pathogenic
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microorganisms throughout host tissues (Janeway 2002).  The innate immune system 
utilizes a limited number of germline-encoded receptors to distinguish self from non-self 
biomolecules through conserved microbial patterns.  As a testament to the success of the 
innate immune system, invertebrates, comprising more species in nature than 
vertebrates, rely exclusively on this system to mount host defensive responses.  In 
contrast, vertebrates also utilize the adaptive immune system to combat pathogen 
invasion.  The adaptive immune system functions to generate immunological memory 
thus providing adaptive fitness. This response relies on the generation of antigen 
receptors (the T- and B-cell receptors, TCR and BCR, respectively) whose broad 
diversity is based on random gene rearrangements.   However, the activation of these 
antigen receptors results in a delayed response due to the clonal distribution of the 
antigen receptors.  As this delayed response takes approximately 4-7 days it is too slow 
for rapidly-replicating organisms such as microbes (Janeway 2002).  Thus, the innate 
immune system is indispensable as the primary defensive response against pathogenic 
microbes. 
During innate immune system activation, four fundamental activities are 
undertaken: 1) rapid detection of infectious agents, 2) categorization of the cellular 
location (intracellular or extracellular) of the pathogen, 3) elimination or containment of 
the pathogen, and 4) induction of an appropriate adaptive immune response for pathogen 
eradication and prevention of recurrent infection (Krieg 2006).  At the center of these 
activities are the pathogen recognition receptors (PRRs). 
 The pathogen recognition receptors are non clonal, germline-encoded receptors 
that monitor the intracellular and extracellular environments for pathogen invasion.  
Although limited in number, the PRRs have evolved the ability to recognize highly 
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diverse microbial organisms through recognition of invariable molecular structures.  
These structures include molecules such as outer cell membrane components 
[lipoteichoic acid (LTA), lipopolysaccharide (LPS)], nucleic acids (DNA and RNA) and 
proteins (flagellin) (Janeway 2002).  As these conserved structures cannot be easily 
altered by microorganisms they have remained fairly invariable throughout microbial 
evolution but are absent or highly suppressed within the host.  Although not identical 
across microbial species, the microbial patterns recognized by the PRRs are always 
found within the context of a conserved molecular structure.  The conserved molecular 
patterns recognized by PRRs allow for several strain- and species-specific variations 
(Janeway 1989).  As an example, Gram-negative bacterial species exhibit significant 
variance amongst LPS molecules, particularly within the O-antigen portion.  The PRR 
Toll-like receptor 4 has, however, evolved to recognize a conserved molecular pattern 
within LPS, the lipid-A portion.  Accordingly, these microbial biomolecules have been 
termed microbe- or pathogen-associated molecular patterns, MAMPs or PAMPs, and 
describe the conserved microbial targets of the innate immune system (Watson 2006).   
As targets of the innate immune system, PAMPs have three conserved features 
(Medzhitov 2001).  Firstly, PAMPs are microbial-specific biomolecules that are absent 
or suppressed within the host cell.  This broad definition is not completely unambiguous 
as activation of innate immune responses may in some instances be triggered to self-
biomolecules.  For example, hypomethylated cytosine-phosphate-guanine (CpG) motifs, 
although a PAMP for Toll-like receptor 9, are found within host organisms, albeit in 
reduced frequency in comparison to microbial DNA.  Secondly, PAMPs are absolutely 
required for microbial survival; hence their invariance across microbial classes.  Lastly, 
as demonstrated by the lipid-A portion of LPS, PAMPs are invariant between 
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microorganisms of a given class.  This recognition of invariant patterns has reduced the 
total number of PRRs required to mount an innate immune response and is typified by 
the Toll-like receptor (TLR) family.   
 
1.2 Drosophila Toll and TLR Identification 
 The discovery of Drosophila Toll, the first member of the Toll family, was not 
predicated on it being a PRR involved in innate immune activation.   Rather, Toll was 
one of twelve maternal effector genes found to control dorsoventral axis formation in 
fruit fly embryos (Belvin 1996, Hashimoto 1988).  The Toll system was found to 
involve a Toll ligand (Spätzle), an adapter protein (Tube), and a protein kinase (Pelle).  
An NF-kB family transcription factor (Dorsal) and the Dorsal inhibitor (Cactus) were 
also found to be involved in the Toll system.   
The role of Toll in the innate immune response of Drosophila was suggested by 
the homology between Toll and the human Interleukin-1 (IL-1) receptor (IL-1R).  The 
intracellular domains of these receptors were found to be homologous and suggested 
conserved functions (Janeway 2002).  In support of this, activation of either receptor 
resulted in the induction of Nuclear Factor kappaB (NF-kB) activation, with a concensus 
NF-kB binding site found in the promoter regions of Drosophila antimicrobial peptides 
(Engstrom 1993).  It was also found that signaling through Toll and IL-1R proceeded 
through homologous protein kinases, Pelle (in the case of Toll) and IL-1 receptor-
associated kinase (IRAK) in the case of IL-1R (Belvin 1996, Anderson 2000).   
As activation of Toll leads to induction of antimicrobial peptide transcription, 
and antimicrobial peptides are rapidly induced in response to infection, a connection 
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between Toll and the induction of Drosophila immune responses was suggested.  
Furthermore, Toll mutants of Drosophila rapidly succumbed to fungal infection and fruit 
flies with loss-of-function mutations to spatzle, tube or pelle were also highly 
susceptible to fungal infections (Lemaitre 1996).  Thus, the Toll pathway controls both 
dorsoventral patterning within embryos and the antifungal immune defense in adult fruit 
flies (Medzhitov 2001).  The recognition of Toll’s involvement in Drosophila innate 
immune responses led to the identification of a family of Toll homologues in 
vertebrates. 
 
1.3 The Toll-like Receptors 
 Following the identification of Toll and its central role in the immune response 
of Drosophila, homology searches in vertebrates uncovered the first characterized Toll 
homologue, Toll-like receptor (TLR) 4.  The role of TLR4 in the vertebrate innate 
immune system was suggested following demonstration that a constitutively active form 
of TLR4 was able to induce inflammatory cytokine expression (Medzhitov 1997a).  
Subsequent studies confirmed the role of TLR4 in the induction of innate immune 
responses with lipopolysaccharide (LPS) identified as the ligand for TLR4 (Poltorak 
1998, Qureshi 1999, Hoshino 1999).  This has culminated in the identification of 13 
TLR family members in mammals and 10 members in the human family. 
The mammalian TLRs are activated by unique ligands that share diversity in 
structure and origin.  Thus, three common themes have emerged regarding the 
relationship between the receptors and their ligands: 1) the majority of TLR ligands are 
PAMPs (in contrast endogenous nucleic acids, heat-shock proteins, and extracellular 
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matrix breakdown products have been regarded as self-TLR ligands), 2) TLRs can 
recognize structurally unrelated ligands, and 3) some TLRs require accessory proteins 
for ligand recognition (Medzhitov 2001).   The TLR family also displays diversity 
between species in regards to expression and function: TLRs 1 through 9 are conserved 
in both mice and humans, yet TLR10 is present only in humans and TLR11 (also known 
as TLR12) and TLR13 have only been characterized in mice (Akira 2004). 
 
1.3.1 Members of the Toll-like Receptor Family 
 
TLR1, TLR2, and TLR6: 
LPS was originally considered to be the ligand for TLR2; however, subsequent 
studies challenged this hypothesis.  Wetzler demonstrated that contaminating bacterial 
lipoprotein in the LPS preparations was responsible for TLR2 activation (Wetzler, 
2003).  More recently, TLR2 ligands have been broadened to include Gram-positive 
peptidoglycan (Takeuchi 1999), mycobacterial cell-wall lipoarabinomannan (Underhill 
1999a), Trypanosoma cruzi glycosylphophatidylinositol (Campos 2001), Staphylococcus 
epidermidis modulin (Hajjar 2001), and yeast cell walls (Underhill 1999b).   
That TLR2 recognizes such a broad-range of ligands is a function of 
heterodimerization events with TLR1 or TLR6; associations which dictate ligand 
binding specificities (Ozinsky 2000, Takeuchi 2001).  For example, the TLR2/TLR1 
heterodimer recognizes a variety of lipoproteins whereas the TLR2/TLR6 heterodimer is 
involved in recognition of diacylated lipoproteins (Takeuchi 2002, Wetzler 2003, 
Takeuchi 2001).  In addition, it has been speculated that TLR2 possibly functions as a 
homodimer, or heterodimer with an as of yet unidentified TLR, in the recognition and 
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binding of lipoteichoic acid (LTA), liparabinomannan, porins, and atypical LPS 
molecules (Massari 2002, Wetzler 2003).  The expression of TLR2 has been found to be 
regulated and restricted to antigen-presenting cells and endothelial cells (Muzio 2000) 
whereas the expression of TLR1 and TLR6 are constitutively expressed on a variety of 
cell types (Medzhitov 2001). 
 
TLR4 
TLR4, the first characterized Toll-like receptor, remains the most well studied of 
the TLR family largely due to its role in sepsis.  Trace amounts of LPS, the TLR4 
ligand, activate the innate immune system and produce numerous proinflammatory 
mediators, such as Tumor Necrosis Factor-alpha (TNF-α), IL-1, and IL-6 (Akira 2004).  
During sepsis, TLR4 hyperactivity results in excessive proinflammatory responses 
ultimately leading to cell and tissue injury (Dauphinee 2006).   Indeed, sepsis is the 
leading cause of mortality in critically ill patients associated with approximately 200,000 
deaths per year in the United States (Angus 2001).  
 TLR4 is expressed in a variety of cell types, predominantly those of the immune 
system (Poltorak 1998, Qureshi 1999, Hoshino 1999).  The recognition event between 
LPS and TLR4 requires several accessory proteins and the formation of a TLR4 
complex with several membrane-linked and soluble molecules, including CD14 and 
MD-2 (West 2006).  LPS-binding protein (LBP), a serum protein, first binds LPS and 
transfers the LPS monomer to CD14, a high-affinity LPS leucine-rich repeat (LRR) 
receptor.  CD14 in turn is thought to transfer LPS to the TLR4 complex at the cell 
membrane (Ulevitch 1993, Wright 1990). 
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Although LPS is the most well characterized ligand for TLR4, TLR4 is also 
suggested in the recognition of LTA and heat-shock protein 60 (HSP60).  The 
recognition of HSP60, although not well understood, has been suggested to represent a 
necessary inflammatory response due to necrotic cells (Medzhitov 2001) and has been 
speculated to have a role in tissue re-modeling and wound healing (Li 2001)  
 
TLR5 
TLR5 is involved in the recognition of flagellin, the Gram-negative bacterial 
flagella protein (Hayashi 2001).  The recognition of ligand by TLR5 relies on a highly 
conserved, central core structure of flagellin essential for protofilament assembly and 
bacterial motility (Smith 2003).  The TLR5 recognition site is presumed to be highly 
conserved amino- and carboxy-termini sequences within the central core of flagellin 
(Samatey 2001).  A binding site for flagellin on the TLR5 ectodomain is speculated to 
be present between residues 386-407 as mutants lacking this domain are unable to 
interact with flagellin in vitro (Mizel 2003).  As flagellin is proteinaceous in nature and 
does not contain atypical features, such as post-translational modifications, it may share 
similarities to host proteins and thus potentially remove the self-tolerance found within 
the innate immune system.   
 As TLR5 expression is polarized to the basolateral side of the intestinal 
epithelium, this might provide a unique feature that allows for the discrimination of 
commensal and pathogenic bacterium since the epithelial barrier is crossed by 
pathogenic bacteria but not commensal flora (Medzhitov 2001). 
 
TLR3, TLR7, TLR8, and TLR9 
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 TLR3, -7, -8, and -9 represent a subset of TLRs that interact with both RNA and 
DNA nucleic acids.  These PAMPs are of particular importance because of their close 
resemblance to host molecules.  In comparison to the cell surface-localized TLRs 
already described, this subset of TLRs is localized to intracellular organelles.  This 
cytoplasmic shielding of the nucleic acid-activated TLR subfamily has been suggested 
as a potential safety mechanism to ensure differentiation of self- and non-self nucleic 
acids (Akira 2006). 
 
 TLR3 
TLR3 expression confers responsiveness to purified dsRNA and polyriboinosinic 
polyribocytidylic acid [poly(I:C)] in cultured cells and TLR3-deficient mice display 
impaired responses to these ligands (Akira 2004).  Upon activation, TLR3 induces NF-
kB and Interferon (IFN) regulatory factor 3 (IRF3), ultimately leading to the production 
of antiviral molecules such as type I IFN (Alexopoulou 2001).  As the PAMP for TLR3 
is dsRNA, this receptor is involved in virus recognition during infectious cycles.  
dsRNA is a molecular pattern native to the vast majority of viruses and is generated 
during viral infection as a replication cycle intermediate (Akira 2006).  TLR3 is largely 
expressed in cells that function as primary barriers to infection such as epithelial cells 
(including airway, uterine, corneal, vaginal, cervical, biliary, and intestinal) (Akira 
2006).   
 Although the recognition of dsRNA by TLR3 is suggestive of a role in viral 
immunity, it has been demonstrated that TLR3 is not required for the initial induction of 
type I IFN during viral infection (Edelmann 2004).  This suggests that other PRRs may 
be involved in dsRNA recognition. 
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 TLR7/8 
The homologous Toll-like receptors TLR7 and TLR8 recognize PAMPs in a 
species-specific manner.  Mouse /human TLR7 and human TLR8 recognize guanosine- 
or uridine-rich single-stranded RNA (ssRNA) derived from RNA viruses (Diebold 2004, 
Heil 2003, Lund 2004).    In addition, both receptors are also responsive to synthetic 
antiviral imidazoquinoline components and some guanine nucleotide analogs (Akira 
2006).  Mouse TLR8, although expressed, appears to be non-functional (Akira 2006).   
As these receptors are responsive to ssRNA of both host and viral origin (Hemmi 
2002, Heil 2004, Diebold 2004) it is likely that their endosomal localization acts as a 
safety mechanism by reducing the likelihood of such an interaction.   Extracellular 
RNases also act as endogenous safeguards against such an event (Akira 2006).  
Additionally, it has been demonstrated that RNA of host origin is significantly less 
stimulatory that bacterial or viral RNA, suggestive of a host modification strategy to 
distinguish self-RNA from those of non-self origin (Kariko 2005). 
 
TLR9 
TLR9, the last of the endosomal TLRs, is unique amongst the TLRs as the only 
receptor that is responsive to both prokaryotic and viral DNA.  This recognition is 
defined by unmethylated CpG dinucleotides within a particular base context (CpG-
DNA).  CpG-DNA induces powerful immune responses and TLR9-deficient mice are 
unresponsive to challenge with CpG-DNA (Hemmi 2000).  That CpG-DNA is both 
highly modified by methylation and suppressed in frequency within the host genome 
reduces the potential of this receptor to be activated by endogenous DNA. 
 10
Cellular patterns of TLR9 expression are inconsistent amongst different species.  
In humans, TLR9 is expressed primarily in B cells and plasmacytoid dendritic cells 
(pDC) but has also been reported to be functionally expressed in activated neutrophils 
and pulmonary epithelial cells (Krieg 2006).  Mouse TLR9, although expressed in pDC 
and B cells, is also expressed in monocytes and myeloid dendritic cells (Iwasaki 2004).  
As a consequence of this species-variance it is difficult to make predictions regarding 
TLR9-mediated responses based on extrapolation of results from different species 
(Krieg 2006). 
In addition to bacterial DNA, TLR9 is also activated by viral DNA sequences 
that contain unmethylated CpG sequences. The genomes of DNA viruses, such as herpes 
simplex virus 1 and 2 (HSV-1 and HSV-2) and murine cytomegalovirus (MCMV), are 
rich in hypomethylated CpG motifs.   The activation of TLR9 by viral CpG-DNA results 
in the induction of inflammatory cytokines and type I IFN secretion in a TLR9-
dependent manner (Hochrein 2004, Tabeta 2004, Krug 2004, Lund 2003).  
Although much is known about the ligands and signaling pathways of TLRs 1-9 
and 11, the biological roles of TLRs 10, 12, and 13 remain unclear, as their expression 
patterns, ligands, and modes of signaling have yet to be defined (Akira 2004). 
 
1.3.2 TLR-ligand Binding: The Leucine-Rich Repeat Domain 
A conserved feature of the ligand-binding domains of Toll-like receptors is the 
presence of leucine-rich-repeat (LRR) motifs.  TLR ectodomains are comprised of 19-25 
tandem copies of an LRR motif, capped on either end by characteristic N- and C-
terminal structures (Takahashi 1985).  The individual LRRs are comprised of a 24-
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amino acid consensus sequences XLXXLXLXXN (residues 1-10), conserved in all LRR 
subtypes, and XθXXθXXXXFXXLX (residues 11-24, where θ is a hydrophobic residue) 
(Spitzer 2002).  
Many three-dimensional structures of proteins that contain LRR motifs have 
been solved and demonstrate that each LRR forms a loop structure.  As a result, the 
juxtaposition of several LRRs results in an overall coiled or solenoid-like horseshoe 
structure (Bell 2003).  Within individual LRRs, the first 10 residues forms a beta-strand 
and the remaining residues form an alpha-helix (Bell 2003).  As a result, a large concave 
surface is formed by a repeating array of beta-sheets, in concurrence with the overall 
solenoidal shape of the LRR domain, and a convex surface formed by alpha-helices.   
Based on structural investigations of proteins containing LRR domains, it has 
been speculated that the large concave surface of the TLR ectodomain serves as the 
ligand binding site for the TLRs.  For example, Ribonuclease inhibitor (which binds 
both ribonuclease A and angiogenin), Internalin A, and RanGAP have demonstrated that 
the concave surface of the solenoid serves as the primary ligand binding site for these 
receptors (Kobe 1996, Papageorgiou 1997, Schubert 2002, Seewald 2002).  Insertions 
within the LRR repeats have also been demonstrated to facilitate ligand binding such as 
those within RanGAP and the CD42b-von Willebrand factor A1.   
That TLRs also contain characteristic insertions following the 10th and 15th 
positions of the consensus LRR sequence offers evidence of the location of potential 
ligand binding sites.  These insertions have been suggested to be crucial for PAMP 
recognition.  Insertions at position 10 have been speculated to lie in proximity to the  
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Figure 1.1:  The LRR domain of TLR3 highlighting the overall solenoid shape.  
Human TLR3 ectodomain structure (Protein Databank Code 2A0Z) generated with 
Cn3D version 4.1.  Adapted from Bell 2005. 
 
 13
beta-sheet whereas insertions after residue 15 would be predicted to create binding sites 
at the convex surface (West 2006).  Sequence comparisons of the LRR motifs of TLR 7,  
-8, and -9 demonstrate insertions at position 10 of LRRs 2, 5, 8, and 11 (Bell 2003).  
These insertions would be expected to occur on the concave face of the receptor and, in 
the case of TLR9, might create a potential CpG DNA binding site.  As a testament to 
this, the insertion in LRR8 contains two cysteine-rich CXXC motifs, previously shown 
to mediate the direct binding of CpG-DNA by a transcriptional activator termed CpG-
binding protein (Lee 2001).  Lending further support for the importance of the insertions 
to ligand binding, the prospective flagellin binding site on TLR5 (residues 386-407) 
resides in LRR14 and contains a six-residue insertion after position 15 (Mizel 2003).  
Analyses such as these have been suggestive of a central role for the concave surface of 
the TLR ectodomains in ligand binding and a potential role for insertions at positions 10 
and 15 within the LRRs of these domains in this regard.   
 
1.3.3 TLR Signaling 
 The conservation of the cytoplasmic Toll/IL-1R (TIR) domain amongst TLR 
family members results in some commonality in the mechanism of signal transduction.   
The TIR domain is a protein-protein interaction module that is typically ~200 amino 
acids in length.  Sequence conservation among TIR domains is typically in the range of 
20-30% and is suggestive of both sequence and structural diversity (Xu 2000).  The 
highest regions of homology are confined to three short motifs (box 1, box 2, and box 3) 
of conserved sequences (Janssens 2003, Slack 2000).  The importance of these three 
conserved boxes is underscored by the observation that mutations within boxes 1 and 2 
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result in the inactivation of signal transduction (Slack 2000).  Polotrak has also 
demonstrated that a point mutation, residue P712, in box 2 of the TLR4 TIR domain 
results in LPS hyporesponsiveness (Poltorak 1998).   Mice with the P712 mutation are 
unable to recruit downstream effectors, such as Myeloid differentiation primary response 
protein 88 (MyD88) (West 2006).   
The signaling pathway initiated by TLR activation may follow either a MyD88-
independent (TLR3) or MyD88-dependent (all other TLRs) signaling pathway but as the 
work presented in this thesis is based exclusively on TLR9 only the latter will be 
discussed.  MyD88 is a cytoplasmic effector protein that is critical for induction of NF-
kB following TLR activation.  The presence of a C-terminal TIR domain in the effector 
enables interactions with the TIR domains of the TLRs.  As a testament to the central 
role of MyD88, MyD88-deficient cells do not respond to peptidoglycans, flagellin, CpG-
DNA, or ssRNA (Adachi, 1998, Beutler 2005, Takeda 2003, Yarovinsky 2005).  
 The binding interaction between a TLR and ligand induces a conformational 
change within TIR domain, leading to the recruitment of MyD88 to the TIR domain.  
This interaction leads to the recruitment of the serine/threonine IRAK-4, which contains 
a death domain, allowing for the interaction with the N-terminal death domain of 
MyD88. 
Following IRAK-4 recruitment, the kinase IRAK-1 is recruited to the complex 
and is activated following phosphorylation by IRAK-4, resulting in IRAK-1 
autophosphorylation.  Following IRAK-1 autophosphorylation, Tumor necrosis factor 
receptor-associated factor-6 (TRAF6) is recruited to the MyD88/IRAK-4/IRAK-1 
complex.  As a consequence, IRAK-1 and TRAF6 dissociate from the complex with  
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Figure 1.2: Signal Transduction Associated with Activation of Toll-like 
Receptor 9. Binding of bacterial DNA or CpG ODNs promotes activation of TLR9 
through dimerization. The ligand-bound dimer recruits MyD88 to the membrane and 
initiates association with TOLLIP and IRAK4. MyD88 activates IRAK4 to 
phosphorylate IRAK1. Once phosphorylated IRAK1 recruits TRAF6 to activate TAK1, 
resulting in activation of the MAPK signaling cascades, JNK1 and p38. TRAF6 also 
activated the IKKs which phosphorylate IκB. Phosphorylated IκB dissociates from 
NFκB and is degraded. NFκB translocates to the nucleus to induce expression of pro-
inflammatory cytokines, alone or in conjuncture with JNK1 and p38. The resulting 
pattern of gene expression induces several immunomodulatory effects including cell-
mediated immunity, apoptosis as well as direct antimicrobial activity.  Adapted from 
Klinman 2004. 
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subsequent activation of c-Jun N-terminal kinase (JNK) and inhibitor of κB kinase 
(IKK).  As a consequence of this activator protein-1 (AP-1) and NF-kB are activated, 
ultimately leading to the transcription of genes encoding proinflammatory cytokines and 
chemokines (TNF-α, IL-6, IL-8, and IL-1B) and those that produce a TH1-biased 
immune milieu (IFN-γ, and IL-12) (Klinman 1996).  
 
1.4 Activation of TLRs through Dimerization:  
Receptor dimerization is a recurrent theme amongst the type I transmembrane 
receptors (Lemmon 1994).  It has been proposed that dimerization of Toll results in the 
formation of a structurally symmetrical active signaling complex with equivalent ligand 
binding sites on each monomer (Weber 2005).  A similar mechanism has been suggested 
for the TLR family (Weber 2005).  The formation of higher order structures has been 
demonstrated as a prerequisite for activation of a number of TLRs and likely represents 
a conserved mechanism of TLR activation.  As mentioned previously, 
heterodimerization has been observed between TLR2, and TLR1 or TLR6 resulting in an 
increased range of ligands recognized by these receptors thus decreasing the need for 
additional PRRs (Haijar 2001).  Homodimerization has also been observed in TLRs such 
as TLR3, TLR4 and TLR8 as a requirement for receptor activation (Gangloff 2004).   
An investigation by Gangloff demonstrated that the basic mechanism of 
activation within the TLR family is stimulus-induced crosslinking or oligomerization 
(Gangloff 2004).  Although the authors suggested that the crosslinking of two TLR4 
molecules is sufficient for receptor activation, this does not hold true for all TLRs.  
Investigations of TLR3 dimerization have demonstrated that the crosslinking of TLR3 
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dimers in the absence of ligand is insufficient for receptor activation (Matsumoto 2002).  
However, crosslinking of chimeric TLR3 dimers (the TLR3 ectodomain coupled to the 
CD32a cytosolic domain) with poly(I-C) results in rapid induction of Ca2+ mobilization 
(de Bouteiller 2005).  These results suggest that the activation of TLR3 requires 
conformational changes within TLR3 dimers that are dependent upon ligand binding (de 
Bouteiller 2005).  Thus, the formation of TLR dimers is not the defining step leading to 
activation, at least for a subset of the TLRs.  This likely reflects a prerequisite for 
activating structural alterations that are specifically induced upon the binding of 
activating ligands.  
The activation of Toll by Spätzle has been reported to involve ligand-induced 
receptor dimerization and formation of a symmetrical heterotrimeric complex (Weber 
2003).  The authors speculated that conformational changes within the Toll dimers 
following ligand binding are required for activation of the complex.  As full-length Toll 
ectodomains form inactive unstable dimers in solution in the absence of ligand, the 
formation of the dimeric Toll-Spätzle complex is both necessary and sufficient for Toll 
activation (Weber 2003).  Recently, Gay has proposed that the correct orientation of the 
crosslinked domains is the crucial step for receptor activation in Toll (Gay 2006).  Based 
upon the homology between the Toll and TLR families it has been proposed that the 
formation of inactive ligand-free dimers, and ligand-induced conformational changes 
within receptor dimers prior to activation, also extends to the TLR family.  
The potential for multiple structural variations of particular TLRs, including 
monomers, inactive dimers and active dimers, raises the potential for regulation of 
signaling activity through modulation of the equilibrium between the different forms of 
the receptor.   
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1.5 A Model of Toll Binding 
 The investigations of Toll-Spätzle interactions by Weber have culminated with a 
proposed model of ligand binding and receptor activation for Toll (Weber 2003, Weber 
2005).  Previously, the authors demonstrated that the stoichiometry of the active 
signaling complex involved one Spätzle dimer and two Toll monomers.  Building on 
these observations, the authors demonstrated that the binding of a single Spätzle ligand 
to a Toll ectodomain monomer has a higher binding affinity than the second binding 
event involving formation of the activated dimeric Toll- Spätzle complex.   
 Thus, the binding of Spätzle and the formation of an active signaling complex 
involves two non-equivalent steps (Figure 4.1, p. 164).  In the absence of ligand, Toll 
exists in equilibrium between inactive monomers and dimers.  The formation of the 
ligand-free Toll dimer is proposed to involve mediation by the first block of LRRs (Gay 
2006).  This first block prevents the strong dimer contacts of the second block of LRRs 
and provides steric constraint against the formation of active ligand-free Toll dimers 
(Gay 2006).  In the presence of Spätzle, the inactive dimer complexes dissociate to form 
inactive monomeric Toll-Spätzle complexes.  Following this, ligand-free Toll monomers 
are recruited to the Toll-Spätzle complexes with reformation of Toll dimers crosslinked 
by Spätzle.  Promotion of the dimeric Toll-Spätzle complex to an activated form likely 
results from conformational rearrangements between the Toll monomers.   That the 
second binding event involving the formation of the activated Toll complex is of lower 
affinity than the initial binding of Spätzle to Toll monomers indicates negative 
cooperativity.   
As a consequence of negative cooperativity, the effective range of ligand 
required to achieve complete activation of the receptor is dramatically increased.  Based 
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on Michaelis-Menten kinetics, in the absence of cooperativity, an 81-fold increase in 
substrate concentration is required for complete receptor activation.  In the event of 
negative cooperativity, 400-fold increases in substrate concentration are required to 
achieve the same activation (Koshland 1996).  Consistent with the model of negative 
cooperativity proposed by Weber, it has been demonstrated that an approximately 300-
500 fold change in Spätzle concentrations is required to increase Toll activation from 
10% to 90% (Weber 2005).  That the ligand concentrations required to reach 90% 
maximum capacity of signaling activity are very broad has been suggested to increase 
the ability of the cell to produce differential patterns of gene expression in response to a 
stimulus (Gay 2006).  A similar phenomenon has also been noted for the FSH receptor 
(Urizar 2005).  
 
1.6 Structural Information Regarding the TLR-Ligand Interaction 
 Although a paucity of structural information is available regarding the 
interactions between TLRs and their ligands, two independent crystallographic 
determinations of TLR3 have been reported (Bell 2005, Choe 2005).  Both groups have 
reported the conservation of the horseshoe-shaped solenoid structure and curvature 
which is common amongst proteins with LRR domains.  It was also noted that one face 
of the solenoid was dominated by heavy glycosylation whereas the other face was 
glycosylation-free.  Although Choe and Bell have reached consensus on the overall 
three-dimensional conformation of the receptor, they have proposed contrasting dsRNA 
binding sites.   
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The model presented by Choe (Figure 1.3) suggests that although the inner 
diameter of the concave surface is sufficient for dsRNA, ligand binding would be 
compromised due to structural restraints and electrostatic repulsion (Choe 2005).  The 
authors suggested that the glycosylation and the overall negative charge found on the 
concave surface of TLR3 would conflict with the binding of dsRNA.  This negative 
charge would result in significant repulsion to the negatively charged phosphate 
backbone of the RNA.   Choe instead suggests that the receptor uses the glycosylation- 
free convex face for ligand binding.  In agreement with this proposition, the large 
glycosylation-free face of TLR3 provides many basic residues to accommodate the 
negative charge of the phosphate backbone.  In addition, a 10-residue insertion within 
LRR12 also lies on the glycosylation-free face and is in close proximity to this positive 
region.  Notably, LRR12 and LRR20 of TLR3 contain insertions longer than 5 residues; 
LRR12 has a 10-residue insertion that points towards the glycosylation-free side face 
and the 11-residue insertion of LRR20 points towards the outer convex surface (Choe 
2005).  The authors note that although a large proportion of the residues from this 
insertion were disordered in the structure, they could potentially interact with the major 
groove of dsRNA.  Thus, TLR3 monomers could ‘sandwich’ dsRNA by positioning of 
the positive regions of the glycosylation-free faces and the 10-residue insertion of 
LRR12 on either side of the dsRNA molecule.  The authors also propose that TLR3 
might form inactive dimers in solution based on the symmetry-related interactions of the 
receptor in the crystal structure.  Thus, the binding of dsRNA to a pre-existing dimer 
may either strengthen receptor dimerization or induce conformational changes leading to  
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Figure 1.3: Choe model of TLR3 ligand binding.  dsRNA (orange helix) binding near 
the N-terminus of the TLR3 ectodomain can induce receptor dimerization to form the 
active signaling complex or the ligand can bind to preformed inactive dimers.  Adapted 
from Choe 2005. 
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activation of the receptor, such as has been proposed for Toll (Weber 2005).  A similar 
mode of action has also been proposed for the erythropoietin receptor (Livnah 1999).  
Although the binding of ligand to the convex surface of TLR3 contrasts with the 
recurrent use of the concave surface for ligand binding by other proteins with LRR 
domains, several of these proteins can use sites secondary to the concave surface for 
ligand binding (Kobe 2001). 
In contrast to the Choe model, Bell has suggested that dsRNA may bind within 
the concave surface of the receptor (Figure 1.4) (Bell 2005).  The authors noted the 
presence of sulfate ions at the side chains of several amino acids within the concave 
surface.  These were bound to the side chains of His, Asn, Tyr and Arg residues by 
hydrogen bonds and were postulated to mimic the phosphate backbone of nucleic acids 
(Bell 2005).  Although Choe suggested that the glycosylations found within the concave 
surface would impede such an interaction, Bell suggested that the use of insect cells 
rather than human cells for expression of the recombinant protein might account for the 
differences in glycosylation patterns.  Decreased glycosylation along the concave 
surface would reduce the steric constraint to dsRNA binding (Bell 2005).   It is also 
noted in the Bell structure that a shallow groove on the glycosylation-free, convex face 
produced by the two insertions from LRR12 and LRR20 might also act as a dsRNA 
binding pocket for dsRNA.  The authors speculate that this might represent a mode of 
oligomerization whereby TLR3 ectodomains would bind to the two “faces” of the RNA 
duplex (Bell 2005).  A subsequent investigation demonstrated that deletion of LRR20, 
but not LRR12, had a dramatic effect of TLR3 activity providing evidence that dsRNA 
interacts with TLR3 on the glycan-free face of LRR20 (Bell 2006).  
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Figure 1.4: Bell model of TLR3 ligand binding.  dsRNA (orange helix) binds near the 
C-terminus of the TLR3 ectodomain and induces receptor dimerization to form the 
active signaling complex.  Adapted from Bell 2005. 
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Thus, rather than resolving the structural mechanisms of nucleic acid 
recognition, these structures add further controversy by proposing two conflicting 
models of ligand binding.  Choe has proposed the existence of pre-formed dimers that 
could interact without ligand and, upon ligand binding, would move through a 
conformational change leading to receptor activation (Choe 2005).  In contrast, Bell has 
proposed that dimerization of TLR3 is induced following ligand binding (Bell 2005).   
 Adding further controversy, Ranjith-Kumar has demonstrated that deletion of 
loop 1 in LRR12 is not essential for TLR3 function (Ranjith-Kumar 2007).  In 
agreement with the observations by Bell, a charged surface characterized by an 
asparagine-rich region from LRR17 to LRR20 was demonstrated to be critical for TLR3 
function (Bell 2005, Ranjith-Kumar 2007).  The authors also note that the putative 
RNA-binding region and TLR3 dimerization domain are in close proximity to each other 
and suggests overlapping activities between these two regions.  The observations 
reported by Ranjith-Kumar are supportive of both the Choe and Bell models.  In support 
of the Choe model, pre-formed dimers are observed in the absence of ligand.   In 
contrast, the specific residues postulated to be involved in RNA-binding support the 
model proposed by Bell.  Thus, rather than resolving the discrepancy of the Choe and 
Bell structures, the results of Ranjith-Kumar have further fueled the debate.    
 Recently, Gibbard has investigated the conserved structural features of human 
TLR8, that together with TLR3, -7, and -9 is localized intracellularly and recognizes 
microbial nucleic acids as its endogenous ligand (Gibbard 2006).  Notably, TLR7, 8, and 
9 are more closely related to each other than any other TLRs and thus structural features 
within the extracellular domain are conserved.  Therefore, the elucidation of a particular 
structural feature in any one of these three TLRs would likely represent a conserved 
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moiety across all three TLRs.  Indeed, TLR7, 8, and 9 share a characteristic 16 amino 
acid insert, containing four conserved cysteine residues, in LRR8 that is critical for 
TLR8 mediated signaling in response to ligand; mutation of any of the four conserved 
cysteine residues in this short insert sequence abrogates TLR8 signaling (Gibbard 2006).  
This was compounded by the demonstration that a single acidic residue, D543, in 
LRR17 was also critical for receptor activation by ligand.  Interestingly, this residue is 
conserved amongst TLR7, 8, and 9 and has previously been demonstrated by Rutz to be 
critical for binding of CpG-DNA by TLR9 in vitro (Rutz 2004).     
 
1.7 TLR9 and Ligand Recognition 
 Much of what is known regarding the activation of TLR9 by microbial DNA can 
be attributed to key observations made over the last two decades.  In 1984, Tokunaga 
demonstrated that mycobacteria DNA fractions with high GC content possessed strong 
antitumor activity in mice (Tokunaga 1984).  A subsequent investigation revealed that 
short, single-stranded synthetic oligonucleotides with CpG palindromic sequences could 
induce immune responses, highlighting the importance of this particular PAMP 
(Tokunaga 1992).  Adding further support for the role of CpG sequences in the induction 
of immune response, poly-(dC,dG) from purified bacterial DNA, but not vertebrate 
DNA, were demonstrated to induce murine B cell proliferation (Messina 1991).  
Modification of the cytosine residues within these CpG sequences by methylation abated 
their immunostimulatory activity (Messina 1993).  The relevance of the unmethylated 
CpG dinucleotide and relation to the mitogenicity of microbial DNA would not be 
revealed until the elegant work of Krieg and colleagues. 
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Krieg deduced that the mitogenicity of bacterial DNA might be explained by 
unmethylated CpG dinucleotides within microbial genomes, a pattern virtually absent in 
eukaryotic host organisms due to suppression of frequency and modification (Bird 1987, 
Krieg 1995).  This hypothesis was corroborated by the observation that methylation of 
bacterial DNA with CpG methylase abated mitogenicity as did inversion of the CpG to 
GpC.  Although the CpG dinucleotide represents the minimal element of microbial DNA 
that triggered immune cell activation, the authors demonstrated that stimulatory activity 
could be increased or decreased based on a higher order hexanucleotide sequence 
containing a central CpG.  Indeed, human TLR9 knockout cells can be made responsive 
to synthetic CpG sequences in a species-specific fashion following transfection with 
mouse TLR9, and vice versa (Bauer 2001).  The authors speculate that this reflects 
preferential binding of CpG motifs by TLR9 in a sequence- and species-specific manner.  
Activation in mouse and rabbit immune cells is highest when the CpG dinucleotide is 
flanked by two 5’ purines (preferably GA) and two 3’ pyrimidines (preferably TC or 
TT) (Krieg 1995, Yi 1998A, Rankin 2001) whereas the optimal motif in human and 
bovine cells is GTCGTT, a motif that also appears to be optimal for other vertebrate 
species such as sheep, cat, dog, goat, horse, pig, and chicken (Hartmann 2000, Brown 
1998, Rankin 2001).       
Although much of the early work on CpG motifs was suggestive of a potential 
role for the Toll-like receptors in the recognition of microbial DNA, a direct link 
between the receptor and PAMP had not been identified.  The identification of TLR9 by 
Hemmi suggested that this newly identified member of the TLR family utilized 
microbial DNA as an endogenous ligand based on the CpG motif; wild-type mouse 
splenocytes exhibited proliferative responses to CpG-DNA, but not non-CpG-DNA, in a 
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dose-dependent fashion whereas TLR9-/- splenocytes did not proliferate in response to 
either stimulus (Hemmi 2000).   
Krieg identified the unmethylated CpG dinucleotde as the discriminating factor 
between host and foreign DNA.  Although CpGs are present in prokaryotes at the 
expected 1:16 frequency, eukaryotes mask these dinucleotides by the suppressing the 
frequency of these sequences by as much as 100-fold (Wagner 1994).  Eukaryotes also 
modify the cytosines of CpG sequences by methylation (Krieg 1995).  The methylation 
of DNA in mammals provides a method for suppression of gene transcription.   The 
modification stabilizes chromatin in an inactive configuration as gene expression is 
inhibited by DNA hypermethylation (Sekigawa 2006).  In mammalian cells, enzymes 
such as DNA methyltransferases (Richardson 1999), methyl-CpG binding protein 
(Nakao 2001), and histone-modifying enzymes (Sekigawa 2003) methylate the 5-
position of deoxycytidine residues to form deoxymethylcytosine.  Highlighting the 
importance of DNA methylation within eukaryotes, 60% to 90% of all CpG sequences 
within mammalian genomes are methylated and are normally clustered within the CpG-
rich CpG islands of gene promoters (Richardson 1999).   It has been speculated that the 
CpG sequences of CpG islands, which are predominantly unmethylated, can initiate 
innate immune responses upon apoptotic release of nucleosomes (Sekigawa 2006).  
From the perspective of the higher order CpG motif, the immunostimulatory activity of 
the unmethylated CpG dinucleotides in vertebrate DNA is suppressed as a result of the 
propensity for a 5’C and a 3’G surrounding the CpG (Han 1994).   
 In contrast to the central role of unmethylated CpG motifs in the activation of 
innate immune responses by TLR9, it has been demonstrated that ODNs devoid of CpG 
motifs are able to activate innate immune responses in a TLR9-dependent manner.  
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Although this would appear to contradict the postulate that TLR9 has evolved to 
specifically recognize unmethylated CpG motifs, it has been considered that TLR9 may 
have evolved to recognize general DNA structural abnormalities or modifications as 
well unmethylated CpG motifs (Ishii 2005). 
 
 1.7.1 Oligodeoxynucleotides as TLR9 Ligands
 The identification of the CpG motif as the activating-factor of TLR9 has led to 
the development of synthetic oligodeoxynucleotides (ODNs) that selectively trigger 
TLR9-mediated innate immune responses (Krieg 1995).  As potential therapeutic 
agonists of TLR9, ODNs have a considerable advantage over bacterial DNA due to 
simplicity of manufacturing, ease of sequence alterations, low developmental cost and 
chemical stability.  Optimally, ODNs are 8-30 bases in length with the most potent ODN 
usually containing two or more CpG motifs (Krieg 2002).  As the phosphodiester 
backbone of native DNA is rapidly digested by serum and cellular nucleases, in vivo 
applications of ODNs have typically adopted a phosphothioate-modified (PTO) 
backbone.   
The PTO backbone (Figure 1.5) imparts nuclease resistance due to the 
replacement of one of the non-bridging oxygen atoms with sulfur.  This nuclease-
resistant moiety has been shown to improve the half-life of modified ODNs, with an 
approximate 200-fold increase in CpG-induced B-cell activation (Krieg 1995), as well as 
to increase their avidity for cell membranes and cellular uptake (Zhao 1993, Zhao 1994, 
Crooke 1998).  The modification is not completely neutral, however, as PTO-ODNs 
exhibit non-specific binding to a wide variety of proteins (Stein 1993, Stein 1994).  
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Figure 1.5: Chemical Structure of a phosphothioate CpG.  Structure generated with 
ChemDraw Standard Version 10.0. 
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PTO-modified ODNs have also demonstrated sequence-independent activities such as 
transcription factor activation (Perez 1994) and non-specific immune stimulation 
(Monteith 1997). 
It should also be noted that unlike PD-ODNs, PTO-modification introduces a 
chiral center to the DNA backbone.  Thus, each internucleotide PTO linkage can be of 
either Rp or Sp absolute configuration.  The question of stereospecificity with respect to 
the interaction of PTO-ODNs with proteins has been investigated (Krieg 2002).   Snake 
venom phosphodiesterase and human 3’-exonuclease demonstrate preference for the Rp 
stereoisomer (Burgers 1979, Tang 1995, Koziolkiewicz 1997).  Thus, all Sp-PTO-ODNs 
are more stable intracellularly than their all-Rp counterparts (Krieg 2002).  An 
investigation by Gilar has speculated that the increased nuclease resistance of PTO- 
ODNs may be related to increased non-specific adsorption of the PTO-ODN to the 
nuclease enzyme (Gilar 1998).  The stability of the Rp stereoisomer was 300-fold less 
than those with the S-configuration which invites speculation that the Sp stereoisomer is 
better able to adsorb to the enzyme.  In contrast to the aspect of intracellular stability, the 
Rp stereoisomer appears to more effectively interact with TLR9 (Krieg 2002).  Indeed, 
PTO-CpG-ODNs with the R-configuration demonstrate much greater 
immunostimulatory activity than their S-configuration counterparts, although cellular 
uptake rates are identical for both (Krieg 2002).  
 
 1.7.2 Classes of ODNs  
Three classes of ODNs, which differ in their sequences and in the presence and  
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ODN  
Type 
Example Structural 
Characteristics 
Associated 
Activity 
A GGTGCATCGATGCAGGGGGG PD and PTO (underlined) 
backbone.  Single CpG motif 
(italics).  Poly G Tail 
Hairpin. forming sequences 
(bold) 
Stimulate pDCs to 
release IFN-α.  
IFN-α mediated 
APC maturation 
 
B TCCATGGACGTTCCTGAGCGTT PTO(underlined) 
backbone.  Multiple CpG 
motifs (italics) 
 
Maturation of pDC 
and TNF 
production, B-cell 
proliferation and 
Il-6 production 
C TCGTCGTTCGAACGACGTTGAT PTO(underlined) 
backbone.  Multiple CpG 
motifs (italics).  Hairpin 
forming sequences (bold) 
Stimulate pDCs to 
release IFN-α. 
B-cell proliferation 
and Il-6 production 
 
 
 
Table 1.1: Representative Sequences, Structures and Biological Actions of the 
Different ODN Classes. Table adapted from Klinman 2004. 
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location of backbone modifications, have been defined on the basis of their ability to 
elicit unique cellular responses (Table 1.1). 
A-Class ODNs (CpG-A), also referred to as type D, are structurally typified by a 
central phosphodiester region, with one or more CpG motifs in a self-complementary 
palindrome and poly-G sequences of three or more guanines at the 5’ and/or 3’ ends.  
These poly-G sequences result in the ability of the A-class ODNs to form stable higher-
order G-tetrads (Krieg 2006).  These ODNs are especially potent at inducing IFNα 
production by pDCs. IFNα production results in the subsequent activation of natural 
killer (NK) cells and IFN-γ secretion (Krug 2001).  
B-Class CpG ODNs (CpG-B), or type K ODNs, are potent B cell activators 
resulting in increased Major Histocompatibility Class II complex (MHCII) expression, 
secretion of immunoglobins and B cell proliferation (Krieg 2002).  Structurally, CpG-B  
ODNs have a completely phosphothioate backbone and are typically contained in a 
linear conformation (Krieg 2006). 
 Finally, C-Class CpG ODNs (CpG-C), induce both A-Class and B-Class 
signaling effects (Marshall 2003). CpG-C ODNs are comprised of an entirely 
phosphothioate backbone with one or more 5’ CpG motifs and a 3’ palindrome that is 
thought to induce duplex formation within the endosome (Krieg 2006). 
 It has been suggested that the differences in signaling between the CpG ODN 
classes may be due to differential cellular trafficking in terms of uptake and retention 
(Honda 2005, Latz 2004, Gursel 2002).  Differences in intracellular localization patterns 
between the A- and B-class CpG ODNs have been demonstrated by Gursel (Gursel 
2002).  The authors noted that the uptake of CpG-A ODNs exceeded that of CpG-B 
ODNs and that the two classes occupied discrete areas within the same cells with limited 
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co-localization (Gursel 2002).  Notably, this difference in localization patterns was 
directly related to the ability of CpG-A to form G-tetrads as control ODN with a poly-G 
tail had similar distribution patterns.   Class-specific responses suggest that although all 
CpG ODNs can interact with TLR9, there are likely differences in the mechanism of 
trafficking, recognition and/or signal transduction induced by each class of ODN either 
due to the sequence/structure of ODN or differences in accessory proteins or co-
stimulatory molecules that are recruited to the TLR9-ODN complex which has not yet 
been identified.  
A recent investigation suggests that the different ODN classes induce different 
post-TLR9 signaling pathways leading to the induction of different transcription factors 
(O’Neill 2006).  This is also consistent with the discovery of secondary signaling 
pathways that have been identified for other Toll-like receptors involving unique 
adaptors and IRF transcription factors (Oshiumi 2003a, Oshiumi 2003b). 
 
 1.7.3 TLR9 and Sequence Specificity 
 A common benchmark often employed to demonstrate the specificity of CpG 
activation is negative control ODNs in which the activating dinucleotide is reversed to a 
GpC (GpC-ODNs).  A wealth of cell stimulation experiments demonstrates the 
preferential ability for CpG, rather than GpC-ODNs, to initiate innate immune 
responses.  This biological specificity is generally assumed to reflect sequence-specific 
binding by TLR9.  However, ligand binding investigations have reached contradictory 
conclusions with respect to the ability of TLR9 to discriminate nucleic acids in a 
sequence-specific fashion.   
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SPR Analysis 
Most of the ligand binding investigations of TLR9 employ surface plasmon 
resonance (SPR) technology (Figure 1.6).  SPR analysis is based on the reflection of 
light by thin metal films, typically gold or silver.  At a specific angle, the energy from 
the incident photons interacts with delocalized electrons within the metal film 
(plasmons) resulting in total attenuation of the light.  The angle at which this occurs is 
dependent on the refractive index of the interface at the two sides of the metal surface.  
Target molecules are immobilized on the back of the metal surface and addressed by 
ligands, which are suspended in a mobile phase running along a flow cell.  If binding 
occurs between the ligand and immobilized target, the local refractive index will change, 
leading to changes in the SPR angle.  These changes to the SPR angle are detected as 
changes in the intensity of the reflected light.  The magnitude of the SPR signal change 
is directly proportional to the immobilized mass and can be interpreted in terms of the 
stoichiometry of the interaction. 
Arguing in favor of sequence-specific binding by TLR9, investigations by Rutz 
(Rutz 2004) and Cornelie (Cornelie 2004) utilized SPR analysis to investigate ligand 
binding by a recombinant form of the receptor.  Investigations by Rutz, utilizing 
immobilized PD-ODNs, noted that the recombinant murine TLR9 ectodomain exhibited 
sequence-dependent binding of PD-ODNs with the most favorable interactions occuring 
at acidic pH, reflective of the endosomal environment (Rutz 2004).  These results 
support the in vivo demonstrations that ODNs, in a sequence-dependent manner, 
undergo favorable interactions with TLR9 within the endosome.   
In contrast, but equally convincing, is an investigation by Latz in which CpG and  
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Figure 1.6: SPR analysis.  Target molecules (blue and red) are attached to the 
underside of the sensor chip and may interact with ligands (green circles) suspended in 
the mobile phase. 
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GpC-containing ODNs were shown to be equally effective in mediating co-
immunoprecipitation of TLR9 from cellular extracts, supportive of the physiological 
interaction of the receptor with nucleic acids in a sequence-independent fashion. That 
GpC-ODNs can inhibit CpG-mediated cellular activation was suggested by the authors 
to represent competition between CpG- and GpC-ODNs for the same binding sites on 
TLR9 (Latz 2004).  
Adding further controversy to the specificity of binding by TLR9, Rutz 
demonstrated that the ability of TLR9 to discriminate higher order species-specific CpG 
motifs was limited to PD-ODNs (Rutz 2004).  PTO-ODNs were found to be 
indiscriminate in their ability to bind TLR9, and also demonstrated non-specific binding 
to other TLR family members (Rutz 2004).  In direct contrast, Roberts demonstrated 
through functional assays that PTO-modified ODNs were associated with higher 
sequence specificity and that the ability for cells to discriminate higher-order CpG 
motifs was dependent upon the PTO-modification (Roberts 2005). They, and others, 
have suggested that the ability for different sequences to preferentially activate TLR9 in 
a species-specific fashion is an artifact of the PTO-modification (Yasuda 2006, Roberts 
2005).  
Clearly the PTO-modification is not a neutral substitution, although it is not clear 
whether the consequence is to increase or decrease the specificity of interaction with 
TLR9. PTO-ODNs have been described as “sticky” with the tendency to interact with 
other proteins, including other Toll-like receptors (Rutz 2004). The interactions with 
proteins other than TLR9 may account for the ability of PTO-ODNs to exert CpG-
independent side effects including induction of B cell proliferation, splenomegaly, and 
tissue infiltration by mononuclear cells (Baek 2001, Khaled 1996, Monteith 1997). 
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Collectively, the differences between natural and PTO-ODNs are perhaps best 
summarized by the observation that “the rules governing TLR9 activation by PTO-ODN 
and PD-ODN differ from each other” (Yasuda 2006). 
These results appear to contradict the proposed sequence-dependency of TLR9 
activation.  The observations by Roberts, however, suggest that sequence-dependency is 
limited to PTO-ODNs and cannot be recapitulated with PD-ODNs (Roberts 2005).  This 
is supported by the observations of Yasuda and Rutz that appear to resolve the 
discrepancies between TLR9 sequence-dependency in regards to PTO- and PD-ODNs 
(Yasuda 2005, Rutz 2004).  An investigation by Yasuda demonstrated that the enforced 
endosomal translocation of vertebrate DNA, via 1,2-dioleoyl-3-trimethylammonium 
propane (DOTAP) coupling resulted in TLR9 activation (Yasuda 2005).   In contrast to 
the dogma of CpG motif-specific TLR9 activation, these observations suggest that the 
limiting factor for TLR9 activation may be endosomal translocation efficiency rather 
than the binding proclivities of the receptor.  Recent investigations by Yasuda support 
this argument. High concentrations of DOTAP-coupled PTO-GpC-ODNs have 
immunostimulatory activity and PD-ODNs coupled to DOTAP activated TLR9 in a 
sequence-independent fashion (Yasuda 2006).  These results were also corroborated by 
SPR analysis and introduced a significant caveat from previous analyses; DOTAP-
coupling results in the endosomal translocation of up to 10-fold more ODN than the 
natural endocytic pathway.  Thus, although SPR analysis demonstrated that at equimolar 
concentrations, PD-CpG-ODN bound to TLR9 with approximately 3-fold greater 
efficiency than that of the non-activating motif, this sequence-dependent binding could 
be abolished by increasing the concentration of PD-GpC-ODN.  This was reasoned by 
the authors to be representative of the “low-affinity” binding of TLR9 to the PD-ODNs 
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and that this low affinity could be overcome by simple introduction of a CpG motif or, 
alternatively, by increasing the concentration of PD-GpC-ODN.  Thus, ligands that 
would normally be regarded as “low-affinity” ligands, such as GpC-ODNs, upon 
enhanced endosomal translocation have the propensity to activate TLR9 once an 
undefined threshold concentration is exceeded.   
Thus, the relationship between DNA binding and TLR9 activation remains 
controversial; PTO-ODNs are able to bind TLR9 in a sequence-independent fashion 
whereas natural PD-ODNs and plasmid DNA containing CpG sequences have higher 
affinities to TLR9 than non-CpG ODNs or methylated plasmid DNA although this can 
be overcome by increasing the functional concentration of the non-optimal ligands.  This 
would represent a unique deviation from the accepted TLR9 DNA ligand paradigm; the 
species- and sequence-specific activation of TLR9 is confined to those molecules that 
are translocated to the endosome through the natural uptake route (Yasuda 2005). 
 
 1.7.4 Single- and Double-Stranded TLR9 Ligands  
Investigation of TLR9 activation by cell stimulation assays have been biased to 
the use of single-stranded ODNs.  The ultimate challenge to PRRs is to discriminate self 
from non-self and a differentiating factor between eukaryotic and microbial organisms is 
the presence of plasmid DNA.  Thus, it is intriguing to speculate that TLR9 might 
possess the ability to bind DNA of single- and double-stranded nature in both linear and 
plasmid forms.  Indeed, previous investigations have noted that the initiation of innate 
immune responses by plasmid DNA is suggestive of TLR9 activation (Sawamura 2005, 
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Spies 2003, Sato 1996) and that the stability of plasmid DNA within the endosome 
would allow for such an interaction (Bennett, 1985).   
Investigations of single- and double-stranded DNA ligand recognition by TLR9 
have reached opposing conclusions.  Cornelie has demonstrated TLR9-dependent 
induction of NF-kB in response to plasmid DNA and activation is abrogated by plasmid 
methylation or chloroquine administration (Cornelie 2004).  SPR analysis demonstrated 
that recombinant TLR9 bound plasmid DNA effectively in a methylation-dependent and 
sequence-dependent fashion.  Competition experiments demonstrated that CpG-ODNs, 
but not GpC-ODNs, can compete for TLR9 binding with plasmid DNA (Cornelie 2004).  
All of these observations support plasmids as TLR9 ligands.   In contrast, Rutz has 
demonstrated very weak binding of double-stranded linear ODNs by recombinant TLR9 
and minimal NF-kB induction (Rutz 2004).  Furthermore, an investigation of the 
immunostimulatory activities of plasmid DNA and single- and double-stranded ODNs 
by Zelenay reported similar observations (Zelenay 2003).   Plasmid DNA expresses 
adjuvanticity as a single- or double-stranded moiety whereas the immunostimulatory 
activity of CpG-ODNs is reduced when double-stranded.  Although the plasmid binding 
results of Rutz contradict those of Cornelie it should be noted that the nature of the 
double-stranded ligand in the two analyses differs.  Notably, the Cornelie investigation 
utilized plasmid DNA whereas the investigation by Rutz employed linear double-
stranded ODNs.   
Thus, the investigations by Rutz and Cornelie, although contrasting in regards to 
TLR9 activation by single- or double-stranded DNA molecules, would be presumed to 
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reflect the types of DNA released within the endosome following bacterial phagocytosis 
and thus the types of DNA ligands that could potentially interact with TLR9.  
 
 1.7.5 Localization of TLR9 and Endogenous DNA 
That the PAMP recognized by TLR9 is also an endogenous biomolecule presents 
a unique problem for TLR9 in host-pathogen DNA discrimination.  The activation of 
TLR9 has been proposed to be based on unmethylated CpG motifs present within 
microbial DNA.  Although such sequences are rare within eukaryotes, host DNA does 
have the potential to activate TLR9.  As host genome possesses the potential to activate 
unnecessary innate immune responses, a number of protection mechanisms appear to 
limit the potential for this interaction. 
One of the primary mechanisms by which the cell has evolved to limit innate 
immune activation by host nucleic acids is by the intracellular localization of nucleic 
acid binding TLRs.  Prior to CpG stimulation, TLR9 resides within the endoplasmic 
reticulum and upon CpG internalization, is rapidly translocated to the endosome (Leifer 
2004).  The authors also demonstrated that this translocation event might involve a 
direct pathway between the ER and the endosome as TLR9 remains sensitive to EndoH, 
an enzyme that digests immature N-linked sugars added in the ER but modified within 
the Golgi.  Biotinylation studies have demonstrated that following stimulation with 
CpG-DNA, a small fraction of TLR9 becomes accessible to the extracellular 
environment suggesting ER-to-endosome fusion (Latz 2004).  Although this would 
suggest that the localization of TLR9 acts as a safety mechanism to limit access to host 
CpG motifs, it does not define the nature of the interaction between TLR9 and host 
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DNA.  Using a chimeric TLR9 that localized to the cell surface, Barton demonstrated 
that cells transfected with TLR9 or the surface-exposed TLR9 variant responded 
equivalently to CpG ODN stimulation at a broad concentration range of the ligand 
(Barton 2006).  However, stimulation with chromatin-containing immune complexes or 
purified vertebrate genomic DNA resulted in selective activation of the chimeric TLR9 
variant.  The immunostimulatory effect of the genomic DNA was negated when pre-
incubated with DNase-I (Barton 2006).  Thus, it is evident that the localization of 
endogenous TLR9 prevents activation by self-DNA.  In a similar manner it has been 
demonstrated that endosomally translocated self-DNA can activate TLR9 while 
extracellular self-DNA cannot (Yasuda 2006).  This suggests either specificity in the 
uptake of the DNA, with the selective endocytosis potentially limiting exposure of TLR9 
to inappropriate ligands, or that self-DNA is degraded before it has the opportunity to 
serve as a TLR9 ligand. 
 Activation of TLR9 by self DNA may serve a physiological function to initiate 
localized inflammation in response to damaged or dying cells.  Accumulating evidence 
suggests that host DNA has TLR9-activating potential and thus presentation of host 
nucleic acids might allow for induction of innate immune responses (Vallin 1999, 
Marshak-Rothstein 2004, Boule 2004). Recently, Ishii and Akira have suggested that the 
culmination of this phenomenon might be that TLR9 has evolved to detect not only the 
CpG motif within pathogenic organisms, but also some molecular pattern within host-
derived DNA, albeit a CpG motif as of yet unidentified nature or some other conserved 
motif (Ishii 2005).   
The potential for immunostimulation by host DNA is minimized due to cellular 
compartmentalization as DNA is normally sequestered within the nucleus or 
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mitochondria.  This is not the case, however, with damaged cells as nucleic acids may be 
released into the cytoplasm or extracellular environments.  It has been suggested that 
DNA released in the situations may lead to activation of innate immune responses (Ishii 
2005).  Thus, although the sub-cellular localization of TLR9 serves to protect the host 
from the immunostimulatory activity of self-nucleic acids, this does not remove the 
potential of self-DNA to bind to and activate TLR9.  As a secondary protective 
mechanism, host DNA minimizes the potential for TLR9 activation through the presence 
of suppressive DNA sequences.  These sequences have been found to selectively block 
CpG-mediated immune stimulation by suppressive motifs rich in poly-G of GC 
sequences, or optimally the sequences found within the telomeric regions of mammalian 
DNA (the repeat TTAGGG) (Gursel 2003).   
The mechanisms for limiting TLR9 activation by host DNA highlight two 
important considerations for design of TLR9 immunotherapeutics.  Firstly, it would be 
anticipated that the interaction between TLR9 and its ligand would have evolved to be 
optimized for physiological environment in which they occur.  As the late endosome 
provides a unique chemical environment with an acidic pH, changes in the protonation 
state of either the receptors or ligands may be prerequisite for formation of an activated 
complex.  Secondly, that TLR9 has the ability to be influenced functionally by inhibitory 
nucleic acid sequences implies the receptor has the ability to bind both stimulating and 
non-stimulating sequences, highlighting the functional distinction between ligand 
binding and receptor activation. This would be of particular consequence as it limits the 
potential to discover novel agonists through screening assays based solely on their 
ability to interact with the receptor. 
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 1.7.6 TLR9 and Systemic Auto-immune Disease 
 As mentioned in the previous section, self-DNA immunoglobulin G (IgG) 
complexes have been demonstrated to contribute to the pathogenesis of systemic auto-
immune diseases.  Indeed, self-DNA-IgG complexes contribute to the pathogenesis of 
systemic auto-immune diseases such as systemic lupus erythematosus (SLE) and have 
been demonstrated to activate innate immunity in a TLR9-dependent fashion (Leifer 
2006, Ishii 2005).  Systemic auto-immune diseases refer to diseases in which 
pathogenesis is attributed to the production of auto-antibodies specific to a varied, but 
limited, set of self-biomolecules.  As many of these self-determinants are derived from 
macromolecular structures with similar features to PAMPs, such as chromatin (Rifkin 
2005), self-tolerance may be lost.  From the perspective of TLR9, these host 
biomolecules may interact with the receptor due to of structural conservation between 
host and pathogen DNA as a consequence of the limited number of unmethylated CpG 
dinucleotides found within the vertebrate genome.  
 It has been suggested that the onset of systemic auto-immune disease and the 
process of apoptosis are intricately linked in that apoptotic bodies not rapidly cleared 
from the system could potentially serve as a source of auto-antigen.  As a testament to 
this, many of the recurring auto-antibody targets in diseases such as SLE and 
scleroderma are protein/DNA or protein/RNA complexes (Rifkin 2005).  This represents 
the specific paradox of TLR9 activation by self-DNA; how is the physical interaction 
between receptor and ligand mediated and why do the security measures found in 
mammalian DNA not reduce TLR9 activation?   
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Several lines of evidence suggest that abnormal DNA methylation is a key 
determinant in SLE.  Indeed, DNA methylation has been implicated in the development 
of several diseases (Sekigawa 2006).  For example, DNA hypomethylation within proto-
oncogenes has been reported to increase expression of proto-oncogenes, potentially 
promoting malignant transformation, and has also been demonstrated to increase 
mutation rates (Laird 1994, Chen 1998).  CpG island methylation has been associated 
with conditions such as retinoblastoma (Laird 1994).  From the perspective of TLR9, the 
chromatin isolated from apoptotic or dying cells exhibits modifications such as aberrant 
DNA methylation patterns.  Huck has observed an increased release of nucleosomes 
enriched in hypomethylated CpG-rich DNA due to accelerated apoptosis rates and 
defective apoptotic cell clearance in SLE patients (Huck 1999).   It has also been 
demonstrated that therapeutics for drug-induced lupus inhibit the action of DNA 
methyltransferases (Cornacchia 1988).  Huck has demonstrated that over 90% of 
patients treated with procainamide, an anti-arrhythmic therapeutic, develop anti-nuclear 
antibodies with approximately 20% exhibiting lupus-like symptoms (Huck 1999).  This 
is supported by reports that SLE patient sera are enriched in hypomethylated CpG-rich 
low molecular weight DNA (Sano 1989, Krapf 1989, Corvetta 1991).  These examples 
are supportive of a role for TLR9 in autoimmune disorders such as SLE. 
 The physical boundary between TLR9 and the extracellular matrix has been 
regarded as one of the primary defense mechanisms limiting the activation of TLR9 by 
host DNA.  It has been proposed that the interaction between DNA-IgG complexes and 
cellular receptors might promote the delivery of host DNA to the endosome in patients 
with SLE (Marshak-Rothstein 2006).  Indeed, the Fcγ receptor (FcγR), specific for the 
Fc portion of IgG on pDCs, is required for detection of immune complexes; pretreatment 
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of SLE patients with FcγR blocking agents ablates the ability of pDCs to be stimulated 
by sera containing immune complexes (Bave 2003).  Thus, receptor-mediated 
endocytosis of DNA-immune complexes in patients with systemic auto-immune disease 
represents one of the limiting factors for TLR9 activation.  It has also been proposed that 
the DNA within immune complexes in cases of systemic auto-immune disease might 
differ from normal mammalian DNA; DNA isolated from immune complexes is often 
enriched in CG content as (Sano 1982).  They have demonstrated that DNA extracted 
from T cells of SLE patients is hypomethylated compared to that of normal T cells.  The 
efficient removal of DNA from sera might also represent a limiting factor for the 
development of DNA-immune complexes.  Nucleases such as DNase-I, the primary 
nuclease within serum, have been correlated with the suppression of SLE-like auto-
immune diseases development.  DNase-I KO mice demonstrate symptoms of SLE-like 
auto-immune diseases and DNase-I mutations have been observed in SLE patients 
(Napirei 2000, Yasutomo 2001). 
 Although the precise mechanism by which the interaction between TLR9 and 
host DNA is mediated has yet to be determined, treatments have thus far focused on the 
inhibition of the interaction.  Anti-malarial agents such as chloroquine have been used 
therapeutically for more than a century to treat SLE and have recently been 
demonstrated to interfere with the binding of CpG-DNA by TLR9 (Marshak-Rothstein 
2006, Rutz 2004).   
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 1.7.7 pH Dependence of TLR9 Ligand Binding  
 It has been demonstrated that TLR9 and CpG DNA co-localize within the 
endosomal compartment and that this is an essential component for cellular activation 
(Ahmad-Nejad 2002, Rutz 2004).  As such, compounds such as bafilomycin A1, a 
specific inhibitor of the endosomal and lysosomal V-type ATPase, and chloroquine, a 
weak base that perturbs endosomal pH by partitioning into the organelle, interfere with 
endosomal acidification and inhibit CpG-driven TLR9 signaling (Hacker 1998, Yi 1998, 
Yoshimori 1991, Macfarlane 1998).   
 Previously, an investigation by Rutz demonstrated that the recombinant 
extracellular domain of TLR9 binds CpG-DNA in a pH-dependent manner.  Binding 
between the receptor and CpG-DNA was highest at the acidic pH of the endosome 
(pH4.5-6.5) and was drastically reduced at neutral pH (7.4) (Rutz 2004).  The authors 
noted that chloroquine and its analog quinacrine, inhibited the binding between the 
receptor and CpG-DNA in a dose-dependent fashion.   
The dependence on acidic pH for ligand binding has also been demonstrated for 
other endosomal TLRs.  Ligand binding and receptor dimerization were demonstrated to 
be more efficient at acidic pH for TLR3 and TLR8 (de Boutellier 2005, Ranjith-Kumar 
2007, Gibbard 2006).  de Boutellier demonstrated that the activation of TLR3 by poly(I-
C), and the induction of receptor dimerization by the ligand, could be effectively 
blocked by bafilomycin A1 and chloroquine (de Bouteiller 2005).  Optimal 
responsiveness of TLR3 to poly(I-C) requires acidic pH and progressively decreased 
towards neutral pH, at which receptor activation was completely ablated (de Boutellier 
 47
2005).  Similarly, Gibbard demonstrated that the activation of TLR8 is highly pH-
dependent and is abolished by bafilomycin A1 (Gibbard 2006).  The pH-dependency of 
TLR8 signaling was speculated by the authors to be largely due to the influence of pH 
on receptor homodimerization.  Ranjith-Kumar has reported similar observations and 
demonstrated that TLR8 can form inactive dimers in the absence of ligand at acidic pH 
(Ranjith-Kumar 2007). 
The pH dependence exhibited by the interaction between TLR9 and DNA has 
been postulated to be the result of two potential, but not mutually exclusive, mechanisms 
(Gibbard 2006).  Firstly, the acidic environment within the endosome might induce 
conformational changes in the receptor that either increase the ligand-binding 
proclivities of TLR9 or provoke receptor dimerization to an activated complex.  The 
authors speculate that this may result from the ionization of histidine sidechains within 
the receptor ectodomain; TLR7, 8, and 9 have a conserved histidine residue in LRR18.  
A conceptually similar, but functionally inverted, mechanism to regulate ligand binding 
during intracellular trafficking has been characterized for the low density lipoprotein 
receptor.  In this example binding of the low density lipoprotein ligand occurs at neutral 
pH at the cell surface.  During endosomal acidification, changes in the protonation state 
of a pseudoligand of the ectodomain displace the ligand (Rudenko 2002).  
 Alternatively, changes in the protonation state of the ligand might promote 
ligand binding by the receptor.  The ionization of nucleic acids, and in particular 
cytodine residues of the CpG repeat, may change during the endosome maturation.  The 
pKa for cytodine in 4.2; however, the pKa is likely considerably higher when the base is 
found within the context of a polynucleotide due to the phosphate backbone and would 
result in a positively charged ligand.  In support of this hypothesis, the mutation of 
 48
ectodomain residue Asp-543 in TLR9, resulting in loss of a negatively charged region 
within the receptor ectodomain, ablates TLR9 ligand binding (Rutz 2004).  It is 
hypothesized that TLR9 activation may therefore involve binding of the positively 
charged CpG ligand to negatively charged regions of the receptor ectodomain (Gibbard 
2006).  Based on these observations, the potential may exist for the design of more 
effective TLR9 agonists through the incorporation of modifications that influence the 
protonation state, and thereby ligand efficiency, of nucleic acids. 
 
1.8 Therapeutic Applications of ODNs  
As oligodeoxynucleotides are easy to manufacture, highly stable, and of low 
manufacturing cost, they are attractive as therapeutic modulators of TLR9 activation.  
Supporting the efficacy of synthetic ODN administrations, there has been minimal 
concern regarding the systemic toxicity of either the PD- or PTO-backbone ODNs.  
Previous investigations for anti-sense and aptamer therapeutics can be applied to the 
therapeutic applications of TLR9 modulators as all are oligodeoxynucleotide molecules.  
Extensive characterizations of ODNs in terms of absorption, distribution, metabolism, 
and elimination properties have been completed over the past decade (Geary 1997, 
Levin 2001).  These investigations have noted that synthetic PTO-ODNs exhibit rapid 
clearance into tissues but do not show signs of crossing the blood-testis (which restricts 
cytotoxic agents from passing into the seminiferous tubules) or blood-brain barriers.  
Sequence-independent activities of PTO-ODNs related to the phosphothioate backbone 
have also been characterized.  Chronic dosing of PTO-ODNs in rodents noted high local 
ODN concentrations in the kidneys following repeated high concentration ODN doses 
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with the potential for induction of degenerative lesions and necrosis in the proximal 
tubules (Levin 2001, Jason 2004).  In contrast, investigations of human renal function in 
relation to PTO-ODN administration have reported no adverse effects.  Thus, a species-
specific bias may exist in the prediction of PTO-ODN toxicity.  That TLR9 expression 
in rodent immune cells is much broader than that of primates has been suggested as a 
potential mechanism for this phenomenon (Krieg 2006).    
Following the demonstration that ODNs containing CpG motifs could selectively 
activate TLR9, half a dozen TLR9 agonists have been taken into human clinical trials, 
including two in Phase III trials (Krieg 2006).  These applications have focused on four 
primary areas of development: 1) infectious disease prevention and therapy, 2) as 
vaccine adjuvants, 3) treatments for the reduction of allergic responses, and 4) in cancer 
therapies.  As a testament to the potential of these novel TLR9 agonists as future 
therapeutics, CpG-ODNs have been administered in over a dozen clinical trials.  The 
vast majority of Phase I studies have focused on the immunomodulatory activities of 
CpG-ODNs when administered alone, or in combination with vaccines, passive 
immunization, or allergens.  Currently, two controlled Phase III human clinical trials are 
underway (initiated in 2005 by Pfizer) for the class B CpG-ODN PF-3512676 (Adis 
Intern. Lim. 2006).  These trials are evaluating PF-3512676 administration in 
combination with chemotherapy for treatment of patients with advanced non-small-cell 
lung cancer (NSCLC).  Phase II clinical trials demonstrated promising results as 
response rates were significantly improved from 19% in patients undergoing standard 
chemotherapy treatment to 37% in patients who also received PF-3512676 (Krieg 2006).  
Further supporting the application of TLR9 agonists as novel therapeutics, a Phase IIa 
clinical study of a class C CpG-ODN, CPG 10101 (Coley) investigating its activity as a 
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monotherapy against hepatitis C virus (HCV) is in preparative stages following a Phase 
1b trial that demonstrated up to a 1.6 mean maximum log reduction of viral RNA with 
ODN administration (Krieg 2006).  That inappropriate TLR9 activation may contribute 
to the pathogenesis of disorders such as SLE and rheumatoid arthritis suggests TLR9 
antagonist therapeutics may also be beneficial.  Indeed, pre-treatment of mice with 
suppressive ODN significantly reduced CpG-induced inflammatory arthritis in mice 
(Zeuner 2003).  These examples highlight the promise of TLR9 agonists and antagonists 
as future therapeutics. 
The activation of TLR9 by CpG-ODNs has the potential for deleterious side 
affects, in particular the potential to trigger autoimmune disorders.  It has been 
demonstrated that CpG-ODN treatments can aggravate auto-immune disorders in mouse 
models of lupus (Hasegawa 2003), multiple sclerosis (Ichikawa 2002), colitis 
(Obermeier 2002), and arthritis (Ronaghy 2002). Normal mice have also proven 
susceptible to the deleterious effects of TLR9 over-stimulation as the administration of 
high does of bacterial DNA led to the development of auto-antibodies against double-
stranded DNA (Gilkeson 1993).  Concerns have also been raised regarding the ability of 
CpG-ODN therapies to facilitate the development of toxic shock by lowering the 
pathological threshold of lipopolysaccharide-tolerance.  Co-administration of CpG-
ODNs with sub-lethal doses of LPS and D-galactosamine resulted in severe mortality 
and morbidity (Sparwasser 1997, Cowdery 1996, Hartmann 1996).  However 
investigations in mice using weekly administrations of CpG-ODNs over a four month 
period demonstrated no adverse health effects.  Similarly, therapeutic administrations of 
high dosages of antisense ODNs (synthetic ODNs that are complimentary to the sense 
sequence of a particular mRNA) to patients with Crohn’s disease had no adverse effects 
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(Yacyshyn 2002).  Thus, it would seem that although no major toxic effects are observed 
upon administration of DNA alone, the presence of multiple TLR agonists may 
contribute to the pathogenesis of sepsis based on the combined sensitization of each 
agonist. 
Therapeutic development of novel TLR9 modulators has been hindered by the 
paucity of information regarding the direct interaction between the receptor and ligand.  
The advent of a convenient screening assay would allow for the evaluation of TLR9 
agonists and antagonists based on a combination of the direct characterization of the 
receptor-ligand interaction and on the basis of the cellular responses they elicit rather 
than the current biased approach that utilizes only cell stimulation results.  This bias is 
inherently dangerous as the numerous points of regulation within the TLR9-mediated 
cell signaling pathway are reduced to a single output thus removing the ability to 
discriminate specific events from the overall biological process.  The danger of this 
approach is that the reduction of numerous potential points of regulation to a single 
output does not permit discrimination of specific events, such as ligand binding, from 
the overall biological process.  
 
1.9 Host Defense (cationic) Antimicrobial Peptides 
 
 1.9.1 General Characteristics of Host Defense Peptides 
 Host defense antimicrobial peptides (HDPs) are ubiquitous defense biomolecules 
found in virtually all forms of life - including bacteria, fungi, plants, invertebrates, and 
vertebrate species (Jenssen 2006).  Currently more than 900 different HDPs have been 
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identified or predicted from nucleic acid sequences 
(http://www.bbcm.univ.trieste.it/~tossi/amsdb.html).  That HDPs have been retained 
within the innate immune system during the co-evolution of eukaryotic hosts and 
prokaryotic pathogens suggests that they play a pivotal role in the innate immune 
response.  As lower organisms lack adaptive immunity, these peptides form a central 
component of the innate immune system against pathogen invasion.  Although the 
vertebrate immune system has both innate and adaptive immune components, HDPs still 
serve an essential role in infection resolution.  This is highlighted by the observation that 
genetic disorders such as specific granule deficiency syndrome (Ganz 1988), atopic 
dermatitis (Ong 2002), and morbus Kostmann syndrome (Putsep 2002) increase the 
frequency and severity of bacterial and viral infections within the host.  As the primary 
role of HDPs in lower organisms is the resolution of microbial infection, these peptides 
have traditionally been characterized based on their antimicrobial activities (McPhee 
2005).  Recently, in has become clear that they also play a pivotal role in the regulation 
of mammalian immunity, thus the title of  “host defense peptides” rather than 
“antimicrobial peptides”.   
Cationic HDPs are gene-encoded and are normally produced as inactive 
precursor peptides.  Peptide activation follows proteolytic cleavage of the pre-peptide 
region.  As such, HDPs are normally defined based on a set of criteria: they are short 
(10-50 amino acids, generally <10 kDa), an overall positive charge (+2 to +10) with 
high concentrations of lysine and/or arginine residues, and a high proportion of 
hydrophobic residues (≥30%) (McPhee 2005).   
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 1.9.2 Host Defense Peptide Families 
 As host defense peptides typically exhibit minimal sequence similarity, they are 
often grouped according to the major structural conformation adopted in the membrane-
associated state.  It should be noted however that the structural class given has little, if 
any, relationship to its biological activity (McPhee 2005). 
The amphipathic alpha-helical class of HDPs is the most abundant and well 
characterized class of HDPs.  Upon interaction with the hydrophobic membrane 
environment this class of HDPs adopts an amphipathic alpha-helical conformation with 
one helical face containing the majority of the hydrophobic residues, the opposite 
containing a large proportion of the polar residues (McPhee 2005).  These peptides are 
often short (<40 amino acids), devoid of cysteine residues, and found to be unstructured 
or linear in non-hydrophobic environments.  Notable HDPs of this class include the 
antimicrobial peptide alamethicin (Payne 1970), the food preservative nisin (Van de Ven 
1991), the magainins (Zasloff 1987), and the human cathelicidin LL-37.  
 The beta-stranded cationic peptides are the second largest class of HDPs.  These 
peptides are highly diverse at the level of primary structure.  Commonly, the beta-
stranded HDP class is comprised of several antiparallel beta-strands with stabilization by 
one or more disulfide bonds (Yount 2005).  Recently, a common motif that integrates all 
cysteine-containing HDPs has recently been elucidated by multidimensional proteomic 
analysis.  The γ-core, characterized two antiparallel beta-sheets and basic residues along 
its axis, has been found to recur in all major classes of cysteine-stabilized HDPs, across 
all biological kingdoms, and may represent a unifying structural motif in HDPs (Yount 
2004).   The beta-stranded HDP class includes the highly antimicrobial tachyplesins 
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(Yang 2001) and polyphemusins (Miyata 1989), protegrins (Chen 2000), and the 
commercialized antibiotic gramicidin S (Gibbs 1998). 
The last class of HDPs, the extended peptide class, is defined by the absence of 
secondary structure (McPhee 2005).  These peptides normally contain high proportions 
of amino acids such as histidine, tryptophan, or proline and tend to adopt an overall 
extended conformation upon interaction with hydrophobic environments.  Examples of 
peptides belonging to the extended class include indolicidin, a bovine neutrophil peptide, 
and the porcine peptide fragment, tritpticin (McPhee 2005).  These structures are 
stabilized by hydrogen bonding and van der Waals forces as a result of contact with 
lipids in contrast to the intra-molecular stabilization forces found in the former peptide 
classes. 
Traditionally, the name “antimicrobial peptide” has been limited to small 
cationic peptides.  The demonstration that larger polypeptides and proteins also possess 
antimicrobial activity may expand the number of biomolecules falling under this 
nomenclature.  Acid hydrolysis products of lactoferrin, an 80 kDa glycoprotein of the 
transferrin family, have been demonstrated to have direct antimicrobial activity (Gifford 
2005, Hoek 1997).  Interestingly, molecules with previously demonstrated 
immunomodulatory activity have now been found to possess direct antimicrobial 
activities as well.  The microbicidal chemokines, or kinocidins, traditionally regarded as 
chemoattractive immunomodulatory signaling molecules, have recently been ascribed 
antimicrobial activity to a specific C-terminal domain of the protein (Bjorstad 2005).  
The C-terminal domain is similar in structure and composition to many alpha-helical 
antimicrobial peptides and is typically cationic and amphipathic (Yount 2006). 
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1.9.3 Host Defense Peptide Distribution 
Host defense peptides are involved in both intracellular and extracellular 
defensive responses.  HDP synthesis is constitutive or inducible and occurs within the 
granules of phagocytic cells, or alternatively, HDPs are secreted by epithelial cells 
(Devine 2002).   
In vertebrates, two groups of host defense peptides are prominent, the 
cathelicidins and the defensins.  Cathelicidins, characterized by a conserved N-terminal 
cathelin domain, are a large and diverse group of HDPs.  The significance of the cathelin 
domain is due to the inactivity of the peptide in the absence of the proteolytic cleavage 
of this segment to generate the mature peptide (Jenssen 2006).  Thus, cathelicidins are 
naturally stored in an inactive propeptide state and are normally found within the 
secretory granules of neutrophils, mucosal surfaces in the mouth, lung, and 
genitourinary tract (Bowdish 2005a).  Structurally, the cathelicidins are extremely 
diverse, with the exception of the N-terminus, and are represented by alpha-helical, beta-
hairpin, and proline/arginine-rich peptides.  The second prominent mammalian HDP 
group is the cyclic defensins.  In an analogous manner to the cathelicidins, defensins are 
synthesized as prepeptides and require proteolytic processing to become active; 
however, the structural diversity of the defensin family has led to their division into 
three subfamilies: the α-, β-, and θ-defensins.  The α- and β-defensins are categorized 
based on the pattern of disulfide bonding between the six conserved cysteines in these 
two subfamilies and are widely distributed in vertebrate species; θ-defensins, identified 
only in Old World monkeys, are subgrouped based on their macrocyclic nature (Jenssen 
2006).  The defensins, much like their HDP counterparts, the cathelicidins, are normally 
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found within immune cells (neutrophil granules, macrophages, NK cells) or at epithelial 
surfaces (respiratory mucosal surfaces, intestinal epithelial cells, and urogenital tract 
mucosal surface) and their expression may be either constitutive or inducible. 
 
 1.9.4 Biophysical Properties of Host Defense Peptides 
 The role of host defense peptides in the innate immune system requires their 
selective toxicity towards a pathogenic target.  Thus, HDPs share unifying 
characteristics that are quintessential for antimicrobial activity, including catioinicity, 
amphipathicity, and hydrophobicity.  These characteristics produce a selective affinity to 
microbial determinants that are easily accessible, are conserved across the broad 
spectrum of microbes, and are relatively immutable (Yount 2005).  During the co-
evolution of host and pathogen, HDPs development has met these constraints.    
 
  1.9.4.1 Catioinicity 
 The majority of HDPs have a conservation of cationicity with enrichment in 
lysine and arginine residues.  Thus, HDPs carry positive charges that range from +2 to 
+10, depending on pH and the number of basic residues (Giangaspero 2001).  The 
cationicity of HDPs likely acts as a key determinant for the initial electrostatic 
interaction with the highly electronegative cell envelopes of bacteria (Giangaspero 
2001).  Unlike eukaryotic cell membranes, comprised primarily of zwitterionic and 
neutral membrane lipids, bacterial cell membranes are comprised of highly 
electronegative phospholipids including phosphatidylglycerol, phosphatidylserine, and 
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cardiolipin.  These components confer an overall negative charge to the microbial cell 
surface and thus an attractive target for HDPs.  Additionally, microbial membranes 
contain acidic compounds such as LPS (Gram-negative bacteria) and teichoic and 
teichuronic acids (Gram-positive bacteria) that impart additional negative charge and 
therefore additional attraction to the cationic HDPs (Yount 2005).  
It has also been demonstrated that the transmembrane potentials of prokaryotes 
are typically 50% greater than their eukaryotic counterparts.  This chemiosmotic 
potential has been proposed to act eletrophoretically on HDPs attached to the microbial 
surface (Hancock 1997).  It should also be noted that although increased HDP 
cationicity is generally associated with increased antimicrobial activity there are limits to 
this relationship.  Investigations of HDP cationicity have demonstrated that increased 
cationicity in the magainin HDPs led to an increased hemolytic propensity and loss of 
antimicrobial activity (Dathe 2002).  
 
  1.9.4.2 Amphipathicity 
 In addition to cationicity, the specificity of interaction between HDPs and the 
microbial membrane is also influenced by amphipathicity.  Traditionally, HDPs form 
amphipathic structures upon contact with the hydrophobic environment of the microbial 
membrane.  Peptide amphipathicity reflects the polarization and relative proportions of 
hydrophobic and hydrophilic elements within a peptide.  Although many protein 
conformations can achieve amphipathic structures, the alpha-helix represents one of the 
simplest.  Most alpha-helices have a periodicity of polar and apolar residues of 
approximately 3-4 residues per turn (Yeaman 2003).  The resulting structure, with the 
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polar side chains aligned along one side of the helix and the apolar residues lining the 
opposite side, is optimized for interaction with the amphiphilic microbial membrane 
(Dathe 1999).  It has been demonstrated that the amphipathicity of an HDP correlates 
with both antimicrobial activity and cytoxicity (Yount 2005).  However, a high degree of 
peptide helicity and/or amphipathicity has been correlated with increased toxicity 
towards the neutral cell membrane of the host (Jelokhani-Niaraki 2000, Lee 2003).  
 
  1.9.4.3 Hydrophobicity 
 The hydrophobicity of an HDP is defined as the proportion of hydrophobic 
residues within a peptide (Yeaman 2003).  Typically, HDPs are comprised of ≥30% 
hydrophobic residues.  As peptide hydrophobicity governs the ability of a peptide to 
partition into the lipid bilayer, it is an essential requirement for HDP-membrane 
interactions.  As described previously for peptide amphipathicity, increasing HDP 
hydrophobicity above a specific threshold correlates with increased host cell toxicity and 
diminished antimicrobial activity (Wieprecht 1997, Tachi 2002).  Therefore, 
hydrophobicity represents another feature of HDPs that has been optimized through 
evolution to achieve selective toxicity against microbial cell membranes. 
 
 1.9.5 Targeting the Bacterial Membrane and Self-Promoted Uptake 
As discussed in the previous sections, host defense peptides have been optimized 
to interact with the bacterial membrane.  Structurally, the Gram-negative bacterial outer 
membrane is an asymmetric bilayer, with the inner leaflet dominated by phospholipid 
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and a highly divergent outer leaflet primarily composed of LPS (McPhee 2005).  Due to 
a high content of phosphates and acidic sugars, LPS molecules carry a negative charge.  
The juxtaposition of LPS molecules in the microbial membrane creates the potential for 
significant destabilizing repulsive forces between the LPS molecules.  As a stabilization 
mechanism, divalent cations, such as Mg2+ or Ca2+, are bridged between LPS molecules 
to partially neutralize the electrostatic repulsion between the negatively charged groups 
(Nicas 1980).  Thus, the initial interaction between an HDP and the microbial membrane 
involves the binding of the peptide at the divalent cation binding sites on LPS at the cell 
surface (McPhee 2005).  The affinities of HDPs for LPS have been demonstrated to be 
at least three orders of magnitude higher than those for divalent cations (Hancock 1997).  
This displacement of the divalent cation bridges results in local destabilization of the 
outer membrane.  As a consequence, local transient “cracks” are formed within the 
membrane with subsequent uptake of the HDP through the destabilized membrane 
culminating in the “self-promoted uptake” of the HDP (McPhee 2005). 
  
  1.9.5.1 Attraction 
The association of HDPs with lipid bilayers has been observed to be directly 
related to the ratio of peptide to lipid (Yount 2005).  At low peptide/lipid ratios, peptides 
can be found in oriented parallel to the membrane.   As the ratio increases, the peptides 
reorient themselves perpendicular to the membrane, ultimately inserting into the bilayer.  
Following membrane insertion transmembrane pores are formed (Yount 2005).  The 
insertion of peptides into the lipid membrane, with the subsequent formation of 
transmembrane pores, has been described by three models. 
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  1.9.5.2 Membrane Insertion 
The barrel-stave model (Figure 1.7) describes the insertion of helical peptide 
bundles or “barrels” in a ring around an aqueous pore (Brogden 2005).  The hydrophobic 
regions of the HDPs are aligned with the lipid core regions and the hydrophilic peptide 
regions form the interior region of the pore.  The “stave” moniker refers to the individual 
transmembrane spokes within the “barrel”.  In the second model, a high density of HDPs 
accumulates at the bilayer surface forming an HDP “carpet” (Figure 1.7).  During this 
associative phase the cationic regions of the HDP interact with the anionic phospholipid 
head groups.  As a threshold concentration of peptide is reached, unfavorable membrane 
energetics result in membrane disruption.  In contrast to the barrel-stave model, 
membrane dissolution occurs in a dispersion-like manner rather than through the 
formation of transmembrane pores (Yount 2005).  The third model, the “torroidal pore” 
model, is functionally similar to the barrel-model (Figure 1.7).  Although both models 
ultimately result in the formation of transmembrane pores, the torroidal pore model 
differs in the association between the HDPs and the membrane.  Rather than forming an 
amphipathic barrel the HDPs are continuously associated with the polar head groups of 
the lipids due to the induction of lipid monolayer bending throughout the pore (Brogden 
2005).  The resulting transmembrane pore is formed by the intercalation of HDPs with 
lipid and the pore lining formed by the hydrophilic regions of the inserted peptides and 
the lipid head groups. 
Although there is evidence to support all of the above models, it has been 
suggested that membrane permeabilization may include elements from all three models 
(Brogden 2005).   
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Figure 1.7: Host Defense Peptide Membrane Insertion Models. A. The carpet model 
of host defense peptide-induced killing.  B. The barrel-stave model of host defense 
peptide-induced killing.  C. The torroidal model of host defense peptide-induced killing.  
Adapted from Brogden 2005. 
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1.9.6 Host Defense Peptides and Cell Death 
 The paradigm for the antimicrobial activity of host defense peptides has long 
been considered to be a consequence of insurmountable defects in the microbial 
membrane.  Thus, cell death would ensue based on the leakage of ions and metabolites, 
depolarization, defective biopolymer synthesis, and loss of cellular respiration (Yount 
2005).  Although it is likely that these effects contribute to cell death, recent 
observations suggest dissociation between membrane perturbation and microbial death 
(Yount 2005).  Koo has demonstrated that HDP-mediated membrane permeabilization 
does not invariably result in microbial death (Koo 2001).  It has also been demonstrated 
that depolarization of Pseudomonas aeruginosa following gramicidin S exposure does 
not effectively kill the microbe (Zhang 2000).        
 Thus, the direct microbicidal activity of HDPs has been speculated to involve 
perturbation of both extracellular and intracellular architecture.  At the bacterial 
membrane, HDPs have been demonstrated to disrupt peptidoglycan synthesis (Chitnis 
1990).  In a similar manner, the disruption of intracellular processes as a consequence of 
HDP exposure has also been observed.  Exposure of Staphylococcus to HDPs has been 
demonstrated to inhibit DNA and/or RNA synthesis prior to cell death (Xiong 2002).  
The authors speculated that this was due to the direct interaction between the cationic 
HDP and nucleic acids as has been observed for histone proteins.  Similarly, the HDP 
PR-39 has been demonstrated to bind directly to DNA and RNA (Boman 1993).  The 
targeting of intracellular biomolecules by HDPs is not limited to nucleic acids.  Kragol 
has demonstrated that pyrrhocidin, drosocin, and apidaecin (all insect antibacterial 
peptides) bind to the bacterial heat shock protein DnaK (Kragol 2001).  An investigation 
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by del Castillo has also demonstrated a direct interaction between the HDP microcin 
B17 and DNA gyrase (del Castillo 2001).  
 
 1.9.7 Direct Antimicrobial Activity of Host Defense Peptides 
 Traditionally, host defense peptide investigations have focused on the direct 
antimicrobial activity of these peptides.  Recently however the relevance of the direct 
microbicidal activity of HDPs in vivo has been called into question.  Firstly, the 
physiological concentrations of many HDPs are far lower than those required to exert 
antimicrobial activity (Bowdish 2005a).  HDPs such as LL-37 and the beta-defensins are 
found in physiological concentrations far lower than those required to exert 
antimicrobial activity in vitro (Bowdish 2005a).  Secondly, the physiological niches in 
which HDPs are normally sequestered would be highly antagonistic to antimicrobial 
activity.  Physiological concentrations of salt and cations have been found to suppress 
the antimicrobial activities of HDPs (Bowdish 2005a, Friedrich 1999).  It should also be 
noted that a large proportion of HDP antimicrobial activity investigations have used 
assays that do not directly mimic physiological conditions.  Traditionally, antimicrobial 
activity has been assessed in buffers devoid of physiological concentrations of divalent 
cations such as Mg2+ or Ca2+ (1-2mM), monovalent cations such as Na+ and K+ 
(100mM), and polyanionic biomolecules such as glycosaminoglycans and mucins 
(Hancock 2006).    Thirdly, that virtually every peptide sequence possesses some degree 
of antimicrobial activity in vitro suggests that this may be a general phenomenon 
associated with all peptides as opposed to specifically HDPs (Bowdish 2005a).  
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Although numerous arguments can be made against the physiological relevance 
of the direct antimicrobial activity of HDPs, there have also been observations that 
corroborate such a role for these peptides.  Indeed, it can be argued that in the 
appropriate physiological setting HDPs would be expected to have meaningful direct 
microbicidal activity.  The α-defensins present within azurophilic granules of 
neutrophils have been estimated to reach mg/ml concentrations (Ganz 1987).  That HDP 
genes are subject to positive selection, and belong to the most rapidly evolving group of 
mammalian proteins, has also been suggested to indicate a physiological role for HDPs 
in host immune defense (Maxwell 2003, Peschel 2006).   
Although arguments for and against a direct antimicrobial activity for HDPs have 
been raised, it is evident that these peptides play a pivotal role in the innate immune 
response.  The deficiency of α-defensins in human neutrophils can increase 
susceptibility to recurrent infections (Bowdish 2005).  Further supporting a role for 
HDPs in innate immunity, the deficiency of the human cathelicidin LL-37 and human α-
defensins (HNP1-3) has been correlated with frequent oral bacterial infections and 
severe periodontal disease in morbus Kostmann (Putsep 2002).  In rodent models the 
deficiency of matrilysin, required for the cleavage and activation of murine intestinal α-
defensins, led to increased susceptibility to oral S. typhimurium challenge in transgenic 
mice (Wilson 1999).  
   
 1.9.8 Immunomodulatory Activities of Host Defense Peptides  
Recently, the protective functions of host defense peptides have been observed to 
result partially from activities not related to their microbicidal activity (Finlay 2004).    
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Rather, HDPs have been demonstrated to modulate the innate immune response.  
Importantly, these immunomodulatory activities are retained under physiological 
conditions.  As such, it has been speculated that immunomodulation may represent the 
primary action of these peptides in vivo (Bowdish 2005b).   
The immunomodulatory activities of HDPs have been attributed to specific roles 
in the orchestration of innate immune responses.  HDPs have been demonstrated to 
recruit phagocytic cells to the site of infection (Bowdish 2005a).  Indeed, α-defensins 
have been demonstrated to reduce microbial load in mice, an activity that was associated 
with an influx of phagocytes to the site of infection (Welling 1998).  The induction of 
chemokine synthesis by HDPs has been reported.  LL-37 and the defensins have been 
demonstrated to enhance the release of the chemoattractant IL-8 (Scott 2002, Van 
Wetering 1997).  Angiogenesis stimulation has been observed following exposure to 
HDPs.  LL-37 has been observed to increased endothelial cell proliferation and 
formation of vessel-like structures (Koczulla 2003).  Immunomodulatory activities such 
as mast cell degranulation promotion, dendritic cell differentiation, nonopsonic 
phagocytosis promotion, and fibrin clot lysis inhibition have also been reported (McPhee 
2005).  
In addition to the activities described above, many HDPs have been 
demonstrated to neutralize the potentially deleterious effects of endotoxin in vivo and in 
vitro.  During an innate immune response, the induction of excessive inflammatory 
mediators can lead to tissue damage or sepsis.  If left unchecked, this uncontrolled 
inflammatory response can be lethal (McPhee 2005).  Thus, in addition to the 
immunomodulatory activities associated with HDPs, the ability to suppress LPS-induced 
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inflammatory response is a favorable activity.   Although the direct binding of LPS by 
HDPs has been observed (Rustici 1993, Gough 1996), recent evidence suggests an 
alternative mechanism.  Peptides such as CEME (also known as MBI-27) and 
polymyxin B have been observed to neutralize TNF-α synthesis in mice, even when 
administered 60 minutes following LPS exposure.  Similarly, microarray experiments of 
the interaction of CEMA, a synthetic insect-derived peptide, with LPS demonstrated 
selective modulation of LPS-induced gene expression (Scott 2002, Tjabringa 2003) 
adding further support for a non-LPS binding mechanism during endotoxemia 
neutralization.   
The demonstration that anti-endotoxin activities of host defense peptides require 
relatively high concentrations of peptide has raised concerns regarding host toxicity.  
Addressing this concern, an investigation by Bowdish demonstrated that the therapeutic 
administration of multiple peptides at low concentration might resolve these concerns 
(Bowdish 2005b).    
    
 1.9.9 Therapeutic Applications of Host Defense Peptides 
 The therapeutic development of conventional antibiotics has often been biased 
towards a “single-target, single-action” clinical mechanism.  Since their inception more 
than a half-century ago, antibiotic therapies have been a cornerstone in the battle against 
infectious disease.  However, the extensive application of conventional antibiotics, in 
addition to the limited introduction of new antibiotic classes, has served as a selective 
pressure for the emergence of multi-drug resistant microbial strains.  This has provoked 
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the exploration for new antimicrobial agents and strategies.  Host defense peptides are 
regarded as a leading candidate for alternative antimicrobial therapies. 
Host defense peptides have significant advantages over conventional antibiotics.  
In contrast to the single mode of action of conventional antibiotics, HDPs are multi-
functional components of the innate immune system.  As such, HDPs have demonstrated 
direct antimicrobial activity, immunomodulatory and/or endotoxin-neutralizing 
activities, and synergism with conventional antibiotic therapies (Zasloff 2002).  Further 
supporting the therapeutic application of HDPs, these molecules have retained their 
activities throughout evolution in the face of continual microbial pressure.   
As a testament to this, many HDPs are currently advancing through discovery, 
development and clinical trials.  For example, Migenix is investigating the indolicidin-
like peptides in the treatment of catheter-associated infections with advancement to 
Phase IIIb clinical trials (Hancock 2006).  Administration of the indolicidin-like MX-
226 peptide resulted in a 49% reduction of local catheter site infections and a 21% 
reduction of catheter colonization (Marr 2006).  To date however, only four cationic 
peptides have advanced into phase 3 clinical trials (Pexiganan, Iseganan, Neuprex, and 
Omiganan) with only two demonstrating efficacy (Hancock 2006).   
Concerns have been raised however regarding the efficacy of HDP therapies.  
Central to this are concerns that therapeutic applications of HDPs may serve as a 
selective pressure for the induction of microbial resistance.  As these molecules 
represent a central component of the innate immune system, HDP therapies may have 
severe consequences if cross-resistance to endogenous HDPs is induced.  Concerns have 
also been raised regarding the cytoxicity of HDP therapies.  Thus far, clinical trials of 
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HDPs have focused on topical application of peptide to address surface infection.  As 
such, there is limited information regarding the potential systemic toxicities associated 
with HDP treatments.  A phase I study of the protegrin analog IB-367 demonstrated no 
clinically significant adverse effects at peptide concentrations that reduced oral 
microflora (Mosca 2000).  Investigations of the hemolytic activities of HDPs continue to 
focus on strategies to minimize systemic toxicity concerns for HDPs.  Recent 
demonstrations that antimicrobial peptides share features with eukaryotic nuclear 
localization signal peptides (Lau 2005), and HDPs can translocate freely into cells 
(Sandgren 2004), argue for more focus on subtle toxicities that may be associated with 
HDP therapy. 
 The pursuit of HDP therapies has also been limited by high costs of peptide 
production.  HDP therapies range in cost from $100 and $600 per gram (the average 
daily dose for most systemic therapeutics).  This contrasts sharply with the low cost of 
conventional antibiotics (aminoglycosides cost $0.80/gram) (Marr 2006).  Thus, the 
development and testing of large numbers of peptide derivatives has been limited and 
has created new impetus to create large-scale peptide production platforms.  Recently, 
investigations of have focused on a variety of recombinant DNA methods (using 
bacterial, fungal, plant, and animal production systems) for the large-scale production of 
HDPs.  Novozyme Inc. has reported the large-scale production of plectasin, a natural 
fungal peptide, in a proprietary fungal expression system at the scale and purity 
necessary for therapeutic administrations (Mygind 2005).   In addition, reductions in 
HDP sizes and methods for increasing the systemic stability of HDPs (thus reducing 
dose quantities and frequency) are also being pursued (Hilpert 2005).   
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High-throughput screening methods for monitoring HDP activities are also being 
employed to reduce HDP development costs.  Recently, the Hancock laboratory has 
developed a novel system for the high-throughput generation of HDPs with improved 
activity which forms the basis for the HDP studies presented in this thesis.  Using this 
screen, the authors investigated the individual substitution of each residue within the 
synthetic HDP Bac2A with all of the 19 conventional amino acids.  This method 
provides the sensitivity needed to monitor general antimicrobial activities while 
employing low sample volumes.  
That host defense peptides are labile to endogenous protease enzymes limits their 
therapeutic potential.  That basic residues are an obligate feature of HDPs, endogenous 
trypsin-like enzymes represents a significant therapeutic impediment.  HDP are 
significantly sensitive to proteases with half-lives of minutes in vivo (Finlay 2004).  
Peptides that are resistant to proteases, while retaining the activities of the natural parent 
peptide, would offer a potential resolution to this problem.   
As potential alternatives, all D-amino acid peptides and retro-inverso peptides 
have been explored as potential HDP variants.  Ideally, these modifications decrease the 
lability of peptides to proteases while retaining the activities of the natural peptide.  
Investigations by Hamamoto et al. and Chen et al. have demonstrated that enantiomeric 
peptide derivatives retain the antimicrobial activity of the natural peptides, are 
completely resistant to protease treatment, are mirror-images in terms of secondary 
structures, and display negligible cytotoxicity (Hamamoto 2002, Chen 2006).  That the 
antimicrobial activity of HDPs is retained in the enantiomeric peptide derivative 
suggests that HDPs do not undergo a stereoselective interaction at the bacterial 
membrane.  Although all D-amino acid HDPs are intriguing for the design of 
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antimicrobial peptides they are of limited for applications involving the 
immunomodulatory activities of these peptides.  As the immunomodulatory activities of 
HDPs is linked to receptor-mediated activation of signaling pathways their interaction 
with chiral moieties is a requirement (Bowdish 2005a).  A unique modification has been  
proposed for peptides that would bestow protease resistance and maintenance of amino 
acid side chain topology: the retro-inverso modification. 
Retro-inverso (RI) peptides are directional isomers of the natural peptide (amino 
acid assembly in reversed order from that of the natural peptide) with inverted 
stereochemistry at all alpha carbon chiral centers (Figure 1.8) (Fischer 2003).  As such, 
the overall side-chain topology of the RI analogue is analogous to that of the natural 
peptide and might allow for the accommodation of the peptide derivative in a protein 
binding site.  Reversal of the peptide bond direction inverts the backbone amide bonds 
resulting in shifted hydrogen bond patterns from that of the parent peptide.  This has 
been speculated to account for the inability of RI derivatives to universally mimic native 
peptides (Howl  1999, Apletalina 2000, Beglova 2000, Sahu 2000, Warner 2001).  RI-
modification of peptide hormones has also been investigated and in general the 
modification is not well tolerated (Fischer 2003).  For example, investigations of RI-
modified osteogenic growth peptide, which promotes bone anabolism and 
haematopoieses, demonstrated that the RI-modified peptide lacked biological activity 
(Bab 2002).   In contrast, Snyder has demonstrated that that an RI derivative of p53 can 
restore endogenous p53 activity; the RI derivate induced apoptosis by activation of 
endogenous p53 and by restoration of function to several p53 DNA contact mutants 
(Snyder 2004).  RI-modified peptides have also been investigated as potential 
alternatives for natural protease-sensitive HDPs.  Notably, an investigation of an  
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Figure 1.8: Structure of Peptides and their Retroinversed Counterparts.  Retro-
inverso peptides present the same three dimensional structures with respect to side 
chains but have a reversal of the peptide bonds. 
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RI-derivative of indolicidin (RI-indolicidin) by Nagpal demonstrated that the RI- and 
natural-peptide had identical functional behaviors; antimicrobial activities and endotoxin 
binding properties of both peptides were identical (Nagpal 2002).  These results would 
argue that for some HDPs there is at least partial conservation of immunomodulatory  
activities upon retro-inversion, highlighting the potential of this modification in HDP 
development for therapeutic applications.   
   
 
 1.9.10 Bacterial Host Defense Peptide Resistance     
The ability of pathogenic microorganisms to survive host defense peptide 
exposure results from either constitutive (passive) resistance or inducible (adaptive) 
resistance.   
Constitutive resistance mechanisms, which bestow HDP resistance as a result of 
ubiquitous expression of resistance factors, have been demonstrated for a variety of 
bacterial species including Serratia sp., Proteus sp., and Providencia sp. (Yeaman 
2003).  These resistance mechanisms are predominantly due to alterations in structural 
features that decrease HDP attraction.  For example, Staphylococcus aureus has a unique 
cell membrane lipid composition with enrichment of unsaturated menaquinones and 
lysyl-phosphatidylglycerol, a less electronegative derivative of phosphatidylglycerol 
(Nahaie 1984).   Capsule production as a means of combating opsonization and 
phagocytosis has also been demonstrated in many virulent bacterial and fungal 
pathogens (Friedrich 1999).  It is speculated that capsule production confers HDP 
resistance as a result of the anionic nature of both the carbohydrate and phosphate 
moieties of the capsule (Friedrich 1999).  It has also been demonstrated that pathogens 
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may exploit physiological niches as a means of conferring HDP resistance.   For 
example, P. aeruginosa preferentially colonizes tissue with abnormal osmotic and ionic 
strengths that ablate the antimicrobial activity of the HDPs within the particular niche 
(Yeaman 2003).  As HDPs are an evolutionarily conserved defense molecule, it is not 
surprising that bacteria have also co-evolved resistance mechanisms. 
Conversely, inducible (adaptive) resistance refers to mechanisms that are 
induced in response to host defense peptides.  Central to inducible resistance 
mechanisms are the two-component sensory systems (TCS).  These systems induce 
diverse adaptive responses and provide pathogens with increased survival capabilities 
(Yount 2005).   The physiological relevance of such defensive modifications is 
demonstrated in isolates of P. aeruginosa from cystic fibrosis (CF) patients.  These 
isolates possess adaptive resistance responses such as Lipid A modifications and N4-
aminoarabinose modified Lipid A changes, which have been presumed to increase the 
stability of the outer membrane (Ernst 1999).  Structural changes such as these would be 
presumed to decrease the outer membrane permeation by HDPs.  For example, the pre-
exposure of wild-type Pseudomonas to sublethal concentrations of HDPs has been 
correlated with increased resistance to cationic HDPs.  It has been speculated that 
sublethal HDP concentrations would be reflective of HDP concentrations found within 
the lungs of CF patients (McPhee 2003).  Induction of HDP resistance in P. aeruginosa 
can be attained with multiple passage of the bacterium in sub-lethal concentrations of 
HDP (Zhang 2005).  However, it must be appreciated that HDP resistance was modest, 
with only a 2- to 4-fold increases (Nizet 2006).  Conversely, resistance to the 
aminoglycoside gentamicin under the same conditions induced resistance by 190-fold 
(Steinberg 1997).   
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Although rare, HDP resistance has been observed in nature in microbial species 
such as Staphylococci, Streptococci and Salmonellae (Peschel 2002, Ernst 2001, Nizet 
2005).  It has been demonstrated that such species possess genes related directly to HDP 
resistance (Weidenmaier 2003, Miller 2005).  That HDPs have remained as an integral 
component of the innate immune system questions the concerns regarding HDP 
resistance within bacteria.  Several peptides such as polymyxin B, gramicidin S, and 
nisin have been used in over-the-counter products without significant impact on the 
development of resistant strains.  Much of the success of HDPs in combating pathogens 
is due to the metabolic cost of constitutive resistance as mutations of the microbial 
structures targeted by HDPs are not well tolerated by microbes (Peschel 2006). 
Although HDP resistance has remained rare within microbes, it must be 
appreciated that the therapeutic administrations of these peptides may provoke resistance 
phenotypes.  Indeed, the introduction of antibiotics as novel microbial eradicators was 
met almost instantaneously with bacteria that had manifested various forms of resistance 
(Tenover 2006).   That noted bacteriologist and immunologist Sir Almroth Wright 
warned that the use of antibiotics would perpetuate the development of antibiotic 
resistance suggests that precautions should be taken to minimize similar resistance 
against HDPs. 
 
1.10 The PhoPQ Two-Component System of Salmonella 
 Two-component systems (TCS) are amongst the primary mechanisms by which 
microbes assess the surrounding environment (Bishop 2006).  These systems have been 
demonstrated to be integral for microbial virulence amongst a broad-range of bacteria, 
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including Salmonella, Pseudomonas, Shigella, Yersinia, and others (Groisman 2001).  
Typically, a TCS consists of a membrane-bound sensor histidine kinase and a 
cytoplasmic response regulator.  Upon stimulation by a specific environmental signal, 
the sensor kinase autophosphorylates from ATP at a conserved histidine kinase.  
Following this, the sensor kinase then phosphorylates the cytoplasmic response regulator 
on a conserved aspartic acid residue within the ‘receiver domain’.    
The PhoPQ two-component system, found across a wide-range of Gram-negative 
bacteria, has been identified as the master regulator of virulence within many pathogenic 
bacteria (Figure 1.9) (Groisman 2001).  The expression of more than 100 genes are 
governed by this system and  approximately 1% of the open reading frames encoded 
within the Salmonella genome are directly regulated by PhoP (Groisman 2006, 
Groisman 2001).  Although PhoPQ was initially identified as the primary controller of 
the expression of a non-specific acid phosphatase, hence the pho designation, the PhoPQ 
system has since been implicated in governance of virulence characteristics, adaptation  
to Mg2+-limiting conditions, and regulation of numerous cellular activities (Groisman 
2001).  The PhoPQ system regulates the expression of a plethora of genes indispensable 
for survival within the phagosome.  As a testament to the role of PhoPQ in Salmonella 
pathogenesis, the PhoPQ system is activated within the acidic environment of the 
phagosome (Alpache Arandra 1992).  It has been demonstrated that PhoP-activated 
genes are maximally expressed within this cellular compartment (Bader 2003). It has 
also been demonstrated that phoP- and phoQ-null mutants are attenuated for virulence 
(Miller 1989).  The PhoPQ system controls the expression of several genes required for 
microbial survival in Mg2+-limiting environments (Groisman 2001).  The survival of 
Salmonella within such environments requires the expression of Mg2+ transporters. This  
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Figure 1.9: The PhoPQ system of Salmonella.  Activation of the PhoPQ system within 
magnesium-limiting (micromolar concentrations) environments results in the induction 
of PhoP-regulated genes that are necessary for adaptation responses and microbial 
survival.  Adapted from Groisman 2001. 
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is controlled by the mgtA and mgtB genes (Groisman 2001).  Highlighting the 
importance of Mg2+ transporters for microbial survival, mgtA and mgtCB null mutants 
reach plateau phase growth earlier than their wild-type counterparts in low Mg2+ 
environments (Soncini 1996).  PhoPQ also promotes the expression of genes that 
promote cell envelope remodeling.  For example, the PhoP-regulated PagP is an outer 
membrane protein responsible for incorporation of palmitate into the lipid A moiety of 
LPS and is required for bacterial virulence (Groisman 2001).  pagP mutants exhibit 
hypersensitivity to the synthetic alpha-helical peptide C18G (Guo 1998).  PagL is also 
regulated by PhoPQ and is responsible for lipid A deacylation (Guo 1998).  In contrast, 
PgtE, an outer membrane protease directly regulated by PhoP, is not directly involved in 
outer membrane remodeling.  Rather, PgtE is involved in HDP inactivation by 
proteolytic cleavage (Sieprawska-Lupa 2004, Guina 2000).  PhoPQ is also involved in 
the repression of genes associated with invasion phenotypes.  The transcription of HilA, 
the primary regulator of the type III secretion apparatus and effector proteins, is 
repressed following activation of PhoPQ and represents a critical point of pathogen 
survival following invasion of host cells (Bajaj 1996).  The direct and indirect 
expression of several transcription factors required for virulence, including SsrB 
(Bijlsma 2005), SlyA (Norte 2003, Shi 2004), PmrA (Kox 2000), and RpoS (Groisman 
2006) are also regulated by PhoPQ.   
In addition, PhoPQ also controls other two-component regulatory systems at 
transcriptional, post-transcriptional and post-translational levels (Bishop 2006).  For 
example, the activation of the PhoPQ system induces transcription of pmrD.  PmrD 
regulates a second two-component system, PmrAB, by preservation of the 
phosphorylation state of the response regulator PmrA (Kato 2004).   The PmrAB-
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regulated ugd gene and the seven-gene operon pbgPE, a set of PhoP-regulated genes 
required for growth in low Mg2+ solid media, mediate the synthesis and incorporation of 
4-aminoarabinose in the lipid A portion of LPS leading to a net reduction in the negative 
charge found on the bacterial membrane (Gunn 1998).  It has also been recently 
demonstrated that PhoPQ also controls the expression of the TCS SsrBA, which 
regulates the transcription of the type III secretion system (Bijlsma 2005).   
The TCS signaling cascade relies on an environmental signal to activate the 
sensor histidine kinase.  In vitro analyses indicated that the PhoQ sensor kinase protein 
responded to the periplasmic levels of divalent cations such as Mg2+ and Ca2+ (Garcia 
Vescovi 1996).  As PhoPQ was demonstrated to be activated in vivo within acidified 
macrophage phagosomes, the general hypothesis was formed that phagosomal Mg2+ 
concentrations act as the primary environmental cue for the PhoPQ system.  It has been 
generally accepted that low (micromolar) Mg2+ concentrations induce the virulence-
associated phenotypic changes found following phagocytosis of bacteria by activation of 
PhoPQ whereas high (millimolar) Mg2+ concentrations are PhoPQ repressive (Garcia 
Vescovi 1996, Kato 1999, Soncini 1996).  This hypothesis has recently been challenged 
with the demonstration that in vivo divalent cation concentrations are of millimolar 
concentrations following acidification of the phagosome and would therefore be PhoPQ-
repressive (Alpuche Aranda 1992, Christensen 2002, Martin-Orozco 2006).  As such, 
the potential for host-derived biomolecules naturally found to co-localize with bacteria 
in the phagosome have been investigated as prospective PhoPQ ligands.   Recently, 
Bader has demonstrated that a central component of the innate immune system, host 
defense peptides, can activate PhoQ (Bader 2005) 
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1.11 PhoPQ and Host Defense Peptides 
As many of the phenotypic changes induced following PhoPQ activation involve 
host defense peptide resistance characteristics, it has been postulated that HDPs may 
serve as an endogenous ligand for PhoQ (Bader 2003).  Indeed, the exposure of S. 
typhimurium to sublethal concentrations of cationic antimicrobial peptides results in 
activation PhoPQ regulon and HDP resistance phenotypes (Bader 2003).   
Employing a novel PhoPQ reporter system, the exposure of Salmonella to varying 
concentrations of HDPs (under repressing Mg2+ concentrations) results in the direct 
activation of PhoQ  (Figure 1.10) (Bader 2005).  Supporting the role of HDPs as PhoQ 
ligands, the activation of PhoQ by HDPs was similar to that found during exposure to 
activating Mg2+ concentrations (Bader 2005).   HDP-mediated activation of PhoQ was 
also demonstrated to species-specific. A Salmonella mutant expressing a chimeric PhoQ 
in which the periplasmic domain of the sensor was replaced with that from P. 
aeruginosa failed to respond to antimicrobial peptides (Bader 2005).  The chimeric 
receptor demonstrated wild-type responsiveness to environmental Mg2+.  This suggests 
that the ability of HDPs to act as endogenous ligands may have evolved in species 
expected to encounter host defense peptides in their respective physiological niches 
(Bader 2005).  It was also postulated that an acidic periplasmic patch of the receptor 
represents the binding domain for HDPs.  Bader confirmed this region as the 
endogenous Mg2+ binding site by way of the crystal structure of the PhoQ periplasmic 
sensor domain, recapitulating the argument that this region also could act as a potential 
binding domain for antimicrobial peptides (Cho 2006).  The authors confirmed that 
HDPs could bind to this region of the sensor domain and displace Mg2+.  The authors 
hypothesize that Mg2+ serves to bridge the acidic periplasmic domain of PhoQ to the  
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Figure 1.10: Activation of Salmonella PhoPQ by HDPs.  Adapted from Hancock 
2005. A. In the presence of millimolar Mg2+ (blue circles) or other divalent cations (and 
the absence of HDPs), the divalent cations form a bridge between the negatively charged 
membrane outer leaflet and the anionic surface of the PhoQ binding domain. B. If 
micromolar concentrations of Mg2+ are encountered the PhoQ protein undergoes a 
conformational change resulting in increased kinase activity of its cytoplasmic domain. 
This results in PhoP phosphorylation and the modulation of transcription of the phoPQ 
operon. C. Host defense peptides enter the bacterial outer membrane and bind to the 
anionic patch of the PhoQ binding domain.  This results in Mg2+ displacement and thus 
the activation of PhoQ (as in B).  Adapted from Hancock 2005. 
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electronegative bacterial cell membrane.  As the divalent cations shield the repulsive 
forces between the receptor and the membrane, the displacement by HDPs would be 
predicted to result in a significant repulsive force between the two moieties.  Thus, it is 
postulated that this repulsion leads to a conformational change in PhoQ, resulting in 
activation (Cho 2006).  This hypothesis was corroborated by the authors through 
mutational analysis of the highly acidic region of the PhoQ periplasmic sensor domain.  
Although it has been demonstrated that PhoQ is directly activated by host 
defense peptides, this observation has been met with skepticism.  That these systems, 
and in particular PhoPQ, are found in both pathogenic and non-pathogenic bacterial 
species calls into question the applicability of such a host defense molecule acting as an 
environmental signal for activation.  It has been argued that commensal organisms that 
contain PhoPQ, such as Escherichia coli K-12, would not be found within tissues that 
harbor HDPs thus reducing the likelihood that such a ligand would be physiologically 
relevant in this situation (Groisman 2006).  It has also been demonstrated that although 
micromolar Mg2+ modulates the expression of the entire PhoP regulon, the antimicrobial 
peptide polymyxin B led to activation of only a subset of PhoP-regulated genes (Bader 
2003).  However, it has been argued that this is not unexpected as the pathogen would 
fine-tune the breadth of systems activated by PhoPQ depending on the stimulus, low 
cation concentration of HDPs (Bishop 2006). 
 That antimicrobial peptides do not target chiral moieties within the bacterial 
membrane has also questioned the ligand-potential of these host defense molecules.  
Indeed, the antimicrobial activity of HDPs appears to involve the direct perturbation of 
the bacterial cell membrane, a system that lack inherent chirality.  It has also been 
demonstrated that the D-enantiomers of antimicrobial peptides exert similar bactericidal 
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activities of their natural counterparts, as well as being active across highly divergent 
species, reducing the potential for such peptides to be involved in classic “receptor-
ligand” interactions (Chen 2006).  It should be mentioned, however, that the recent 
demonstration of a binding domain on the sensor kinase PhoQ rather than a highly 
specific binding site per se would argue that the specificity of classical receptor-ligand 
relationships is deviated in PhoQ; a binding domain would allow for a more dynamic 
relationship between the sensor kinase and a potential ligand (Cho 2006).   
 That convincing arguments both for and against the physiological relevance of 
host defense peptides as ligands for the PhoPQ system reiterates the need to investigate 
further the potential of HDPs to initiate bacterial defensive responses and potentially the 
development of strains resistant to a key component of the host innate immune system 
arsenal. 
 
1.12 Aims and Objectives 
The primary objective of this research is the analysis of sensory systems from 
prokaryotic and eukaryotic organisms that are critical to the host-pathogen responses of 
each organism.  From the perspective of the eukaryotic host, the Toll-like receptor 
system, and in particular TLR9, is examined as the biochemical characterization of the 
interaction between the receptor and ligand has remained inconclusive.  Sensory systems 
within prokaryotes, and specifically Salmonella typhimurium, are represented by the 
PhoPQ two-component sensory system.  As there has been a lack of consensus regarding 
the natural ligand of PhoPQ, host defense peptides have been recently demonstrated to 
activate PhoPQ (Bader 2003, Bader 2005).  A set of previously characterized HDP 
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derivatives will be examined for their ability to either activate or evade the PhoPQ 
system.  Retro-inverso modification of HDPs as a mechanism for increasing therapeutic 
stability will also be examined for the conservation of antimicrobial and 
immunomodulatory activities of the natural peptide.  
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2.0 Materials and Methods 
 
2.1 Chemicals and Enzymes 
Lists of all specialty enzymes and chemicals used in these experiments are 
provided in Table 2.1 and Table 2.2. 
 
2.2 Bacterial Strains 
Salmonella typhimurium is selected as the model pathogen because the majority 
of investigations of the PhoPQ two-component system, as well as the initial 
characterization of the ability of HDPs to serve as PhoQ ligands, have been performed in 
this bacterium. As both an enteric and intracellular pathogen, S. typhimurium is 
physiologically relevant for investigations of the host defense peptide bactenecin as the 
pathogen encounters bactenecin during the natural course of its infective cycle, in 
particular within neutrophil phagolysomes.   
The strains used in this study are: American Tissue Type Culture (ATCC) 14028, 
a smooth virulent strain of S. typhimurium, PhoQ- (strain CS009 phoQ101:: MudJ),  
PhoP- (strain  CS053 phoP103:: MudJ).  To study the host defense peptide-mediated 
induction of the PhoP regulon, a reporter strain of S. typhimurium was selected (strain 
CS120 phoN::TnPhoA) (Miller 1989). 
The bacterial strains used for the investigation of retro-inverso modified 
BMAP28 were Salmonella typhimurium ATCC14028, Escherichia coli O157:H7,
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Table 2.1: List of selected chemical supplies, enzymes, and proteins 
Chemicals Supplier 
Acetic Acid EMD 
Acrylamide Sigma 
Agarose, electrophoresis grade Invitrogen 
Aim V medium Gibco, Invitrogen Corp. 
Ammonium chloride J.T. Baker 
Ammonium persulfate J.T. Baker 
N,N-Bis(2-hydroxyethyl)-glycine Sigma 
Boric acid EMD 
5-Bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) 
Eppendorf 
Bromophenol Blue Sigma 
5-bromo-4-chloro-3-indolyl phosphate 
(BCIP) 
Sigma 
Chloroform:isoamyl alcohol Amersham Biosciences 
Coomassie-Brilliant Blue R250 Biorad 
Dithiothreitol (DTT) Biorad 
Ethidium bromide Parmacia Biotech 
Ethylenediamine tetraacetic acid (EDTA) Fluka BioChemika 
Ferrous Sulfate J.T. Baker 
Fetal Bovine Serum (FBS) Gibco 
Glycerol Amersham Bioscience 
Glycine ICN Biomedicals 
Isopropyl β-D-thiogalactopyranoside Promega 
Magnesium Chloride Sigma 
2-mercaptoethanol Sigma 
Methanol EMD 
N,N’-Methylene-bis-acrylamide ICN Biomedicals 
p-nitro-blue-tetrazolium (NBT) Sigma 
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p-nitro-phenol Sigma 
Percoll Amersham Biosciences 
Phenol (glass distilled) Sigma 
Potassium chloride Sigma 
Potassium phosphate monobasic EMD 
Potassium phosphate dibasic EMD 
Sodium acetate Sigma 
Sodium chloride Sigma 
Sodium dodecyl sulfate EMD 
Sodium hydroxide EMD 
Sodium phosphate monobasic EMD 
Sodium phosphate dibasic EMD 
N,N,N’,N’-Tetramethylethlene-diamine 
(TEMED) 
Pharmacia Biotech 
2,2,2-Trifluoroethanol (TFE) J.T. Baker 
Tris-[hydroxymethyl]aminomethane (ultra 
pure) 
Biorad 
Tween 20 Biorad 
Xylene cyanol Sigma 
  
Radio Chemicals Suppliers 
[γ-
32
P] deoxycytosine 5’-triphosphate Mandel 
H
3
-thymidine Amersham Pharmacia 
  
Chromatographic Supplies Suppliers 
Ni-NTA Superflow Resin Novagen 
  
Microbiological Supplies Suppliers 
Agar BD Biosciences 
Bacto-agar BD Biosciences 
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Bacto-tryptone BD Biosciences 
Bacto-yeast extract BD Biosciences 
Enzymes/Proteins Suppliers 
Bovine Serum Albumin (BSA) Sigma 
T4 DNA ligase Novagen 
Pfu DNA polymerase Stratagene 
Taq DNA polymerase New England Biolabs 
Klenow fragment Promega 
PNGase F New England Biolabs 
RNaseH New England Biolabs 
Bovine TNF-α Genetech Inc. 
Human TNF-α eBioscience 
Trypsin Boehringer Ingelheim 
Antibiotics Suppliers 
Ampicillin Shelton Scientific 
Chloramphenicol Boehringer Ingelheim 
Kanamycin Calbiochem 
  
Antibodies Supplier 
α-TLR9 mouse mAB EMD  
Goat-α-mouse IgG Kirkegarrd & Perry Laboratories 
 
Supplier Addresses 
Amersham Pharmacia Amersham Biosciences, Pittsburgh, PA, 
USA. 
BD Bioscience BD Bioscience, Mississauga, ON, Canada. 
Biorad Bio-Rad Laboratories Ltd., Mississauga, 
ON, Canada 
Boehringer Mannheim Boehringer Ingelheim Ltd., Laval, QC, 
Canada. 
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Calbiochem VWR Canlab, Mississauga, ON, Canada. 
eBioscience eBiosciences, San Jose, CA, USA. 
EMD Bioscience VWR Canlab, Mississauga, ON, Canada. 
Eppendorf Eppendorf Canada Ltd., Mississauga, ON, 
Canada. 
Fisher Fisher Scientific, Ltd., Nepean, ON, 
Canada. 
Fluka BioChemika Sigma-Aldrich Canada Ltd., Oakville, ON, 
Canada. 
Genetech Inc. Genetech, Inc., San Francisco, CA, USA. 
Gibco Invitrogen Ltd., Gaithersburg, MD, USA. 
ICN Biomedicals ICN Biomedical Canada Ltd., Saint 
Laurent, PQ, Canada. 
Invitrogen Invitrogen Canada, Inc., Burlington, ON, 
Canada. 
J.T. Baker Mallinckrodt Baker, Inc., Phillipsburg, NJ, 
USA.  
Kirkegarrd & Perry Laboratories, Inc. KPL, Inc., Gaithersburg, MD, USA. 
Mandel Mandel Scientific Co., Inc., Guelph, ON, 
Canada. 
New England Biolabs NEB Ltd., Pickering, ON, Canada. 
Novagen VWR Canlab, Mississauga, ON, Canada. 
Pharmacia Biotech Pfizer Canada, Inc., Mississauga, ON, 
Canada. 
Promega Fisher Scientific, Ltd., Nepean, ON, 
Canada. 
Qiagen Qiagen, Inc., Mississauga, ON, Canada. 
Shelton Scientific VWR Canlab, Mississauga, ON, Canada. 
Sigma Sigma-Aldrich Canada Ltd., Oakville, ON, 
Canada. 
Stratagene VWR Canlab, Mississauga, ON, Canada. 
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 Serratia marcescens ATCC 274, Yersinia enterocolitica O:9 E40 (pYV40), 
Pseudomonas cepacia ATCC 53795, and Salmonella enteritidis 27655R PT4. 
2.3 Plasmid Vectors: 
 Plasmid pFLAG-CMV2 (CMV) was purchased from Sigma and pET15b was 
purchased from Novagen.  Plasmid pBBRMCS1-4 was kindly provided by Dr. Kenneth 
M. Peterson, Louisiana State University. 
 
2.4 Bacterial Growth Media 
 Media was prepared as described by Miller (Miller 1972) for Luria broth (LB) 
and Maniatis (Maniatis 1989) for M9 minimal media.  All media was autoclaved 
following preparation at 125°C and 18 psi for 20 min.  Liquid Luria broth (LB) media 
was prepared with 10 g of Bacto tryptone, 10 g NaCl, and 5 g of yeast extract in one liter 
of distilled water.   Salt-free LB media was made as above with the exception that NaCl 
was not added.  M9-minimal media was prepared as follows:  12.8 g of Na2HPO4, 3.0 g 
of KH2PO4 and 1.0 g of NH4Cl were combined in 950 ml of distilled water.  The pH of 
the solution was adjusted to 7.4 with NaOH and the media was autoclaved for 20 min at 
125°C and 18 psi.  Following cooling, the following were dissolved in 50 mL of distilled 
water and cold filtered into the media: 2.0 g glucose, 0.01 g Thiamine, and 0.01 g 
FeSO4-7H2O. 
 
2.5 Hazardous Materials 
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2.5.1 Ethidium Bromide 
 Ethidium bromide (EtBr) is a potent mutagen following inhalation, swallowing,  
or upon contact with skin.  Latex gloves were used in all cases to ensure that no contact 
with open skin could occur.  Where EtBr was used in agarose gels, EtBr (10 mg/mL) 
was added prior to polymerizing of the agarose and gels were disposed of in a 
designated EtBr waste container (Quillardet 1988).  
 
2.5.2 Phenol 
 Phenol is toxic upon inhalation, swallowing, or contact with exposed skin.  
Phenol was always used in well-ventilated areas and contact minimized by use of latex 
gloves.  All samples containing phenol were collected and discarded as chemical waste. 
 
2.5.3 Chloroform 
 Chloroform is toxic upon inhalation and may result in kidney and/or liver 
damage.  All work utilizing chloroform was conducted in a fumehood and contact with 
skin was minimized by use of latex gloves.  Samples containing chloroform were 
collected and treated as chemical waste. 
 
2.5.4 Acrylamide 
 In the unpolymerized form, acrylamide is a potent neurotoxin and potential 
carcinogen upon inhalation, swallowing, or contact with exposed skin.  Acrylamide 
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solutions (40%) were prepared by dissolving 38.0 g of acrylamide and 2.0 g of bis-
acrylamide in 100 mL of deionized water with vigorous mixing and heating.  
Preparation of acrylamide solution was conducted in a well ventilated area with a facial 
filtering mask and latex gloves.  All acrylamide solutions were polymerized prior to 
disposal as regular waste. 
 
2.6 SDS-PAGE Analysis 
 SDS-PAGE gels were prepared using the Laemmli method (Laemmli 1970), and 
run using a discontinuous buffer system as described by Sambrook (Sambrook 1989).   
Following electrophoresis, gels were stained for 1 hour in Coomassie Brilliant Blue 
(45% methanol, 10% glacial acetic acid, 0.25% w/v Coomassie Brilliant Blue R250) and 
destained in destaining solution (7.5% methanol, 10% glacial acetic acid) overnight.  
 
2.7 ‘Mini-prep’ Isolation of Plasmid DNA 
 DNA plasmid isolation was performed through the mini-prep procedure as 
previously described (Birnboim 1979, Maniatis 1982).  E. coli tuner DE3 pLysS cells 
transformed with the appropriate plasmid were grown overnight at 37°C with constant 
shaking in LB media supplemented with ampicillin (50 μg/mL) and chloramphenicol (34 
μg/mL).  Cells were isolated from the cultured media by centrifugation (14,000 x g for 
10 min) of a 1.5 mL aliquot in a microfuge tube.  The supernatant was removed by 
suction and the pellet was resuspended in 100 μl of Solution I (50 mM glucose, 25 mM 
Tris-HCl buffer pH 8.0 and 10 mM EDTA) and placed on ice for 1 minute followed by 
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addition of 200 μl freshly prepared Solution II (0.2 N NaOH, 1% SDS).  The mirofuge 
tube was then gently swirled by hand and stored on ice for 5 min followed by the 
addition of 150 μl of Solution III (5 M sodium acetate, pH 5.2) and subsequent vigorous 
vortexing.  The tube was then incubated on ice for 5 min followed by centrifugation for 
5 min at 12,000 x g and subsequent transfer of the resultant supernatant to a fresh 
microfuge tube.  Equal parts (250 μL) of phenol and chloroform:isoamyl alcohol (1:24) 
were added and the solution was mixed by inversion and centrifuged for 2 min a 14,000 
x g.  The upper aqueous layer was transferred to a new Eppendorf tube and the plasmid 
DNA was precipitated with the addition of 2 volumes (1 mL) of cold 95% ethanol, 
followed by an incubation of ice for at least 10 min and subsequent centrifugation for 15 
min at 14,000 x g at 4°C.  The supernatant was gently removed with care to not disrupt 
the pellet, and the pellet was then washed with cold 70% ethanol and centrifuged at 
14,000 x g for 15 min at 4°C.  The supernatant was again removed gently and the pellet 
was air dried.  Finally, the dried pellet was resuspended in 30 μL of TE buffer (10 mM 
Tris-HCl buffer pH 7.5, 1 mM EDTA) with 1 μl of RNase (10 mg/mL solution, boiled 
for 10 min) and stored at -20 C.   
 
2.8     In vitro and in vivo Analysis of the Interactions of Single-Stranded ODNs and 
Double-Stranded DNA Plasmids with TLR9 
 
2.8.1 Cloning of TLR9 
With some species-specific variations, TLR9 is a protein of approximately 1030 
amino acids; the N-terminal 750 residues contain 25 LRR motifs, residues 750-810 an 
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extracellular C-terminal motif, residues 810-825 represent the transmembrane region 
and residues 825-1030 the intracellular TIR domain.  The entire ectodomain, residues 1-
815, were selected to represent the TLR9 ligand-binding domain, TLR9(LBD), as the 
specific ligand-binding region of the receptor has not yet been identified.  
For expression of the TLR9(LBD) protein, a eukaryotic expression system 
employing the bovine hsp70A gene promoter was utilized.  This system directs the heat-
regulated synthesis of proteins in transfected bovine kidney epithelial cells and has 
proven highly effective for the overexpression of other glycosylated proteins (Kowalski 
1993).  
DNA for the TLR9 ectodomain was PCR amplified, with the addition of a six 
residue histidine tag at the carboxy-terminus, using a plasmid containing the human 
TLR9 ORF as a template (kindly provided by Grayson Lipford). The resulting PCR 
product was cloned downstream of a bovine hsp70A gene promoter and the expression 
cassette was stably introduced into MBDK cells by Lentiviral delivery (Rouas 2002).  
 
2.8.2 TLR9 Overexpression 
The eukaryotic expression system utilized in this analysis results in the secretion 
of recombinant proteins into the culture media, greatly facilitating subsequent 
purification steps and represents an inherent advantage of this system.  Due to the non-
destructive cyclic nature of this expression system, cultures could be split during 
ongoing heat-shock cycling yielding relatively low quantities of protein (approximately 
10 μg of protein per liter of culture media).  The large-scale production of protein due to 
the ongoing cycling steps allow for sufficient quantities of protein to be generated.  
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Sufficient quantities of the protein could be produced from 10 rounds of temperature 
shifting, six hours at 39°C followed by 18 hours at 37°C, of forty T150 flasks. The 
secreted protein was further purified using commercially available Nickel-columns 
(Novagen). Purified TLR9(LBD) was dialyzed against 20 mM phosphate buffered saline 
(pH 7.2), 100 mM NaCl, 0.5 mM β-mercaptoethanol.  
 
2.8.3 Deglycosylation of TLR9(LBD) 
Purified TLR9(LBD) was treated with peptide N-glycosidase F (PNGase F) as 
follows: 20 μg of TLR9(LBD) was denatured in 5% SDS and 0.4 M DTT for 10 minutes 
at 100 °C.  Following this, reaction buffer (0.5 M sodium phosphate, pH 7.5) and 10% 
NP-40 were added at 1/10 reaction volume with 500 units of PNGase F. The 
deglycosylation was allowed to proceed at 37 °C for 1 hour.  
 
2.8.4 Agarose Electrophoretic Mobility Shift Assays  
Unless otherwise specified, DNA binding assays were performed with the 
incubation of 8 μg of TLR9(LBD) [20 mM phosphate buffered saline (pH 7.2), 100 mM 
NaCl, 0.5 mM β-mercaptoethanol] with 1.4 μg of DNA (pFLAG-CMV-2 expression 
vector (Sigma)) in the presence of 10 mM MgCl2. Reactions were buffered with 100 
mM Na acetate (pH 5.2) unless otherwise specified. The final volume of each reaction 
was 50 μL. Reactions were incubated at 37°C for 10 min and stopped with the addition 
of 10 μL agarose loading solution (30% glycerol) and immediately electrophoresed 
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through a 0.8% agarose gel at 95 V for 1 hour. DNA visualization was through ethidium 
bromide staining.  
2.8.5 Agarose Electrophoretic Supershift Assays  
Supershift assays were performed by the same methodology as described for the 
mobility shift assays with the exceptions that the TLR9(LBD) was dialyzed against (50 
mM phosphate buffered saline (pH 7.2), 100 mM NaCl) and the reactions were 
performed at pH 7.2 (50 mM Tris). The TLR9 monoclonal antibody was purchased from 
Oncogene Research Products. The reaction mixture was incubated for 1 hour at 37°C 
prior to electrophoresis.  
 
2.8.6 Freeze-Squeeze Method for Protein Extraction from Agarose 
Following agarose electrophoresis, bands corresponding to the nucleoprotein 
complexes were excised and placed in microfuge tubes.  The tubes were frozen at -80°C 
overnight.  Samples were thawed at room temperature and centrifuged at 14,000 rpm for 
10 minutes.  The supernatant was extracted for further analysis.   
 
2.8.7 Western Blot Analysis 
Proteins were resolved through a 7.5% SDS-PAGE gel. Following 
electrophoresis, the proteins were transblotted onto polyvinylidene difluoride 
membranes (PolyScreen; Perkin Elmer Life Sciences) for 1 hour at 0.3 Amps. 
Membranes were blocked with 3% BSA in TBST (20 mM Tris pH 7.6, 0.14 M NaCl., 
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0.02% (v/v) Tween 20) for 1 hour at room temperature and then exposed overnight to 
the primary antibody at 4°C.  Following the primary incubation, membranes were rinsed 
in TBST and incubated with the secondary antibody for 1 hour at room temperature in 
TBST with 3% molecular grade fat-free skim milk powder. Membranes were 
subsequently washed with TBST and developed in AP buffer (100 mM Tris pH 9.5, 100 
mM NaCl, 50 mM MgCl2) supplemented with 15mg/ml 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) and 30 mg/ml p-nitro-blue-tetrazolium (NBT).  The monoclonal 
antibody to human TLR9 (Oncogene Research Products (EMD Biosciences)), α−hTLR9 
was used at a dilution of at 4 μL/mL. The secondary antibody [goat-α−mouse IgG (H+L) 
(Kirkegarrd & Perry Laboratories, Inc.)] was used at 0.5 μL/mL to probe for TLR9-
antibody complexes.  
 
2.8.8 Acrylamide Electrophoretic Mobility Shift Assays  
ODNs were labeled with 
32
P using [γ-
32
P]-dCTP (3000 Ci/mmole) and Klenow 
fragment of DNA polymerase I as follows: 2 μl of 10x Klenow fragment of DNA 
polymerase I buffer (500 mM Tris–HCl (pH 8.0), 50 mM MgCl
2 
and 10 mM DTT), 2 μl 
of 20 μM duplexes (mouse and human CpG motif sense ODNs and the respective 
antisense ODNs) were annealed before use in equimolar amounts and 16 μl of H
2
O were 
added to 120 μCi [γ-
32
P]-dCTP. After 15 min at room temperature, 1 μl of 10 U/μl 
Klenow fragment of DNA polymerase I (Promega) was added. After 15 min, 2 μl of 100 
mM dNTP was added, and after 15 min incubation, the reactions were stopped with 1.5 
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μl of 0.5 M EDTA. The reaction mixtures were purified by MicroSpin G-25 columns 
(Amersham Pharmacia Biotech) to remove free [γ-
32
P]-dCTP. 
Binding reactions containing 0.2 ng of double-stranded labeled probe, 8 μg 
TLR9(LBD), 10 mM Tris (pH 7.8), 50 mM NaCl, 1 mM EDTA, 0.5 mM DTT and 5% 
glycerol were incubated at 37°C for 20 minutes.  Non-denaturing polyacrylamide gels 
(5%) containing 8.9 mM Tris (pH 8.0), 8.9 mM Boric Acid, 1 mM EDTA were pre-run 
at 5 v/cm for 30 minutes at 20°C prior to loading of the binding reactions.  Samples were 
loaded onto acrylamide gels with the addition of 5 μl non-denaturing loading dye (50% 
v/v glycerol, 0.005% w/v bromophenol blue, 0.005% xylene cyanol) and 
electrophoresed for 2 hours at 10 V/cm.  Gels were dried for 1 hour at 80 °C and 
exposed to a Kodak Storage Phosphor screen GP.  Storage Phosphor Screens were 
scanned with a Bio-Rad Molecular Imager FX using Bio-Rad Quantity One Software.  
 
2.8.9 Cell Proliferation Assays 
The isolation and culture of bovine peripheral blood mononuclear cells (PBMC) 
was as previously described (Mena 2003).  Briefly, PBMC were isolated from 3, mature 
(> one year old), male and female cattle.  Lymphocyte proliferative responses for each 
animal were assayed by stimulating triplicate cultures (2 X 10
5 
cells/well) in a U-bottom 
96-well culture plate. Cells were cultured for 72 h at 37°C in a humidified atmosphere of 
5% CO2 and 0.4 μCi of H
3
-thymidine (Amersham Pharmacia, Piscataway, NJ) was 
added to each well.  Cells were harvested using standard liquid scintillation protocols 
and the incorporation of H
3 
was measured using a beta-counter (Topcount, Packard 
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Instrument Company, Meriden, CT).  The lymphocyte proliferative response was 
calculated as the mean counts per minute for the triplicate cultures.  
 
2.8.10 Oligodeoxynucleotides 
The sequences of the ODNs used in this investigation are presented in Table 2.2.  
The PTO versions of the 2007 ODNs consist exclusively of phosphothioate linkages. 
PD-ODNs were purchased from Invitrogen and PTO-ODNs were kindly provided by 
Qiagen.  
 
 
 
Table 2.2: Oligodeoxynucleotides Used in this Investigation. 
 
ODN Name Sequence 
 
 
Human CpG GGATCAGCGGAGGTCGTTTTGTCGTTCTCTGTC 
Human GpC GGATCGACAGAGAACGACAAAACGACCTCCGCT 
Mouse  CpG GGATCAGCGGAGGACGTTCTGACGTTCTCTGTC 
Mouse  GpC GGATCGACAGAGAACGTCAGAACGTCCTCCGCT 
2007 CpG TCGTCGTTGTCGTTTTGTCGTT 
2007 GpC TGCTGCTTGTGCTTTTGTGCTT 
 
2.9  Investigation of HDPs for Antimicrobial Activity and Bacterial Defensive 
Response Stimulation in Salmonella typhimurium 
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2.9.1 Cloning and Expression of PhoPQ from S. typhimurium 
Plasmid pBBR1MCS-4-phoPQ was constructed through PCR amplification of 
the chromosomal phoPQ operon, including promoter region, from wild-type S. 
typhimurium with primers A AAAGTCGGGCCAGTTAAG and B 
CGCCGGCAAATTATATCG using S. typhimurium chromosomal DNA as template. 
The resulting PCR product was cloned directly into the EcoRV site of pBBR1MCS-4 to 
generate plasmid pBBR1MCS-4-phoPQ (Kovach 1995).   
 
2.9.2 Functional Reconstitution of PhoP- and PhoQ-  
The vector containing the Salmonella PhoPQ operon, pBBR1MCS-4-PhoPQ, 
was transformed into Salmonella PhoP- and PhoQ- strains to the creation of PhoPrecon 
and PhoQrecon, respectively. 
2.9.3 Host Defense Peptide Selection 
The HDP bactenecin, also known as bovine dodecapeptide, is a small 
cathelicidin discovered in bovine neutrophils (Romeo 1988).  At twelve amino acids in 
length, bactenecin is one of the smallest active HDPs.  Its small size and extensive 
characterization make it an ideal model peptide for examination of the consequences of 
amino acid substitutions on antimicrobial efficiency.  While the natural peptide is 
stabilized by an internal disulfide bridge, a linear variant, Bac2A, (RLARIVVIRVAR-
NH2), shows a similar activity against Gram-negative bacteria and higher activity 
against Gram-positive bacteria (Wu 1999). Others have reported on the antimicrobial 
properties of a complete substitution library of Bac2A against P. aeruginosa, as well as 
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a partial screen against S. typhimurium (Hilpert 2005).  A series of Bac2A derivatives 
was selected based on the reported antimicrobial efficiencies against Salmonella, which 
have improved, maintained or compromised antimicrobial activity as a consequence of 
the sequence manipulation. The nomenclature of the peptide derivatives is maintained 
from the original publication (Hilpert 2005). A negative control (NC) peptide of 
unrelated sequence, GATPEDLNQKLS-NH2, is also included (Hilpert 2005).  
 
2.9.4 Peptide Synthesis
Peptides were chemically synthesized by Chemistry Services at VIDO on a 
Pioneer solid-phase peptide synthesizer (PerSeptive Biosystems, Foster City, CA) using 
Fmoc (9-fluorenylmethoxy carbonyl) chemistry.  The peptide chains were synthesized 
from the carboxyl terminus to the amino terminus onto [5-(4-Fmoc-aminomethyl-3,5-
dimethyloxyphenoxy) valeric acid]-polyethylene glycol-polystyrene (PAL-PEG-PS) 
resin.  Both Fmoc-protecting groups at the amino terminus were deprotected with 
piperidine.  The peptides were cleaved from the resin with concurrent deprotection of the 
side chain-protecting groups by treating the resin-bound peptide with trifluoroacetic acid 
(TFA) (9.3 parts) in the presence of scavengers (anisole-ethyl-methyl sulfide-1,2-
ethanedithiol [3:3:1]), for 7 h.  The crude peptides were filtered from the resin, and the 
TFA was evaporated.  Diethyl ether was added to the residues to precipitate the crude 
peptide.  The peptides were isolated and purified by high-performance liquid 
chromatography (HPLC) on Vydac protein C4 columns (1.0 by 25 cm) eluting with a 
linear gradient of 35% buffer A (H2O-0.1% TFA)-90% buffer B (acetonitrile-H2O 
[90/10]-0.01% TFA) for 40 min at a flow rate of 3 ml/minute.  The purity and molecular 
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weight of the respective peptides were confirmed by matrix-assisted laser desorption 
ionization (MALDI)-time of flight mass spectrometry on a PE Biosystems Voyager 
system 4068 (National Research Council, Plant Biotechnology Institute, Saskatoon, 
Canada) and by amino acid analysis. 
 
2.9.5 Determination of Minimal Inhibitory Concentrations (MIC) 
The minimum inhibitory concentrations (MICs) of the peptides were determined 
using a modified broth micro-dilution method (Wu 1999).  Briefly, overnight cultures of 
bacteria were diluted to a concentration of 5 X 105 bacteria per mL in salt-free LB 
medium.  Assays were performed in sterile 96-well, round-bottom polypropylene 
microtitre plates with a 45ul aliquot of the appropriate bacterial strain in the presence of 
varying concentrations of the HDP (15ul of peptide in each well).  Peptide stocks were 
made in dH2O at a concentration of 2 mg/mL and stored at -20°C.  Appropriate dilutions 
of the peptides were made fresh prior to each MIC trial in 0.2% BSA, 0.01% acetic acid 
as previously described (Wu 1999) and added to the culture following addition of the 
bacterial inoculum in the appropriate microtiter plate well position.  The plates were 
incubated at 37°C for 16 h, and well solutions spotted onto LB-agar plates.  The MIC 
was taken as the concentration at which no growth was observed.  Each MIC assay was 
performed in triplicate from three different bacterial growths.  The MICs reported 
represent the averages of these results. 
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2.9.6 Activation of Adaptive Responses by Low Magnesium and Host 
  Defense Peptides 
The extent to which host defense peptides can activate adaptive responses, as 
determined by increased MIC values, was determined through a modification of the 
standard MIC assays. Bacterial cultures were pre-incubated in a 96 well plate for 4 h in 
the presence of increasing sub-lethal concentrations of the HDP under investigation (1 
µg/ml of HDP administered at time 0, 1 µg/ml addition at 1 h, 2 µg/ml addition at 2 h, 
and a final addition of 4 µg/ml at 3 h). Following this adaptation period, bacteria were 
examined through standard MIC assays to quantify shifts in HDP susceptibility. For 
induction of adaptive responses by low magnesium conditions, bacteria were grown 
overnight in N-minimal media with the inclusion of either 10 μM or 10 mM MgCl2. 
 
2.9.7 PhoPQ Reporter Assays 
S. typhimurium strain CS120 (kindly provided by Dr. Samuel I. Miller, 
University of Washington), expressing a PhoP-regulated fusion between PhoP-
dependent acid phosphatase (PhoN) and E. coli alkaline phosphatase (PhoA), was 
utilized for analysis of PhoPQ activation. The activity of this fusion protein was 
measured in growth media containing varying concentrations of the peptides and/or 
magnesium. The assay conditions utilized are based on previously described protocols 
(Brickman 1975). 
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2.9.8 Alkaline Phosphatase Reactions 
For quantification of alkaline phosphatase induction, S. typhimurium strain 
CS120 was incubated with the appropriate peptide derivative or magnesium for 3 h at 
the varying concentrations in Mg2+-free N-minimal media.  Following the incubations, 
250 μl of culture from each sample was brought to 2.4 ml with 50 mM Tris buffer (50 
mM Tris-HCl, pH 8.0, 1 mM MgCl2) and incubated for 3 min at 37°C.  0.1 ml of 0.5% 
(w/v) p-Nitrophenyl-Phosphate (NPP) was added to each tube and incubated at 37°C.  
The reactions were monitored for a change in color and stopped by addition of 0.5 ml of 
1 M Potassium Phosphate buffer (pH 8.0).  The absorbance of each sample was 
measured at 410 nm. 
 
2.9.9 Proteolytic Digests of BMAP28 and RI-BMAP28  
Both the natural BMAP-28 and RI-BMAP-28 (1 mg/mL) were digested with 
trypsin (0.1 mg/ml) in a 50 μL reaction volume (50 mM Tris pH 7.2) at 37°C for a series 
of time points.  For peptide proteolysis characterization, the peptides were isolated by 
high-performance liquid chromatography (HPLC) for comparison of peak areas relative 
to an undigested standard on Vydac protein C4 columns (1.0 by 25 cm) eluting with a 
linear gradient of 35% buffer A (H2O-0.1% TFA)-90% buffer B (acetonitrile-H2O 
[90/10]-0.01% TFA) for 30 min at a flow rate of 1 ml/minute. 
 
 105
2.9.10 Measurement of Hemolytic Activity (MHC) 
Peptide samples were added to 1% bovine erythrocytes in phosphate-buffered 
saline and reactions were incubated at 37°C for 18 h in microtiter plates.  Appropriate 
dilutions of the peptides were made fresh prior to each MHC trial in HDP dilution buffer 
(0.2% BSA, 0.01% acetic acid) and added following addition of the erythrocytes in the 
appropriate microtiter plate well position.  Hemolysis was determined by withdrawing 
aliquots from the hemolysis assays, removing unlysed erythrocytes by centrifugation 
(800 x g) and determining which peptide concentrations cause hemoglobin release.  
Hemoglobin release was determined spectrophotometrically at 570 nm.  1% erythrocytes 
with no added peptide served as a non-lysis control.  As erythrocytes were incubated in 
an isotonic medium, no detectable release (<1% of that released upon complete 
hemolysis) of hemoglobin was observed from this control during the course of the assay.  
1% erethrocytes were also incubated with the peptide dilution buffer and no detectable 
release of hemoglobin was observed during the course of the assay. 
 
2.9.11 Characterization of Secondary Structure 
The mean residue molar ellipticities of peptides were determined by CD 
spectroscopy, using a Jasco J-720 spectropolarimeter (Jasco, Easton, MD), at 5°C under 
non-denaturing conditions (50 mM KH2PO4/K2HPO4, 100 mM KCl, pH 7), as well as in 
the presence of an -helix inducing agent, 2,2,2-trifluoroethanol (TFE) (50 mM 
KH2PO4/K2HPO4, 100 mM KCl, pH 7 buffer, 50% TFE).  Peptides were diluted 10-fold 
from a 500 µM stock solution and loaded into a 0.02-cm fused silica cell.  Ellipticity was 
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determined by scanning from 190 to 250 nm.  Deconvolution of the CD spectra data was 
carried out using the program CD Spectra Deconvolution Version 2.1. 
 
2.9.12 Capture ELISAs 
Untreated peripheral blood mononuclear cells (PBMCs) or PBMCs treated with 
LPS in the presence or absence of the HDPs were centrifuged at 1000 g for 5 min 
followed by 10,000 g for 10 min to obtain cell-free tissue culture supernatant samples. 
The supernatants were subsequently aliquoted and stored at -20 C until further use. 
TNF-α secretion was monitored with a species-specific capture ELISA.  All assays were 
performed in triplicate. The concentration of the cytokine was quantified by establishing 
a standard curve with serial dilutions of the recombinant human TNF-α (eBioscience, 
San Diego, CA) or bovine TNF-α (Genetech Inc. San Francisco, CA).
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3.0 Results 
 
3.1 Analysis of the TLR9-Ligand Interaction in vitro and in vivo 
 
3.1.1 Expression of TLR9(LBD)  
Central to the biochemical characterization presented here is the requirement for 
substantial quantities of TLR9 with conservation of the normal post-translational 
modifications (PTMs) found on the endogenous receptor.  To provide for PTM patterns 
similar to those found within the host, a eukaryotic expression system was employed.  
Utilizing the bovine hsp70A gene promoter, this expression system directs the heat-
shock regulated synthesis of proteins in transfected bovine kidney epithelial cells.  This 
system has proven effective for production of other soluble glycosylated proteins 
(Kowalski 1993).  Although protein yields per cycle are low, the system is robust and 
the cells can be cycled through multiple heat shock steps to attain the quantity of protein 
desired.  An added feature of the heat-shock expression system is that expressed proteins 
are secreted into the surrounding media.  Thus, the need for cell lysis steps following 
protein expression is circumvented.  
The primarye objective of the eukaryotic expression system was to obtain 
sufficient quantities of the recombinant receptor for the biochemical characterization of 
TLR9 ligand binding.  The characterization of TLR9 ligand binding would
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employ mobility shift assays and, providing verification of the presence of the receptor, 
is not dependent on absolute purification of the receptor. As the ectodomain of the TLRs 
is responsible for ligand binding, expression of the TLR9 ligand binding domain, 
TLR9(LBD), would be adequate for this investigation.  Following TLR9(LBD) 
expression, western blot analysis with a human TLR9 ectodomain monoclonal antibody 
confirmed a single protein species with a mass consistent with previous reports for the 
glycosylated TLR9 (Latz 2004).  Untransfected control cells were devoid of any 
reactivity towards the monoclonal TLR9 antibody (Figure 3.1a).  
To confirm that the TLR9(LBD) was glycosylated, the receptor was treated with 
the deglycosylase PNGase F, which catalyzes the removal of both N- and O-linked 
glycosylations.  Western blot analysis with the human TLR9 monoclonal antibody 
confirmed a protein species of approximately 100 kDa, consistent with the predicted 
mass of the non-glycosylated polypeptide and with previous observations monitoring 
TLR9 deglycosylation (Latz 2004) (Figure 3.1B).  
 
3.1.2 TLR9(LBD) Retains DNA Binding Capabilities   
That the natural ligand for TLR9 is unmethylated CpG motifs suggests that the 
receptor may recognize these microbial signatures within different configurations of 
DNA.  Indeed, plasmid DNA initiates innate immune responses (Krieg 1995), and the 
endosomal stability of plasmids allows them to serve as TLR ligands (Bennett 1985).  
These observations are suggestive of a physiological interaction between TLR9 and 
plasmids.  SPR analyses by Cornelie (Cornelie 2004) and Rutz (Rutz 2004) lack 
consensus regarding the affinity of the receptor for double-stranded DNA.  The   
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Figure 3.1: Expression of TLR9(LBD). Proteins were resolved through a 10% SDS-
PAGE gel and subjected to Western blot analysis with a monoclonal antibody to human 
TLR9. A) Confirmation of TLR9(LBD) Synthesis: Lane 1: Molecular weight marker, 
Lane 2: 10 μg TLR9(LBD) and Lane 3: Media collected from untransfected cells. B) 
Deglycosylation of TLR(LBD) Carbohydrate groups were removed from TLR9(LBD) 
by treatment with PNGase F. Lane 1: Molecular weight marker, Lane 2: 10 μg 
deglycosylated TLR9(LBD).  Protein sources for the molecular weight marker are as 
follows: 175 KDa, MBP-β-galactosidase (E. coli); 83 KDa, MBP-paramyosin (E. coli); 
62 KDa, MBP-CBD (E. coli); 47.5 KDa Aldolase (rabbit muscle). 
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Investigation by Cornelie noted that the receptor bound plasmid with high affinity, 
whereas Rutz reported minimal binding of linear double stranded ODN molecules with 
internal CpG motifs (Cornelie 2004, Rutz 2004). 
To address the interaction of TLR9 with plasmid DNA, a modified agarose 
electrophoretic mobility shift assay (AEMSA) was employed.  This system offers a low-
cost, highly-reproducible method for studying DNA binding.  As an analytical tool, 
AEMSA provides information regarding nucleoprotein complex formation based on 
differential patterns of DNA migration in the presence and absence of DNA-binding 
proteins.  The resolution of the nucleoprotein complexes relies largely on the stability of 
the nucleoprotein complex within agarose gels (Lane 1992).  The stability of 
nucleoprotein complexes within an agarose gel are increased above that of their kinetic 
stabilities within free solution due to “caging effects” of the gel matrix (Lane 1992).  
This caging effect impedes the diffusion of dissociated components thus conserving the 
concentrations of protein, DNA, and nucleoprotein complex at levels equivalent to those 
in the original binding reaction (Fried 1981).  Previous investigation of nucleoprotein 
complex formation between holo-TFIID and the Ea promoter lend support for the use of 
AEMSA in this investigation (Frontini 2002).  This system has two distinct advantages 
in contrast to traditional investigation of DNA-protein interactions.  Firstly, the 
increased porosity of agarose allows large nucleoprotein complexes to be resolved, a 
problem in traditional acrylamide EMSA.  Secondly, AEMSA does not require 
immobilization of either the receptor or ligand.  Thus, the natural dynamics of the 
receptor-ligand interaction are maintained.       
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Within agarose gels, plasmids normally resolve to two predominant species: a 
faster-moving supercoiled form and a slower-moving relaxed form (Oppenheim 1981).  
In the presence of TLR9(LBD), plasmid migration is shifted and results in the formation 
of two distinctly migrating species (Figure 3.2a).  It is also of note that the faster 
moving unbound supercoiled plasmid band is decreased in concentration.  The two novel 
nucleoprotein complexes formed likely correspond to different stoichiometric ratios of 
receptor to plasmid.  These novel species are hypothesized to represent monomeric and 
dimeric forms of the receptor bound to a single plasmid molecule.   Ligand-induced 
dimerization continues to emerge as a common theme within the Toll and Toll-like 
family (Takeuchi 2001, Gangloff 2004).  It has also been reported that the formation of a 
monomeric Toll-Spätzle complex is a prerequisite for the formation of the active dimeric 
Toll complex (Gay 2006, Weber 2005). 
The interaction between plasmid DNA and TLR9 is dependent upon the 
maintenance of a correctly folded structure.   Deliberate disruption of the TLR9(LBD) 
protein structure prior to its addition to the reaction mixture abolishes DNA binding 
activity (Figure 3.2a).  This verifies that the recombinant TLR9 is functional and that 
the receptor is able to bind double-stranded DNA.  Notably, the recombinant receptor 
preferentially binds supercoiled plasmids, which may account for the discrepancies 
previously reported in the literature.  The lack of consensus regarding the interaction 
between TLR9 and double-stranded DNA likely results from different representations of 
the ligand.  The investigation by Cornelie utilized double-stranded linear ODNs which 
cannot adopt a supercoiled configuration (Cornelie 2004). 
To verify that the differential patterns of migration result from the direct binding 
of plasmids by TLR9(LBD), a supershift assay was performed employing the  
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Figure 3.2: TLR9(LDB) Binds Plasmids.  Standard reaction conditions were employed 
as described previously with the exception of the pH adjustment for the supershift assay.  
CMV refers to pFLAG-CMV-2.  A) TLR9(LBD) Binds Plasmid to the Formation of 
Two Distinct Nucleoprotein Complexes.  Lane 1: CMV; Lane 2: CMV and 
TLR9(LBD) and Lane 3: CMV and TLR9(LBD) boiled for 15 minutes prior to addition 
to the binding assay. Reactions were buffered at pH 5.2  B) Supershift Binding Assays. 
Lane 1: CMV and TLR9(LBD) and Lane 2: CMV and TLR9(LBD) and a monoclonal 
antibody specific to the ectodomain of human TLR9 (1.5 μg). For A and B CMV and 
TLR9(LBD) are at constant concentrations of 1.4 μg and 8 μg, respectively, and reaction 
mixtures were buffered at pH 7.2. C) Confirmation of Monomeric and Dimeric 
Nucleoprotein Complexes. The stoichiometry of the shifted nucleoprotein complexes 
was determined by comparing the relative abundances of both nucleic acid and 
TLR9(LBD) within uniquely migrating species hypothesized to represent monomeric 
and dimeric forms of the TLR9 nucleoprotein complex. Relative band intensities were 
calculated for both the ethidium stained agarose gel to determine relative nucleic acid 
content as well as for Western blots of proteins extracted from these gel slices. Results 
represent the averages of two trials.  Densitometry analysis was performed with the 
AlphaEase imaging system. 
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monoclonal human TLR9 antibody.  The incorporation of the monoclonal antibody into 
the nucleoprotein complex will result in a shifted pattern of migration as compared to 
that of the nucleoprotein complex in the absence of antibody.  The addition of the 
monoclonal antibody induced a novel pattern of migration confirming the presence of 
TLR9(LBD) in the nucleoprotein complex (Figure 3.2b).   
The stoichiometry of nucleic acid and TLR9(LBD) within the shifted 
nucleoprotein complexes was determined to confirm existence of monomeric and 
dimeric forms of the receptor.  Shifted bands were excised from the gel shift assay and 
analyzed for plasmid and TLR9(LBD) concentrations.  The concentrations of plasmid 
DNA in both the proposed monomeric and dimeric species were confirmed to be 
equivalent by quantification of band intensity using the AlphaEase imaging system.  To 
determine the relative concentration of TLR9(LBD) present within each complex, the 
shifted bands were excised and proteins were extracted by the freeze-and-squeeze 
method.  Western blot analysis with the monoclonal human TLR9 antibody confirmed 
that the intensity of the signal in the lane corresponding to the proposed dimeric form of 
the receptor is 1.95 times the intensity of signal in the lane corresponding to the 
monomeric form of TLR9 (Figure 3.2c). 
 
3.1.3 pH Dependence of DNA Binding 
 Although limited information regarding the direct interaction between TLR9 and 
DNA has been reported, it has been conclusively demonstrated that the interaction 
between TLR9 and CpG-DNA occurs within the endosomal compartment (Ahmad-
Nejad 2002).  Notably, TLR9 and DNA co-localize to the endosome following 
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endocytosis of ODNs and TLR9-mediated responses require acidification and 
maturation of endosomes (Macfarlane 1998).  Consistent with these results, Rutz has 
demonstrated that the formation of stable nucleoprotein complexes is highly pH-specific 
(Rutz 2004).  The ability of TLR9(LBD) to bind plasmids was monitored at both acidic 
(5.2) and neutral (7.5) pH.  TLR9(LBD) binds plasmids more efficiently under acidic 
conditions as demonstrated by the formation of stable nucleoprotein complexes at lower 
concentrations of the recombinant receptor (Figure 3.3).  This pH dependence is in 
accordance with previous investigations by Rutz and the binding of double-stranded 
RNA by TLR3 (Rutz 2004, de Bouteiller 2005).   
It is of note that complex formation between the receptor and ligand can occur at 
neutral pH, albeit to a lesser extent than at pH 5.2.  This is in agreement with an 
investigation by Barton demonstrating that cell surface-localized TLR9 can be activated 
by endogenous DNA-IgG immune complexes at neutral pH (Barton 2006). 
 
3.1.4 Natural ODNs Exert a Sequence-Independent Cooperative Effect on 
Ligand Binding 
 Although complexes between plasmid DNA and the TLR9(LBD) are easily 
resolved by AEMSA, TLR9(LBD)-ODN complexes cannot be resolved.  This is a 
consequence of both the small size and limited negative charge of the single-stranded 
ODN.  It was hypothesized that the binding of ODNs by TLR9 could instead be 
investigated based on the influence of ODNs on the interaction between plasmid and 
TLR9(LBD).  It was anticipated that ODNs and plasmids would compete for the same  
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Figure 3.3: pH Dependence of TLR9(LBD) Ligand Binding. TLR9(LBD) is better 
able to bind plasmid at acidic pHs. Lane 1:  CMV (1.4 μg); Lanes 2-4:  CMV (1.4 μg) 
with 8, 16 and 32 μg of TLR9(LBD) respectively. Reactions 1-4 were buffered at pH 
5.2; Lanes 5-7: plasmid CMV (1.4 μg) with 8, 16 and 32 μg of TLR9(LBD) 
respectively. Reactions 5-7 were buffered at pH 7.5. 
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binding site on TLR9.   Thus, the competitive inhibition exerted by either nucleic acid 
molecule would indicate preferential binding by the receptor.  Rather than competing 
with plasmid for TLR9 binding, ODNs promoted the binding of plasmid by the receptor.  
Nucleoprotein complex formation occurred at protein concentrations lower than those 
required for formation of TLR9(LBD)-plasmid complexes (Figure 3.4a).  The 
cooperative promotion of nucleic acid binding was exerted in a sequence-independent 
fashion as activating and non-activating PD-ODNs are equally efficient in promoting 
this cooperative effect.  This hypothesis is supported by an investigation by Latz, which 
demonstrated that CpG- and GpC-ODNs immunoprecipitate TLR9 with equivalent 
efficiency, and Roberts, who demonstrated by SPR that although TLR9 demonstrates 
greater affinity for CpG-ODNs, GpC-ODNs can bind to TLR9 at high concentrations 
(Latz 2004, Roberts 2005).  The cooperative effect of ODNs on TLR9 ligand binding 
does not require the incorporation of the ODN into the nucleoprotein complex as 32P-
labeled PD-ODNs do not co-migrate with the distinctly migrating species (data not 
shown).   
 
3.1.5 Phosphothioate ODNs Exert Less of a Cooperative Effect on Ligand 
Binding than Phosphodiester ODNs 
 As phosphodiester ODNs are susceptible to endogenous nuclease enzymes, they 
are poorly suited for in vivo investigations of TLR9.  Thus, many investigations of TLR9 
utilize phosphothioate-modified ODNs (PTO-ODN).  The PTO-ODN modification 
employs the replacement of one of the non-bridging backbone oxygen atoms with sulfur  
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Figure 3.4: Cooperative Influence of ODNs on Plasmid Binding. A) ODNs Exert a 
Sequence-Independent Cooperative Effect on Plasmid Binding. CMV and 
TLR9(LBD) are used in constant quantities of 1.4 μg and 8 μg respectively.  Lane 1: 
CMV; Lane 2: CMV and TLR9(LBD), Lanes 3-8: identical to lane 2 with the addition of 
serial 2-fold dilutions of either CpG of GpC PD ODN 2007 starting at 10 μg. B) 
Phosphodiester ODNs Exert a More Potent Cooperative Effect than Natural ODNs 
Lane 1: CMV; Lane 2: CMV and TLR9(LBD), Lane 3: CMV, TLR9(LBD) and ODN 
PTO-CpG 2007, Lane 4: CMV, TLR9(LBD) and ODN PTO-GpC 2007, Lane 5: CMV, 
TLR9(LBD) and ODN PTO-CpG 2007, Lane 6: CMV, TLR9(LBD) and ODN PTO-
GpC 2007. Each ODN was present at 10 μg. 
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thus bestowing greater stability due to nuclease resistance.  As this investigation has 
demonstrated that ODNs promote plasmid binding, two pairs of ODNs of identical 
sequence, differing in the presence of either a natural phosphodiester or a modified 
phosphothioate backbone, were examined for their influence on the interaction between 
TLR9 and plasmid DNA.  In the presence of either activating or non-activating PD-
ODNs, binding of plasmid DNA by TLR9 is promoted whereas neither sequence, in the 
context of PTO-ODNs, was able to exert this cooperative effect (Figure 3.4b).  
The lack of cooperative influence on plasmid binding by PTO-ODNs in 
comparison to the PD-ODNs contrasts with the ability of PTO-ODNs to mimic bacterial 
DNA-induced innate immune response activation in vivo.  That PTO- and PD-ODNs 
exert different influences on the binding of nucleic acids by TLR9 suggests that they are 
not direct functional analogs.  Thus, these results emphasize the structural and functional 
distinction due to ODN backbone modification.  These results are in agreement with 
reports challenging the neutrality of the PTO modification.  It has been speculated that 
an altered specificity of interaction exists between PTO-ODNs and TLR9 and that PTO-
ODNs can bind other TLR family members (Krieg 2002, Hartmann 2000, Roberts 
2005).   
 
3.1.6 Plasmid DNA Exerts a Cooperative Effect on ODN Binding 
 As phosphodiester ODNs mediates a cooperative effect on plasmid binding by 
TLR9, it was hypothesized that plasmid DNA would also exert the same positive effect 
on the binding of ODNs.  AEMSA analysis relies on large, highly negatively charged 
complexes for efficient resolution and is therefore of limited use in visualizing ODN-
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TLR9(LBD) complexes.  As a consequence of these limitations, a secondary analysis 
was employed that would allow for resolution of TLR9-ODN complexes.  Acrylamide 
EMSA analysis resolves nucleoprotein complexes based primarily on protein 
characteristics with only minor influence from the nucleic acid.  Previous 
characterizations of the binding of transcription factors to promoter elements have 
confirmed the validity of this technique for visualizing DNA-protein complexes 
(Frontini 2001). 
Stable 32P-ODN-TLR9(LBD) complexes can be resolved and visualized through 
acrylamide gel shift assays.  Based on these assays it is apparent that TLR9(LBD) binds 
ODNs more efficiently in the presence of plasmids (lane 6, Figure 3.5).  TLR9-ODN 
complex formation is negligible in the absence of plasmid (Figure 3.5).    
 
3.1.7 TLR Recognizes Higher Order CpG Motifs 
 That CpG-, rather than GpC-, ODNs specifically activate innate immune 
responses in a TLR9-dependent manner has been well documented (Krieg 1999, Bauer 
1999).  The cell stimulation responses from these investigations suggest a sequence-
dependent interaction between the receptor and the nucleic acid ligand.  However, the 
specificity of this interaction has been called into question.  Notably, investigations by 
Latz and Roberts demonstrate a lack of sequence specificity in nucleic acid binding by 
the receptor (Latz 2004, Roberts 2005).  
Previous investigations have demonstrated that TLR9 is activated by higher 
order CpG-containing sequences in a species-specific fashion.  This higher order  
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Figure 3.5: TLR9(LBD) is Highly Sequence-Specific. Constant quantities of CMV 
(1.4 μg), TLR9(LBD) (8 μg) and ODN (0.5 μg) were used in each assay and added 
simultaneously.  Lane 1: TLR9(LBD) and mouse CpG ODN, Lane 2: TLR9(LBD), 
CMV and mouse CpG ODN, Lane 3: TLR9(LBD) and mouse control ODN, Lane 4: 
TLR9(LBD), CMV and mouse control ODN, Lane 5: TLR9(LBD) and human CpG 
ODN, Lane 6: TLR9(LBD), CMV and human CpG ODN, Lane 7: TLR9(LBD) and 
human control ODN, Lane 8: TLR9(LBD), CMV and human control ODN.  
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sequence, termed the CpG motif, is comprised of a hexanucleotide sequence surrounding 
the central CpG dinucleotide.  It has been demonstrated that murine TLR9 is 
preferentially activated with a GACGTT sequence whereas human and bovine TLR9 
respond greatest to (G/T)TCGTT.  It is likely that the single base change within the 
human/bovine and murine CpG motifs influences TLR9 activation as a result of 
modification to the intimacy of the receptor-ODN interaction, although it has been 
speculated that human TLR9 may have less defined sequence specificity (Dalpke 2004).  
This investigation demonstrates that TLR9(LBD) is able to discriminate not only 
CpG- and GpC-ODNs with a high-degree of efficiency, but also the higher order 
species-specific CpG motif.  Stable nucleoprotein complex formation is greatest with 
ODNs containing the human CpG motif (lane 6, Figure 3.5).  A small amount of 
complex formation is also evident with murine CpG motif ODN, although this is 
approximately 10-fold less than that with the human CpG motif (lane 2, Figure 3.5).   
This specificity corresponds to the discrimination of ODNs that are identical at 31 of 33 
positions.   
 
3.1.8 Positive Cooperativity of Endogenous TLR9 
The mutual cooperativity exerted by nucleic acids, in the form of ODNs or 
plasmids, on binding of nucleic acids by TLR9 prompted the consideration of the 
physiological significance of this phenomenon.  Previous investigations of TLR9 
activation have utilized cell proliferation assays, thus providing a valuable platform to 
monitor the significance of this cooperative effect in vivo (Krieg 1999, Bauer 1999).   
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Through cell proliferation assays it was demonstrated that the cooperative effect 
of nucleic acids on TLR9 ligand-binding is preserved in vivo.   The magnitude of 
cellular responses upon co-stimulation with plasmid and either CpG-, or GpC-, ODNs 
was higher than the sum of the individual responses to ODN or plasmid alone (Figure 
3.6).  This data represents the average of experiments performed in triplicate for a single 
animal; three animals, each tested in triplicate, gave unique magnitudes of responses 
although the same trend in the responses is evident.  As previously noted, differences in 
the magnitude of TLR9-mediated responses amongst animals in animal-to-animal 
comparisons are typical of cell-stimulation experiments (Mena 2003).  Notably, the fold 
induction of the responses to the co-stimulation by ODN and plasmid, as compared to 
the sum of the individual responses to plasmid and ODN administered separately, was 
quite consistent across animals.  For CpG-PTO 2007 ODN the magnitude of the 
cooperative effect was a 2.9±0.9 (avg ± 1 std dev.) fold induction while GpC-PTO 2007 
ODN mediated a 1.6±0.7 fold cooperative induction.  The fold inductions represent the 
ratio of the response to co-stimulation with both plasmid and ODN as compared to the 
sum of responses to plasmid and ODN alone.  
These results reflect sequence-dependent activation by TLR9 as co-stimulation 
with GpC-ODN and plasmid resulted in an approximately 2-fold lower induction than 
that of their CpG counterparts.  That a more potent induction of immune responses was 
observed with the CpG-, rather than GpC-, ODNs reflects the cooperative effect of 
plasmid-mediated activation by CpG-ODNs.  It is speculated that during the cell 
proliferation assays TLR9 is primed by the nucleic acids, leading to the formation of a 
sensitized form of the receptor.  This higher affinity form of the receptor is sensitized for  
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Figure 3.6: Endogenous TLR9 Undergoes Cooperative Activation. Bovine PBMCs 
(2 X 105 cells/well) stimulated with either CpG or GpC PTO-ODN 2007 at 5 μg/ml, 
plasmid at 1.0 μg/ml or a co-stimulated with both plasmid and ODN. Cells were 
incubated for 72 h with 3H-thymidine added during the final 6 h of culture. Data 
presented are the mean and one standard deviation of values from triplicate cultures 
taken from a single representative animal. Background counts corresponding to 
activation by media were subtracted from all data. 
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binding activating (CpG) or non-activating (GpC) sequences, culminating in receptor 
activation or inhibition.  It is also demonstrated that GpC-ODNs are able to activate 
TLR9, albeit to a far lesser extent than CpG-ODNs.  This lends support to accumulating 
reports of sequence-independent binding and activation of TLR9 in vivo. 
A point of discrepancy exists between the in vitro and in vivo assays in the 
context of the PTO-ODNs.  In contrast to the ability of PTO-ODNs to elicit strong 
cooperative effects on the induction of immune responses, these modified ODNs were 
less efficient than PD-ODNs in mediating the cooperative effect on TLR9 in vitro.  This 
discrepancy likely reflects the absolute concentration of either ODN presented to TLR9 
under physiological conditions.  As the cellular uptake of PTO-ODNs is approximately 
one order of magnitude greater than that of their phosphodiester counterparts (Sester 
2000), in conjunction with the degradation of PD-ODNs by endogenous nucleases (Zhao 
1993), the total concentration of ODN presented to endogenous TLR9 would be much 
higher when PTO-ODNs are employed in cell stimulation experiments.  
 
3.1.9 Kinetics of TLR9 Activation Support a Cooperative Model 
Investigations of Toll, the Drosophila homologue of the Toll-like receptors, have 
suggested that receptor activation is functionally influenced by both receptor-ligand and 
receptor-receptor interactions.  Recently, Weber has demonstrated that Toll activation by 
Spätzle, the endogenous Toll ligand, is comprised of two non-equivalent binding events 
culminating in the formation of an active dimeric Toll complex (Weber 2005).  
As full-length Toll ectodomains are able to undergo weak dimerization events in 
the absence of ligand the resting state of Toll is hypothesized to be comprised of both 
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ligand-free monomers and dimers (Gay 2006).  In the presence of Spätzle the inactive 
dimers undergo interactions with the ligand and the dimer is split into ligand-bound and 
ligand-free monomers.  Following the first binding event, Toll dimers are reformed 
between ligand-bound and ligand-free monomers culminating in the formation of the 
active Toll- Spätzle complex.  Weber has demonstrated that this second binding step 
proceeds with an approximately three-fold lower affinity than the first binding event, 
suggestive of negative cooperativity (Koshland 1996). 
Based on Michaelis-Menten kinetics, in the absence any of cooperative effect, an 
approximately 80-fold increase in substrate concentration is required to increase receptor 
signaling from 10% to 90% (Koshland 1996).  In the event of positive cooperativity, 
where the subsequent binding events are favored over the first and n, the hill coefficient, 
is >1, less than 5-fold increases in substrate concentration are required to reach the same 
magnitude of activation.  With negative cooperativity (n<1), where the second binding 
event is less favored than the first, up to 400-fold increases in substrate concentrations 
are required for the same increase in receptor activation.  Cell stimulation experiments 
of Toll lend support to the proposed model of negative cooperativity by Weber as 300-
500 fold increases in Spätzle concentration are required to increase signaling activity 
from 10% to 90% (Gay 2006) (Figure 3.7). 
The binding of ligand by Toll through a negative cooperative mechanism has 
physiological implications for Drosophila.  This mechanism of ligand binding results in 
an increased range of substrate concentrations to which Toll is responsive.  A similar 
mechanism of activation has been reported for the follicle stimulating hormone (FSH) 
receptor (Urizar 2005) and the binding of nerve growth factor by p75 (He 2004).   
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Figure 3.7: Kinetics of Activation of Toll and Toll-like Receptor 9. Representative 
data of Toll activation by Spatzle is adapted from [30]. For determination TLR9 
activation, bovine PBMCs (2 X 105 cells/well) were stimulated with CpG PTO-ODN 
2007 at a series of concentrations. Cells were incubated for 72 h with 3H-thymidine 
added during the final 6 h of culture. Percentage activation for Toll (◆) or TLR9 (▲) are 
determined as a percentage of the maximal observed activation. 
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 3.2 Antimicrobial Activities and Virulence Activation Potentials of Host Defense 
Peptides 
 
3.2.1 PhoP- and PhoQ- Mutants Have Increased Susceptibility to HDPs 
 Traditionally, micromolar concentrations of Mg2+ have been regarded as the 
activator of Salmonella PhoPQ.  The physiological relevance of this interaction has 
recently been met with criticism as phagosomal Mg2+ concentrations have been reported 
to be in the millimolar range and therefore PhoPQ repressive (Groisman 2006).  An 
investigation by Bader recently demonstrated that host defense peptides can activate 
PhoQ and thus act as activators of PhoPQ (Bader 2003, Bader 2005).   
As PhoPQ activation results in increased Salmonella virulence phenotypes, and 
HDPs are being actively pursued as novel antimicrobial therapeutics, consideration of 
HDPs from the perspective of bacterial virulence activation must be addressed.  To 
investigate PhoPQ activation potentials of HDPs, a subset of peptides was selected based 
on a previous investigation by Hilpert (Hilpert 2005) in which direct antimicrobial 
activities were established for a parent peptide, Bac2A, and a series of peptide 
derivatives against a broad-range of bacterial species.  From this investigation, a subset 
of peptides was selected representing derivatives with improved (R3 and Sub3), 
maintained (G12) or compromised (P7 and K7) antimicrobial activity, as compared to 
Bac2A.  Modified broth-dilution MIC assays were performed for all of peptides against 
wild-type S. typhimurium and the virulence-attenuated PhoP- and PhoQ- strains.  The  
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Sequence                              Name        WT            PhoQ-         PhoP-        PhoPQcomp
 
  
Table 3.1: Minimum inhibitory concentrations of select Bac2A peptide derivatives. 
A series of peptides were screened against wild type, PhoQ-, PhoP- strains of Salmonella 
typhimurium as well as the functionally reconstituted PhoQ- strain. The MIC values 
represent the averages of triplicate experiments.   
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resultant MIC values for all peptides are in close agreement with those reported 
previously (Table 3.1) (Hilpert 2005). 
As anticipated, resistance to antimicrobial peptides is severely compromised in 
the PhoP- and PhoQ- strains.  The MIC values of all peptides were significantly lower in 
the mutant strains than those against the wild-type strain.  This is in agreement with 
previous investigations in which the loss of either PhoP or PhoQ resulted in ablation of 
bacterial virulence responses (Fields 1989).  The MIC values for the peptide set 
demonstrate that the PhoP- and PhoQ- strains are functionally equivalent as loss of 
either component results in comparable decreases in MIC values for each peptide.  As 
expected, the inability to either detect, or respond to, a particular stimulus results in 
functionally similar phenotypes.  
Given that the removal of either PhoP or PhoQ abrogated bacterial defensive 
responses, it was hypothesized that the reconstitution of PhoPQ in the mutant strains 
would result in wild-type-like responses to antimicrobial peptides.  Following cloning of 
the PhoPQ operon from the wild-type genome, PhoPQ was complimented within the 
PhoQ- and PhoP- mutant strains.  Functional complementation of PhoPQ with a broad 
species-range plasmid (pBBR1MCS-4) expressing the PhoPQ operon (PhoPQcomp) 
returned MIC values to levels comparable with the wild type strain (Table 3.1).  The 
MICs against the PhoPQrecon strain were slightly higher for all peptides tested as 
compared to those against the wild-type bacterium.  These results are indicative of a 
lower HDP susceptibility, or increased bacterial defensive responses.   This is likely a 
consequence of higher levels of expression of the PhoQ and PhoP proteins from the 
plasmid as compared to wild-type levels from the endogenous PhoPQ operon.    
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3.2.2 Changes in Direct Antimicrobial Activity are a Minor Component of 
the HDP Antimicrobial Efficiency 
 The previous analysis established MIC values for the peptide set against wild-
type, and PhoP- and PhoQ- strains.  These MIC values are indicative of bacterial 
susceptibilities to antimicrobial peptides and the initiation of bacterial defensive 
responses.  Information regarding the direct antimicrobial activity and the PhoQ ligand 
potential of these molecules can be extrapolated from MIC assay data.     
 The antimicrobial activity of a peptide against a bacterium compromised in 
defensive responses, such as those of the PhoP- or PhoQ- strains, is defined as the direct 
antimicrobial activity (dAMA).  Thus, the dAMA value for a peptide is equivalent to the 
MIC value for the peptide against either the PhoQ- (MICQ-) or PhoP- (MICP-) mutants.  
As the PhoP- and PhoQ- mutants are functionally equivalent with respect to HDP 
sensitivity, either the MICP- or MICQ- values can be regarded as a measure of dAMA.  
The results presented here calculate dAMA values as the averages of the MICP- and 
MICQ- scores for each of the peptides.  
For any peptide derivative (PD), the relative changes in direct antimicrobial 
activity can be quantified with respect to the parent peptide (PP) by: 
ΔdAMA = dAMA(PD)  -  dAMA(PP)
The difference between the dAMA values of a particular PD and the PP 
demonstrate the influence of peptide sequence alterations on direct antimicrobial 
activities (Table 3.2).  Improvements in direct antimicrobial activity are noted by 
peptides with negative ΔdAMA scores. 
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     Name                 dAMA           ∆dAMA           BDR             ∆BDR             ∆PE 
 
 
 
 
 
Table 3.2: Calculation of changes on direct antimicrobial activity and activation of 
bacterial defensive responses. The peptides R3 and Sub3 are improved antimicrobials 
as indicted by the decreased MIC against wild type Salmonella. This effect is largely 
mediated through the decreased tendency to activate PhoQ-dependent bacterial 
defensive responses, as indicated by the ΔBDR scores.  All values are in units of µg/ml.  
dAMA refers to the direct antimicrobial activity, BDR represents the bacterial defensive 
response and PE is the peptide efficiency. 
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The changes in direct antimicrobial values were found to be moderate amongst 
the peptide set examined.  The peptides R3 and K7 represent the boundaries of the 
∆dAMA values at -2.0 and 6.9, respectively.  This contrasts with the differences in the 
MICs of the same peptides against the wild type strain; MICs for R3 and K7 ranged 
from -21.3 and 36.0, respectively, with respect to Bac2A.  As the ∆dAMA values for 
each of the peptides are similar, amino acid substitutions within the peptide derivatives 
do not have a significant effect on direct antimicrobial activity.  That the largest change 
in direct antimicrobial activity (6.9 μg/ml for peptide K7) is nearly an order of 
magnitude smaller than the range of MICs against wild-type bacteria suggests that the 
primary functional difference amongst the peptides involves mechanisms specific to the 
PhoPQ system.  
 
3.2.3 Activation of Bacterial Defensive Responses Contributes 
Significantly to Antimicrobial Efficiency 
In addition to the direct antimicrobial activity of host defense peptide, the ability 
of a peptide to initiate bacterial defensive responses is also related to overall peptide 
efficiency.  These bacterial defensive responses (BDR) are induced upon recognition of 
a particular peptide by the sensor kinase PhoQ.  
The bacterial defensive response (BDR) is a measurement of the phenotypic 
changes initiated upon recognition of a host defense peptide.  The phenotypic changes 
induced by the BDR decrease the ability of HDPs to interact with the bacterial 
membrane by way of modifications to the negative charge of the membrane and the 
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secretion of proteases.  As PhoPQ is the primary system by which Salmonella initiates 
such defenses, the BDR is more specifically the PhoPQ-dependent alterations induced 
upon peptide recognition by PhoQ.  Thus, BDR, although reflective of a bacterial 
behavioral response to host defenses, is also a characteristic of the peptide in question in 
terms of its ligand potential for PhoQ.   
The magnitude of the BDR can be calculated by direct comparison of wild-type 
and mutant strain responses to peptide.  Specifically, the magnitude of the BDR 
activated by a peptide is calculated as the difference in the MIC values between the wild 
type strain and either of the mutant strains:  
BDR = MICwt – MICQ- or BDR = MICwt – MICP-
As the MIC value of a peptide against the mutant strains was demonstrated to be 
equivalent to the dAMA value, calculation of BDR can be simplified by substitution of 
the dAMA value, such that: 
BDR = MICwt – dAMA 
As the BDR is the magnitude of PhoPQ-dependent resistance mechanisms in the 
presence of peptides, it can also be used for comparisons between peptide derivatives 
and the parent peptide:   
ΔBDR = [MICwt(PD) – dAMA(PD)] – [MICwt(PP) – dAMA(PP)] 
As for ∆dAMA, a negative score indicates a more efficient peptide in terms of 
PhoQ evasion and is anticipated to reflect differences in the abilities of the peptides to 
serve as PhoQ ligands.  Based on the ΔBDR scores, peptides R3 and Sub3 are more 
efficient than Bac2A at evading the PhoPQ system; the ΔBDR for R3 and Sub3 were       
-19.3 and -22.3, respectively (Table 3.2).  In contrast, peptide K7 had an improved 
ability to activate PhoPQ with a ΔBDR score of 29.1.  Thus, peptide K7 represents an 
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improved PhoQ ligand with the propensity to induce bacterial defensive responses 
whereas peptides R3 and Sub3 are improved in evasion of PhoQ. 
 
3.2.4 Relative Contribution of Changes in Direct Antimicrobial Activity 
and Bacterial Defensive Responses to Antimicrobial Efficiency  
The overall change in the net efficiency of a peptide derivative (ΔPE) is taken as 
the change in MIC against the wild type bacteria.   ΔPE can be expressed as a function 
of the contributions of alterations to direct antimicrobial activity and as well alterations 
to bacterial defensive response activation: 
ΔPE = ΔdAMA + ΔBDR 
Negative scores indicate improved peptides where the magnitude of the score 
reflects the degree of improvement.  Notably, the ΔPE score mirrors the change in MIC 
between a parent peptide and its derivative against wild-type bacteria.  The advantage of 
this system is that it allows quantification of the relative changes in each of these peptide 
behaviors.  
Two of the peptides, R3 and Sub3, have significant reductions in their tendency 
to initiate PhoQ-dependent bacterial defensive responses as indicated by their ΔBDR 
scores of -19.3 and -22.3, respectively. The magnitude of these differences corresponds 
very closely with the observed difference in MIC against wild type bacteria.  This 
suggests that the bacterial defensive response component is a principle determinant for 
changes to antimicrobial efficiency. Relative to the Bac2A parent peptide, the R3 
peptide demonstrates improved antimicrobial activity against wild-type bacteria with a 
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reduction in the MIC by -21.3 µg/ml.   As a large proportion of this (-19.3 µg/ml) can be 
accounted for by the reduced bacterial defensive response, it appears that the improved 
efficiency of these peptides is determined almost exclusively by the evasion of PhoQ 
(Figure 3.8, Table 3.2). 
In contrast, the K7 peptide elicits a much stronger defensive response than the 
parent peptide Bac2A, as demonstrated by a ∆BDR score of 29.1.  This implies that the 
K7 peptide is better able to function as a ligand for the PhoPQ system and, as a 
consequence, has reduced antimicrobial efficiency.  The overall change in direct 
antimicrobial activity for peptide K7 (6.9 µg/ml), and the tendency of this peptide to 
induce bacterial resistance phenotypes, contribute to the dramatic reduction in peptide 
efficiency for the K7 peptide.   Based on the ∆BDR and ∆dAMA scores, it appears that 
the tendency of K7 to initiate bacterial defensive responses is the most significant 
determinant in defining its efficiency (Figure 3.8, Table 3.2). 
 
3.2.5 Changes in the Bacterial Defensive Response Correlate with the 
Ability to Activate PhoPQ 
Thus far, the primary conjecture has been that bacterial defensive responses 
induced during host defense peptide challenge reflect the differential PhoQ-ligand 
potentials of the peptides.  As the calculations have been based on direct comparisons 
between wild-type and PhoPQ deletion strains, this would seem a valid assumption.  
Nevertheless, the PhoPQ regulon is complex with the ability to modulate a wide variety  
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Figure 3.8: Net Peptide Efficiencies for Bac2a peptide derivatives. Relative 
contribution of changes in direct antimicrobial activity and tendencies to activate 
bacterial defensive responses towards the change in net peptide efficiency of a peptide 
derivative as compared to the parent peptide. Peptides with negative scores indicate 
more effective antimicrobials.  
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of bacterial behaviors, as well as the ability to influence the workings of other TCSs 
such as PmrAB, implicated in resistance to certain antimicrobial peptides in Salmonella 
and other strains (Bader 2003, McPhee 2003, Tamayo 2002).  Thus, direct verification 
of bacterial defensive response activation through a PhoQ-HDP interaction was sought. 
 Previously, Miller demonstrated that activation of the PhoPQ system in vivo 
could be quantified through an S. typhimurium reporter strain in which expression of an 
acid phosphatase is regulated by PhoP activation (Miller 1989).  Through this reporter 
system, the ability of sub-lethal concentrations of the peptides to activate PhoPQ was 
determined to be a unique characteristic for each peptide.  Importantly, the degree of 
PhoPQ activation by the peptides closely correlates with the patterns of the peptide BDR 
scores.  The peptide K7, which was the least effective antimicrobial peptide, was the 
most potent PhoQ ligand, initiating PhoQ activation approximately 2.3-fold higher than 
what is observed under repressing concentrations (5 mM) of magnesium (Figure 3.9).  It 
is of note that the magnitude of activation by peptide K7 is comparable to that of 
activating Mg2+ concentrations (50 µM).  The activation of PhoQ by the K7 peptide was 
approximately 80% that induced following micromolar magnesium incubation (Figure 
3.9).  This is in accordance with levels of HDP-mediated PhoQ activation reported 
previously (Bader 2005).  Conversely, the most effective antimicrobial peptides, R3 and 
Sub3, initiated the lowest levels of PhoPQ activation which is consistent with their low 
BDR scores (Figure 3.9).  The results of the alkaline phosphatase assays verify that the 
peptides predicted to be the best PhoQ ligands through the MIC analysis are indeed the 
best activators of PhoQ in vivo. 
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Figure 3.9: In vivo Activation of PhoPQ by Low Magnesium and Host Defense 
Peptides. The ability of Bac2A peptide derivatives to initiate activation of a PhoPQ-
dependent reporter was examined by incubation of bacterium in the presence of sub-
lethal (1 ug/mL) concentrations of indicated peptide. Values reported represent the 
averages of three replicates. Activation and repression of PhoPQ by low (50 µM) and 
high (5 mM) magnesium respectively is also reported. 
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3.2.6 Exposure to Sub-lethal Concentrations of HDPs Increases Resistance 
to a Broad Spectrum of Host Defense Peptides  
 Concerns have been recently raised that the therapeutic applications of sub-lethal 
concentrations of host defense peptides might result in persistent infections by induction 
of HDP-resistant bacterial phenotypes.  These concerns prompted the examination of 
sub-lethal HDP concentrations as inducers of bacterial HDP resistance mechanisms by 
way of PhoPQ activation. 
To determine if exposure to sub-lethal concentrations of HDPs initiates bacterial 
defensive responses, and if the magnitude of these responses correlates with the 
calculated BDR scores, bacteria were pre-incubated with an increasing sub-lethal 
concentration of either the K7 or R3 peptides over a 4-hour time period.  These peptides 
represent the two extremes of peptide efficiencies examined in the peptide derivative 
subset in terms of the calculated BDR scores and thus their ability to promote (peptide 
K7) or avoid (peptide R3) bacterial defensive responses.  Following this pre-adaptive 
period, bacteria were subjected to standard MIC assays. The protective effects mediated 
by the pre-adaptive exposure to K7 or R3 were quantified based on the MIC values.  
Consistent with the calculated BDRs, the K7 had the most dramatic shift in MICs scores, 
corresponding to up to 10-fold increases over the values observed for naïve bacteria.  In 
contrast, pre-incubation of bacteria with peptide R3 had limited impact on HDP 
protection with many of the MICs comparable to those observed for naïve bacteria 
(Figure 3.10).  This demonstrates that peptides registering the greatest BDR scores also 
mediate the greatest tendency for induction of adaptive resistance phenotypes within 
bacteria.   
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Figure 3.10: Activation of HDP Responses Following Exposure to Sub-Lethal 
Concentrations of HDPs. The ability of peptide derivatives to induce adaptive 
responses was determined by pre-incubation of bacteria for four hours in the presence of 
sub-lethal concentrations (5 ug/mL) of peptides prior to standard MIC assays. Values 
reported represent the averages of three repeats.  
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3.2.7 RI-BMAP28 is Resistant to Proteolytic Degradation  
 The therapeutic administration of host defense peptides has been limited by the 
high manufacturing costs of peptides and low systemic stabilities; single dosage costs of 
HDPs are approximately 100 times more expensive than that of conventional antibiotics 
(Marr 2006).  Thus, an alternative strategy is presented that focuses on the increased 
stability of HDPs through the introduction of retro-inverso modification.  This 
modification is reminiscent of the phosphothioate modification in PTO-ODNs.  
Retro-inverso peptide modification involves the inversion of the amino acids by 
incorporation of the D-enantiomers and reversal of the amide bonds.  Previously, 
increased peptide stability due to the inversion of the natural L-amino acids to the D-
enantiomers has been reported (Chen 2006).  As the immunomodulatory effects of host 
defense peptides rely on their ability to be recognized by host biomolecules, chirality of 
the peptide must be maintained to allow for proper recognition events.  The 
antimicrobial activities of HDPs rely on the interaction of these molecules with the 
achiral bacterial membrane and therefore requires that the only the overall three-
dimensional conformation of the peptide must be maintained (alpha-helix, beta-sheet, 
and extended).  
    The modification of BMAP28 by retro-inversion results in a large increase in 
protease resistance.  As BMAP28 and RI-BMAP28 are rich in lysine and arginine 
residues, the serine protease trypsin was selected for analysis.  Within 30 minutes of 
protease exposure, all of the BMAP28 peptide was cleaved at least once by trypsin, 
verifying that the protease lability of natural HDPs is a concern in systemic applications.  
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In direct contrast, the RI-peptide remained nearly completely intact throughout the 8-
hour trypsin exposure (Figure 3.11).   
 
3.2.8 BMAP28 and RI-BMAP28 Adopt Similar Conformations 
 The maintenance of the structural and functional characteristics of natural host 
defense peptides is the primary concern for the use of retro-inverso modifications in host 
defense peptide-based therapeutics.  CD spectroscopy provides a method for 
determination of the elements of secondary structure within peptides and proteins and 
allows for the mimicking of physiological environments, such as the hydrophobic 
environment of the cell membrane, during analysis. 
 It is well documented that inverso peptides (containing all D-amino acids) are 
mirror images of their natural counterparts (Chen 2006).  However, it cannot be assumed 
that retro-inverso peptides and natural peptides adhere to the same principle as identical 
higher order structure cannot be assumed (Fischer 2003).  Retro-inverso modification 
alters mainchain hydrogen bonding patterns, as well as dipole moments, that are 
dependent upon the direction of hydrogen bonds.  Thus, an alternate structure may be 
favoured.  Previously, CD investigations have shown that natural peptides and their RI-
counterparts may adopt identical higher order conformations (Merrifield 1995).   
CD spectroscopy was employed to investigate the maintenance of secondary 
structure upon retro-inversion of BMAP28.  Both the natural and RI-peptides were 
found to have highly disordered structures under hydrophilic conditions (results not 
shown).  In aqueous solutions, HDPs tend to adopt random structures and form more 
defined tertiary structures when in contact with a hydrophobic environment (Merrifield  
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HDP Sequence 
BMAP-28 GlyLeuArgSerLeuGlyArgLysIleLeuArgAlaTrpLysLysTyrGlyProIleIle 
ValProIleIleArgIleGly 
RI-BMAP-
28 
Gly(D)Ile(D)Arg(D)Ile(D)Ile(D)Pro(D)Val(D)Ile(D)Ile(D)Pro 
Gly(D)Tyr(D)Lys(D)Lys(D)Trp(D)Ala(D)Arg(D)Leu(D)Ile(D)Lys 
(D)ArgGly(D)Leu(D)Ser(D)Arg(D)LeuGly 
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Figure 3.11:  RI-BMAP-28 is Resistant to Proteolytic Degradation. A) Sequence of 
BMAP-28 and RI-BMAP-28.  The RI-BMAP28 is the reversed sequence of BMAP28.  
B) BMAP-28 and RI-BMAP-28 (1 mg/mL) were digested with trypsin (0.1 mg/ml) in a 
50 μL reaction volume (50 mM Tris pH 7.2) at 37 °C. Digestion mixtures were then 
separated via HPLC chromatography and the extent of peptide degradation quantified 
through comparison of peak areas to that of an undigested sample of the same peptide. 
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1995).  To mimic the hydrophobic environment of the bacterial cell membrane, 
trifluroethanol (TFE) was incorporated with the peptide samples prior to CD 
spectroscopy.  TFE has been used extensively in predictions of membrane-induced 
structural changes within host defense peptides (Lequin 2003).  The CD spectra 
demonstrate that BMAP28 and RI-BMAP28 are relative mirror images of one another 
(Figure 3.12).  Deconvolution of the CD spectra verifies that the formation of secondary 
structure is highly similar in both BMAP28 and RI-BMAP28 and is relatively 
comparable to those previously reported by others for BMAP28 (Skerlavaj 1996).  Thus, 
the retro-inverso modificatied BMAP28 forms a highly comparable higher order 
structure to the natural BMAP28 counterpart. 
 
 
3.2.9 RI-BMAP-28 has Improved Direct Antimicrobial Activity 
The potential of retro-inverso peptides as novel therapeutics hinges on the 
maintenance of natural peptide functions following modification.  Thus, the 
antimicrobial activity for RI-BMAP28 was compared to natural BMAP28 against a 
broad-range of Gram-negative bacterial species by the modified broth microdilution 
MIC assays.  The spectrum of bacterial species used in this investigation removes biases 
that might be found when using smaller species samples.  Across all species tested, the 
RI- BMAP28 exhibited a more potent antimicrobial activity than the natural peptide; 
MICs values for the RI-BMAP-28 were typically a half to a third of that of the natural 
peptide (Table 3.3).  As both Gram-negative and Gram-positive bacterial species secrete 
proteases as an endogenous defense mechanism, it is likely that the increased 
antimicrobial activity is reflective of higher maintained concentrations of peptide in the  
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Figure 3.12: RI-BMAP-28 Adopts Similar Secondary Structures as BMAP-28. A) 
CD Spectra of BAMP28 and RI-BMAP-28. Notably, the two spectra are similar, 
although opposite, images.  B) Percentage Composition of Different Elements of 
Secondary Structure. 
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Table 3.3: Minimum inhibitory concentrations of BMAP28 and RI-BMAP28: The 
MIC values represent the averages of triplicate experiments and are in μg/ml 
concentrations. 
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MIC assay using the RI-variants.  While others have reported maintained or improved 
direct antimicrobial activity of host defense peptides as a consequence of either retro- or 
retro-inverso modifications, the effects were often specific to the particular strain of 
bacteria (Merrifield 1995).  This investigation demonstrated no strain specificity to the 
improved activity of RI-MAP-28 with any of the examined bacteria and is consistent 
with the maintained sequence and overall structure of the RI-BMAP28.  
 
3.2.10 Retro-inversion of BMAP28 Reduces Cytotoxic Activity 
  
 A requirement for the therapeutic application of host defense peptides is low host 
cell toxicity within the range of concentrations required for therapeutic effects.  
Although eukaryotic membranes represent inferior targets for HDPs due to a lack of 
anionic lipids, absence of strong membrane potential gradient, and presence of 
cholesterol, it has been demonstrated that some HDPs do possess hemolytic activity  
(Hancock 1998, Peschel 2006, Yeaman 2003).  To be considered for therapeutic 
administration, RI-modified peptides must not demonstrate significant hemolytic 
activity. 
 To determine the cytotoxic effects of BMAP-28 and RI-BMAP-28 the peptides 
were incubated overnight at a range of concentrations with bovine peripheral blood 
mononuclear cells.  Consistent with previous investigations, BMAP-28 exerts cytotoxic 
effects at concentrations as low 50 μg/mL and resulted in nearly complete lysis of host 
cells by 250 μg/mL (Figure 3.13).  In contrast RI-BMAP28 does not induce lysis of host 
cells at concentrations as high as 250 μg/mL.  Thus, the RI-modification does not  
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Figure 3.13: Cytotoxicity of BMAP-28 and RI-BMAP-28. Hemolysis was performed 
by incubating a 1% (v/v) suspension of bovine erythrocytes in phosphate buffered saline 
(pH 7.4) with a series of peptide concentrations for 12 hours at 37 C. Samples were then 
centrifuged and the supernatant absorbance read at 415 nm. Total hemolysis was 
obtained by resuspending in cells in water rather than PBS. Results are the average from 
four independent experiments. 
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conserve the hemolytic activity of BMAP28 and lends support for the use of this 
modification in therapeutic HDP applications.  The precise mechanism by which 
BMAP28 mediates host cell lysis, and by which it is ablated in RI-BMAP28, has not 
been identified but is being investigated.   
 
3.2.11 RI-BMAP-28 is Equally Effective as BMAP-28 in Suppressing LPS-
Induced TNF-α Release 
Bacterial infections have associated medical risks that not only include the 
presence of a pathogenic organism within the host but also the potential for self-induced 
pathology.  The excessive inflammatory response induced during such a bacterial 
infection can result in significant host tissue damage and sepsis.  To confirm that the 
immunomodulatory activity of BMAP28 was conserved in the RI-derivative, the ability 
of the two isomers to influence secretion of the proinflammatory cytokine TNF-α 
following LPS stimulation was examined.  The secretion of TNF-α as a biomarker of 
inflammation responses is well established.  
Previous studies have suggested that the antiendotoxic activity of cationic 
peptides results in part from LPS chelation as this interaction is proposed to block the 
interaction of LPS with serum LBP (Bowdish 2005a).  However complexes between 
HDPs and LPS tend to be of relatively modest affinities when compared to strength of 
interaction between LBP and LPS (Finlay 2004).  Furthermore, evidence has been 
presented that the suppression of LPS-induced, pro-inflammatory responses by 
endogenous cathelicidin LL-37 involves a variety of mechanisms independent of direct 
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binding to LPS (Bowdish 2005b, Murakami 2002).  That LL-37 and BMAP-27 retain 
the majority of their anti-endotoxin activity when added 30 minutes after LPS 
stimulation, even after removal of LPS from the extracellular media, indicates these 
peptides at least partially suppress LPS-induced, proinflammatory responses by 
mechanism other than direct binding to LPS.   
ELISA assays confirm that the ability to suppress LPS-induced TNF-α secretion 
is conserved in both BMAP-28 and RI-BAMP28 (Figure 3.14).  Importantly, the 
peptide concentration required to mediate this effect is consistent with that required to 
influence patterns of gene expression as demonstrated in ongoing analysis within the 
Napper lab and is supportive of the biological significance of this observation (personal 
communication). 
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Figure 3.14: HDP Inhibition of LPS-Induced TNF-α Secretion.  Bovine PBMCs (5 X 
105 cells/well) from three donors were stimulated with 100 ng/ml of LPS (Sigma) for 48 
h.  The secretion of TNF in culture supernatants was quantified with a capture ELISA.  
Inhibition of LPS-induced TNF secretion was evaluated by adding various 
concentrations of BMAP-28 (▲) or retro-inverso RI-BMAP-28 (■) to duplicate PBMCs 
cultures.
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4.0 Discussion 
 
4.1 TLR9 Interacts With Nucleic Acid Ligands in a Sequence-
Independent Fashion but Activation is Sequence-Dependent 
Throughout millions of years of co-evolution, the interactions between hosts and 
pathogens have resulted from mutual offensive and defensive strategies.  From the 
perspective of the pathogen, these strategies have involved mechanisms for increasing 
the colonization of host tissues and increased evasiveness of the host innate immune 
arsenal.  To this end, microbes rely on two-component sensory systems, such as PhoPQ, 
for increasing virulence characteristics within specific physiological niches.  On the 
other hand, the host has evolved strategies that prevent such colonization through 
defensive early warning recognition systems and offensive antimicrobial molecules.  
These defensive pathogen recognition receptors are responsible for the differentiation of 
self from non-self.  Consequently, the PRRs are responsible for the induction of an 
appropriate response following pathogen encounter and, ultimately, the resolution of 
infection.   
Recently, considerable pharmaceutical interest in the innate immune system has 
been generated due to the potential for therapeutic enhancement and augmentation of 
innate immune responses.  In particular, therapeutic developments of novel therapeutics 
based on innate immune system components have focused on TLR9 agonists and
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antagonists and the cationic host defense peptides.  Novel TLR9 agonists and antagonist 
are being investigated as therapeutics for a broad-range of malignancies.  These 
synthetic nucleic acid TLR9 ligands are particularly attractive due to low associated 
costs of production, manufacturing simplicity, and low systemic toxicites (Klinman 
2004).  Unfortunately, there is limited structural information regarding the direct 
interaction between TLR9 and ligands.  Thus, the development of synthetic TLR9 
ligands must instead be based on the ability of these ligands to activate or repress innate 
immune responses in cell proliferation assays.  Although cell stimulation experiments 
provide valuable information regarding the in vivo interactions between biomolecules 
based on global cellular responses, a failure of this approach is in the reduction of 
complex physiological responses to a single output.  This reductionist approach cannot 
provide information on the discrete events such the direct interactions between a 
receptor and ligand.  On the other hand, investigations of the direct interaction between 
TLR9 and DNA have also met limitations.  Biochemical characterizations of this event 
have been limited due to difficulties associated with purification of sufficient quantities 
of the receptor for analyses and as well the lack of a convenient screening assay.  A 
high-throughput screening assay that could monitor and characterize the binding 
interaction between TLR9 and DNA would be highly advantageous.   
Several key issues surrounding the interaction between TLR9 and DNA have 
remained unanswered.  Thus, the cornerstone of this investigation has been the 
following: 1) the efficiency of the receptor in binding double-stranded DNA, 2) the 
absolute requirement for CpG motifs within nucleic acids to mediate ligand binding and 
cellular activation, 3) the ability of TLR9 to recognize higher order motifs in a species-
specific fashion, 4) the influence of the commonly utilized phosphothioate modification 
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on receptor binding, and 5) the influence of higher order allosteric mechanisms, such as 
those recently been reported for Toll on ligand binding .  In this investigation, a novel 
high-throughput assay system has been proposed for the characterization of the ligand 
binding event - the agarose electrophoretic mobility shift assay.   
 Recent investigations of the TLR9 ligand binding event have utilized Surface 
Plasmon Resonance technology to address TLR9 ligand-binding proclivities.  The 
investigations by Rutz and Cornelie have demonstrated a preference for CpG-, rather 
than GpC-, ODNs, but lacked consensus on the ability of the receptor to associate with 
double-stranded ligands (Rutz 2004, Cornelie 2004).  Limitations in both the 
experimental methodology and the mode of analysis may have contributed to these 
discrepencies and support the methodology of this investigation. 
The Cornelie and Rutz investigations employed insect cell expression systems 
for the expression of recombinant TLR9 protein.  Although the use of insect cells allows 
for post-translational modifications similar to those of the endogenous receptor, the 
glycosylation patterns of the recombinant receptor deviate from those found under 
normal conditions.  In particular, insect cell expression results in glycans lacking the 
high mannonse content normally found in mammalian N-linked carbohydrate (Tomiya 
2004).  Investigations of TLR3, another endosomal TLR involved in recognition of 
microbial nucleic acids, have noted such inconsistencies (Bell 2005).  Indeed, TLR3 
glycosylations have been reported to be a primary contributing factor to the binding of 
double-stranded RNA (Sun 2006).   As structural features are well conserved amongst 
the subcellular TLRs, it would be hypothesized that the glycosylations found on TLR9 
would also influence ligand binding.  This investigation has circumvented the problems 
associated with previous TLR investigations through the use of a bovine expression 
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system.  Although differences in glycosylations patterns have been noted amongst 
mammals, it is expected that species phylogenetically close to humans will have 
common elements of the glycosylations machinery (Jenkins 1996).  As bovine cells were 
employed for expression of recombinant TLR9, the glycosylation pattern of the receptor 
should closely match those of the endogenous receptor therefore conserving the 
influence of these PTMs on TLR9 ligand binding to a high degree.  Another advantage 
of this expression system is that the recombinant protein is secreted into the extracellular 
media following expression.   Thus, cell lysis steps are not required with this protocol.  
The removal of cell lysis decreases the potential for copurification of contaminating 
proteins that may influence receptor characterization.  In contrast, the investigations by 
Cornelie and Rutz utilized expression systems requiring cell lysis steps.  Removal of 
potential contamininating proteins with wash steps were however were not reported in 
either protocol prior to characterization (Rutz 2004, Cornelie 2004).   This is significant 
as cellular proteins possessing DNA-binding properties could result in false positives 
during the binding analysis.  This may reflect the lack of consensus between the two 
investigations regarding the binding of single- and double-stranded DNA ligands.  
Additionally, SPR analyses require the immobilization of either the receptor or ligand.  
As immobilization limits the sampling of multiple conformations by the bound molecule 
it may also influence the interaction between a receptor and ligand.  This limitation is 
removed with AEMSA and the natural receptor-ligand interaction dynamics are 
maintained.   
That plasmid DNA has been demonstrated to activate innate immune responses 
(Krieg 1995), and time-course experiments have verified that the endosomal-stability of 
plasmids would allow for an interaction with TLR9 (Bennett 1985), suggest that it may 
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act as a TLR9 ligand.  Investigations of the binding of plasmids by TLR9 have reached 
opposing conclusions regarding this event.   An investigation by Cornelie demonstrated 
efficient binding of plasmid DNA whereas Rutz noted only low-affinity binding to 
double-stranded ODNs (Cornelie 2004, Rutz 2004).  The results presented here validate 
the observations by Cornelie as the ligand-binding domain of TLR9 bound plasmid 
DNA efficiently.  It is hypothesized that the nucleoprotein complexes formed during 
AEMSA correspond to monomeric and dimeric forms of TLR9 (Figure 3.2).  
Dimerization events are a recurring theme amongst the TLR family and Toll (Gangloff 
2004, Weber 2005).  It is also noted that the recombinant receptor demonstrates a 
preference for plasmids in a supercoiled conformation.  This accounts for the 
discrepancy between the Rutz and Cornelie investigations.  The linear double-stranded 
ODNs utilized by Rutz would be devoid of supercoiling and based on the AEMSA 
analysis would represent low affinity TLR9 ligands.  That TLR9 can undergo 
interactions with both single-stranded DNA molecules and plasmids would be 
anticipated.  Bacterial lysis within the phagosome would result in significantly high local 
concentrations of both molecules in proximity to TLR9. 
 A recurrent theme amongst the intracellular-localized Toll-like receptor family is 
a pH-dependency on ligand binding.  Investigations of TLR3 and TLR8, have 
demonstrated that ligand binding and receptor dimerization are dependent on the acidic 
pH of the endosome (de Bouteiller 2005, Gibbard 2006).  That inhibitors of endosomal 
acidification ablate immune responses to CpG-ODNs suggest a similar pH dependency 
for TLR9 (Hacker 1998, Yi 1998, Yoshimori 1991, Macfarlane 1998).  The SPR 
analysis by Rutz is also supportive of this (Rutz 2004).  AEMSA analysis confirms that 
the recombinant receptor formed and maintained specific nucleoprotein complexes most 
 157
efficiently at a pH comparable to that of late endosomes (Figure 3.3).  It is also of note 
that the receptor can form nucleoprotein complexes at neutral pH, although at much 
lower efficiency.  Although the stability of nucleoprotein complex formation is limited 
at neutral pH it may result in TLR9 activation and the initiation of innate immune 
responses.  This is supported by a growing number of reports detailing the ability of 
TLR9 to be activated by host DNA (Leadbetter 2002, Boule 2004, Means 2005, Barton 
2006). 
The generally accepted paradigm of TLR9 activation postulates that 
unmethylated CpG motifs are the specific ligands for the receptor.  The vast majority of 
supportive evidence for this model has been inferred from cell stimulation experiments.  
Although the sequence-dependent activation of TLR9 has been assumed to represent 
sequence-specific binding by the receptor, recent in vitro investigations have lacked 
consensus with regards to the sequence-specific binding of nucleic acids by TLR9 
(Cornelie 2004, Rutz 2004 , Yasuda 2006).  The demonstration that the sera of SLE 
patients can activate TLR9 also questions the paradigm of sequence-dependent receptor 
activation as CpG dinucleotides are both repressed in frequency and highly modified 
within the vertebrate genome (Leadbetter 2002, Boule 2004, Means 2005). 
Although the direct interaction between TLR9 and ODNs cannot be investigated 
by AEMSA, the influence of these molecules on the binding of plasmid DNA by the 
receptor can.  It is evident that both CpG- and GpC-ODNs increase the propensity of 
TLR9-plasmid complex formation (Figure 3.4).  This is likely due to promotion of 
TLR9 to a sensitized, higher affinity form by the ODNs, resulting in an increased 
affinity of the receptor for binding nucleic acids of activating or non-activating 
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sequences.  The cooperative effect of ODNs on plasmid binding was also confirmed to 
be independent of their incorporation into the TLR9-plasmid complexes.   
Surprisingly, this cooperative influence was largely ablated upon phosphothioate 
modification of the ODN backbone.  As PTO-ODNs are nuclease-resistant analogs of 
their phosphodiester counterparts, active pursuit of novel TLR9 therapeutics have 
focused on these modified ligands.  That the PTO modification is demonstrated to 
functionally influence the interaction of ODNs with TLR9 argues for more thorough 
investigations of this influence.   Thus, the development of novel TLR9 therapeutics 
must consider the effects of this stabilizing modification on TLR9 interactions at the 
level of ligand binding.  Supporting this, Roberts has demonstrated that PTO- and PD-
ODNs display non-equivalent binding affinities for TLR9 in vitro (Roberts 2005).  PTO-
modified ODNs have also been observed to undergo non-specific interactions with other 
TLR family members (Rutz 2004).  This is particularly concerning as the over-
stimulation of the innate immune system through the activation of multiple TLRs could 
result in tissue damage or sepsis (Bishop 2006).   
A discrepancy exists between the influence of PTO- and PD-ODNs on plasmid 
binding by TLR9 in vitro and the activation of innate immune responses by both types of 
ODNs in vivo. Although in vitro PD-ODNs exert a far greater cooperative effect on 
TLR9 binding than their PTO counterparts, the endosomal concentration of PD-ODNs 
required for this cooperative influence would be exceedingly difficult to attain in vivo 
via direct administration.  Indeed, analyses of TLR9 activation by PD-ODNs have 
utilized repeated administrations of the ligand to the growth media in an attempt to 
counterbalance losses due to nuclease degradation (Elias 2003, Zelenay 2003).  In 
contrast, analyses utilizing PTO-ODNs require only single administrations.  These 
 159
discrepancies must however be tempered with an appreciation for the differences 
between cell stimulation experiments and the normal course of bacterial invasion.  
Microbial DNA, although susceptible to degradation by nuclease enzymes, are 
encapsulated within the microorganism therefore protecting these TLR9 ligands from 
degradation by nucleases in the extracellular matrix.  Following phagocytosis of a 
bacterium, high concentrations of the CpG-rich microbial DNA would be liberated 
within the phagosome and in proximity to TLR9.   
In contrast to the sequence-independent functional influence of PD-ODNs on 
plasmid binding by TLR9, the formation of stable TLR9-ODN nucleoprotein complexes 
is a highly species- and sequence-dependent process (Figure 3.5).  TLR9 clearly 
discriminates not only the CpG dinucleotide but also the species-specific higher-order 
CpG motif.  Thus, the sequence-dependent formation of TLR9-DNA complexes is likely 
indicative of the specificity of TLR9 activation in vivo.  Indeed, cell proliferations 
experiments lend support to the hypothesis that sequence-independent functional 
influence of nucleic acids on formation of active TLR9 complexes is physiologically 
relevant (Figure 3.6).  The higher-order regulatory mechanisms reported for TLR9 
activation are consistent with the recent observations that Toll regulation involves both 
receptor-ligand and receptor-receptor interactions (Weber 2005, Gay 2006). 
 
4.2 A Model of TLR9 Activation 
Receptor dimerization prior to ligand binding is a recurring theme amongst the 
members of the TLR family, as well as Toll, and is likely conserved in TLR9 (Gangloff 
2004, Weber 2005).   Recently, the activation of Toll has been proposed to proceed 
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through a two step mechanism involving the formation of a ligand-free inactive Toll 
dimer (Weber 2005).  The authors have speculated that a similar mechanism might 
influence the activation of TLR family members.  
 It is proposed that the sequence-independent cooperative influence of nucleic 
acids on TLR9 ligand binding is likely mediated through the promotion of TLR9 
dimerization to a sensitized ligand-free complex that is primed for binding of activating 
or non-activating nucleic acid sequences.  The cooperative effect exerted by nucleic 
acids is independent of their incorporation into the sensitized dimeric TLR9 complex.  In 
contrast to the negative cooperative mechanism reported for Toll by Weber, the 
mechanism of TLR9 activation is proposed to proceed through positive cooperativity.  
As a result, TLR9 is sensitized to form nucleoprotein complexes with plasmid molecules 
in the presence of ODNs and conversely TLR9 is sensitized to bind ODNs when in the 
presence in plasmids.  This is likely mediated through the initial formation of ligand-free 
TLR9 dimers.  
Non-activating nucleic acid sequences, promote the formation of a sensitized, 
non-active TLR9 dimeric complex, but are rapidly released by the receptor.  Indeed, the 
functional influence of non-activating nucleic acids on the formation of a higher order 
TLR9 complex does not require integration of these sensitizing nucleic acids into the 
complex.  Labeled ODNs, although able to influence the binding of plasmid by TLR9, 
were not incorporated into TLR9-plasmid DNA complexes.    
Following release of non-activating sequences, the ligand-free TLR9 dimer 
persists for a short period of time.  Although this dimer is inactive, it has been 
‘sensitized’ and therefore has increased ligand affinity.  Thus, the sensitized inactive 
TLR9 dimer is primed for ligand ‘sampling’.  The binding of activating sequences by the 
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ligand-free dimer would be hypothesized to induce structural alterations within the TIR 
domains of the TLR9 dimer leading to receptor activation.  In contrast to the Toll model, 
the conformational changes induced within TLR9 following the sequence-independent 
interaction with nucleic acids, increase the affinity of the receptor for the stable binding 
of activating or non-activating sequences.  This results in the second step of TLR9 
activation proceeding with a much higher affinity than the first step.  The equilibrium 
between TLR9 monomers, ligand-bound dimers, and ligand-free TLR9 dimers is 
illustrated in Figure 4.1.  Supportive of this model of higher order functional influence 
of nucleic acids on TLR9 activation, the sequence-independent association of DNA with 
TLR9 has become increasingly well established (Latz 2004, Yasuda 2006). 
Collectively, the results presented here demonstrate that nucleic acids of 
activating and non-activating sequences are able to influence the activation of TLR9.  
These influences are of both sequence-dependent and sequence-independent nature and 
shed light on the wide-range of nucleic acid ligands recognized by the receptor.  
Previous investigations have lacked consensus regarding the sequence-dependency of 
ligand binding by TLR9.  Receptor activation clearly demonstrates a preference for 
nucleic acids of activating sequence in vivo whereas TLR9 has demonstrated sequence-
independent interactions with nucleic acids in vitro.  This investigation adds clarity to 
these discrepancies.  The activation of TLR9 is highly-sequence dependent; however, 
non-activating nucleic acids are able to modulate TLR9 responsiveness through receptor 
sensitization.  Based on these observations and the homology between the Toll and TLR 
receptor families, a two-step model describing TLR9 activation is proposed.  The initial 
binding event of this model determines receptor specificity and the second binding event  
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B) Toll-Like Receptor 9 
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Figure 4.1: Models of Activation of Toll and Toll-like Receptor 9. A) Toll. 
Activation of Toll is mediated through a two-step reaction. The first binding event, to 
the formation of a ligand-bound monomer, occurs with high affinity. The second stage 
of Toll activation, binding of the Toll-ligand monomer by a ligand-free monomer, 
occurs with lower affinity, representing negative cooperativity of activation. B) Toll-like 
Receptor 9. Activation of TLR9 is proposed to follow a similar two-step reaction with 
the distinction being that the second step to dimer formation occurs with positive 
cooperativity. 
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dictates receptor sensitivity, in a positive or negative manner.  This model has 
physiological significance as the sequence-independent cooperative effect of nucleic 
acids on TLR9 may be in the determination of the activation set point for the receptor.  
That increased concentrations of nucleic acids lead to system sensitization, in a 
sequence-independent fashion, suggests that the release of bacterial nucleic acids in the 
phagosome following cell lysis serve to prime the TLR9 system.  Thus, activating CpG 
motifs within microbial DNA will activate the receptor in an expedient fashion for the 
generation of innate immune responses.  This dual requirement for TLR9 activation may 
also prevent the potentially deleterious activation of the system as the primed TLR9 
dimer is also able to be inactivated by inhibitory nucleic acid sequences found within 
host DNA and therefore serves as a safeguard function. 
 
4.3 Host Defense Peptides as Activators of the PhoPQ Two-Component 
Sensory System 
In a manner analogous to that of Toll-like Receptor 9 of the vertebrate host, the 
two-component systems of bacteria act as sensory systems that monitor the extracellular 
environments and initiate responses for increasing microbe survival.  These systems 
have undergone extensive modifications throughout millions of years of evolution for 
maximizing evasion and adaptation strategies (Peschel 2006).  As the TLR family has 
evolved to identify and respond to a broad-range of conserved microbial biomolecules, 
the PhoPQ two-component system has evolved to recognize conserved host molecules.  
These responses culminate in the activation of increased microbial virulence phenotypes.  
Although the traditional ligand for the PhoPQ system has been regarded as extracellular 
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Mg2+ concentrations, host defense peptides have recently been observed to activate 
PhoPQ.  
Host defense peptides are an essential component of innate immunity in both 
higher and lower organisms.  Recently, considerable interest has been generated in 
regards to employing HDPs as templates for the rational design of novel antimicrobials.  
In the face of an increased propensity of multi-drug resistant bacterial strains, HDPs may 
offer an alternative to conventional therapies.  Although the use of an evolutionarily 
refined antimicrobial molecule seems logical, this must be tempered with an 
appreciation for these molecules to promote resistance phenotypes.  As HDPs serve as 
an essential component of the innate immune arsenal, the consequences of microbial 
HDP resistance could be profound.  Indeed, sub-lethal HDP concentrations, as are often 
employed in immunomodulatory therapeutic applications of HDPs, have been 
demonstrated to exert a selective pressure on the development of resistant phenotypes 
(Zhang 2005, Nizet 2006).  Thus, the development of novel HDP therapeutics must also 
consider the ability of these molecules to activate bacterial defensive responses.  
Traditionally, host defense peptides have been regarded as bi-functional 
molecules with direct antimicrobial activity and the ability to modulate innate and 
adaptive immune function (Brown 2006).  This investigation proposes a third activity for 
HDPs: the activation of bacterial defensive responses and virulence characteristics by 
way of PhoPQ.  Thus, the selection of HDPs based on their inability to initiate PhoQ 
activation would provide a rational basis for HDP evaluation.  To this end a 
mathematical model is proposed that discriminates and quantifies HDPs based on direct 
antimicrobial activity and PhoQ activation potential.  This model is based upon MIC 
values against S. typhimurium wild-type and PhoPQ mutant strains.   
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Analysis of a subset of peptide derivatives based on Bac2A, a derivative of the 
bactenecin peptide, demonstrated that the antimicrobial efficiency against either of the 
PhoP- or PhoQ- mutants fell within a limited range of values (Table 3.1).  This suggests 
that most single amino acid substitutions do not impact the direct antimicrobial activity 
of host defense peptides.  A notable exception peptide P7, with proline at position 7 of 
the peptide, has vastly diminished direct antimicrobial activity as compared to other 
members of the peptide set.  This demonstrates the potential for amino acid substitutions 
to affect peptide activities likely resulting from the distortion of secondary structure.  
The primary difference amongst the members of the peptide subset was the ability to 
activate bacterial defensive responses through the activation of PhoPQ.  Based on the 
results presented, peptides that function as the least effective PhoQ ligands tend to be the 
most effective antimicrobials.   Presumably, this likely results from a lack of PhoQ-
dependent bacterial adaptation as peptides with weak PhoQ ligand activity will 
encounter bacterial membranes devoid of HDP resistance characteristics.  Notably, the 
difference in magnitude of PhoQ activation amongst the peptide derivatives is 
comparable with the levels of resitance to cationic peptides resulting from the activation 
of PhoPQ by low magnesium concentrations (MacFarlane 2000).  
Based on the results of the quantitative assay system the ability of HDPs to evade 
PhoQ detection was found to be the most significant factor in determining antimicrobial 
activity (Table 3.2, Figure 3.8).  The physiological relevance of these observations is 
supported by the demonstrations that peptides calculated to elicit the greatest bacterial 
defensive response coincided with those found to initiate the highest levels of PhoQ 
activation in the Salmonella reporter strain.  Peptide K7, having the greatest BDR score 
amongst the peptide derivatives, initiated the greatest induction of PhoQ in the 
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Salmonella reporter strain (Figure 3.9).  Conversely, Sub3 and R3 initiated the lowest 
amount of PhoQ activation in the reporter strain and also had the lowest calculated BDR 
scores.  
It is also of note that the magnitude of PhoQ activation induced by K7 in the 
reporter strain was comparable to that of micromolar magnesium, a highly potent 
environmental PhoPQ stimulus.  This is supportive of concerns that HDP therapeutic 
developments not accounting for the ability of these peptides to initiate bacterial 
defensive responses could induce the development of HDP-resistant bacterial 
phenotypes.  As a testament to the ability of sub-lethal concentrations of HDPs to 
activate PhoPQ, and thus increase bacterial HDP resistance, pre-exposure of bacteria to 
HDPs results in increased resistance to a spectrum of HDPs.   This demonstrates the 
validity of the quantitative assay system as peptides predicted to be the strongest 
activators of PhoQ, based on their high BDR values, also activate the strongest adaptive 
resistance phenotypes in vivo following bacterial pre-exposure.  It is of note that the 
increases in bacterial resistance were of far lower magnitude than those initiated by 
extracellular Mg2+.  This can be explained by two phenomena.  Firstly, the treatment of 
bacteria with sub-MIC concentrations of HDPs will invariably result in the induction of 
bacterial defensive responses by way of the PhoPQ TCS.  The activation of PhoPQ 
results in the induction of the protease PgtE, resulting in the reduction of the effective 
concentration of sub-MIC HDP during the incubation period.  This is in contrast to 
Mg2+, which does not suffer from these same stability concerns.  Secondly, the treatment 
of Salmonella with HDPs results in the induction of a subset of the PhoP-regulated 
genes (Bader 2003).  This contrasts with the micromolar Mg2+ concentrations, which 
induces the entire PhoP-regulon (Bader 2003).  Thus, the treatment of bacteria with sub-
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MIC HDPs may result in only partial modification of the Salmonella cell membrane.  
This must however be tempered with the appreciation that even minor changes to this 
entity can have drastic consequences on bacterial susceptibility to therapeutic treatments 
with HDPs.  These results perhaps foreshadow the potential for HDPs to induce HDP 
resistance bacterial phenotypes and offer a mathematical assay system for prediction of 
these peptide tendencies.  
The quantitative HDP system presented here provides a tool for the rapid 
analysis of direct antimicrobial bacterial defensive response initiation activities.  While 
it can be argued that the PhoPQ system is not the sole mechanism of HDP resistance 
within microbes, it is a system central to such pathogenic responses in a broad spectrum 
of bacteria.  In addition, the crystallographic structure of the PhoQ sensory domain 
enables the rational design of peptides that have increased PhoQ evasiveness.  This 
system provides a less costly and more rapid screening procedure for HDPs than the 
current basis thus allowing for a more focused approach to therapeutic HDP design. 
 
4.3 A Model of PhoQ Peptide Binding 
The determination of a crystallographic structure of the S. typhimurium PhoQ 
sensory domain, in combination with a predicted host defense peptide binding region, 
has afforded the opportunity to form hypotheses regarding the interaction of HDPs with 
PhoQ.  The model presented by Bader predicts that a large acidic region running planar 
to the bacterial cell membrane represents the peptide binding region (Bader 2005).  
According to the authors, the coordination of divalent cations between the negatively 
charged bacterial membrane and the acidic surface of PhoQ removes the electrostatic 
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repulsion between these two electronegative groups and locks the periplasmic domain of 
PhoQ to the membrane in an inactive form.  In a low divalent cation environment, it is 
predicted that the removal of the stabilizing cation bridges results in electrostatic 
repulsion between PhoQ and the cell membrane with displacement of PhoQ from the 
membrane and formation of an active conformation. 
The membrane-associated, ligand-binding region of PhoQ is defined by a 
regularly repeating pattern of acidic side chains contributed by two anti-parallel strands 
comprised of residues 112-125 and 152-167.  It is predicted that residues Asp152, 
Glu154, Glu123, and Glu121 provide a regular pattern of carboxyl-group containing side 
chains that contribute to HDP binding.  This region was demonstrated to responsible for 
divalent cation coordination by Bader through a variety of experimental techniques and 
calcium ions included in the crystallization conditions were found to be coordinated to 
the same region (Bader 2005).   
The ability of host defense peptides to activate PhoQ is dependent upon the 
ability to provide suitable electrostatic interactions to replace those provided by the 
cations.  It is postulated that the ability of peptides to form electrostatic interactions with 
PhoQ would be best achieved when the peptides are in alpha-helical conformation.    
Circular dichroism investigations of linear derivatives of the peptide bactenecin indicate 
that the peptide assumes random conformation in solution but forms alpha-helices in 
hydrophobic environments (Wu 1999).  These peptides model as amphipathic, alpha-
helix with one face of the helix dominated by positively charged residues including 
Arg1, Arg4 and Arg12.  Based on the structural properties of an alpha-helix, it is 
predicted that these positively charged groups would be in close accordance with the 
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negatively charged residues in PhoQ thus permitting the displacement of calcium ions 
(Figure 4.2).  This displacement would culminate in PhoQ activation and may represent 
a conserved feature for host defense peptides that adopt amphipathic alpha-helical 
conformations. 
 
4.4 Host Defense Peptides and Retro-Inversion 
Host defense peptides appear a logical alternative to conventional antibiotics.  
HDPs have demonstrated direct antimicrobial activity against a diverse spectrum of 
bacteria, modulation of innate immune responses, and regulation of inflammatory 
processes (Finlay 2004).  Although these represent promising attributes for the large-
scale production and therapeutic application of HDPs, issues relating to peptide 
manufacturing costs have limited applications to topical treatments such as polymyxin B 
and gramicidin S for surface infections.  Thus far, the predominant strategies for the 
reduction of associated production costs have focused on measures to increase peptide 
production outputs, minimization of peptide size, and the integration of stabilizing 
modifications.  The use of stabilizing modifications in HPDs include all D-amino acid 
peptides, non-standard peptide backbones such as peptidomimetics, liposome 
formulations, and chemical modifications that bestow protease resistance. 
Peptide antibiotic developments that incorporate non-standard amino acids and 
linkages have used nature as a template; non-ribosomal peptide synthetase complexes 
are often employed by microbes to produce peptide-based antibiotics.  These alternative 
peptide strategies often use D-amino acids, non-standard amino acids and unique  
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Figure 4.2: Molecular Structure of the Salmonella PhoQ Sensory Domain and its 
Interaction with Bac2A.  A model of the metal binding region of the sensory domain 
demonstrating how alpha helical cationic antimicrobial peptides could displace bound 
cations leading to activation of the protein.  Structures were generated with Cn3D 
version 4.1. 
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patterns of modification to produce molecules with enhanced evasion of bacterial 
defensive and adaptive strategies.  Host defense peptide development may also draw 
upon the therapeutic applications of TLR9 agonists and antagonists.  Indeed, the use of 
phosphothioate-modified ODNs as novel therapeutics has considerable advantages over 
their natural counterparts due to increased stability against nuclease degradation and 
similar manufacturing costs.  As such, PTO-ODNs have emerged as the standard for 
both the investigations and clinical applications of TLR9 agonists and antagonists.  A 
similar strategy for HDP therapeutic development would drastically reduce the long-
term costs associated with natural HDP applications as increased stability would 
decrease the need for repeat applications. 
Retro-inversion as a means of increasing host defense peptide stability and 
conserving biological activity would seem a likely alternative for therapeutic HDP 
development.  RI-peptides have reversed amino-acid sequences and incorporation of D-
amino acids.  Thus, the RI-modification results in maintenance of three-dimensional 
structure and identical placement of side chain residues, thus conserving biological 
structure/function relationships.  Importantly though, the reversal of peptide bonds 
within these molecules renders the peptide resistant to the action of protease enzymes.   
To examine the application of retro-inversion to host defense peptides, BMAP-
28, a bovine host defense peptide with demonstrated therapeutic potential was chosen.  
BMAP-28 is active at micromolar concentrations against a broad range of Gram-positive 
and Gram-negative microbes, including multi-drug resistant strains, and importantly 
these antimicrobial activities are retained in the presence of physiological salt 
concentrations.  Animal challenge models have also demonstrated that BMAP-28 
protects mice from lethal i.p. infections (Cirioni 2006) and reduces lethality against 
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Staphylococcal species at concentrations below the host toxic threshold (Giacometti 
2004).  Although the immunomodulatory activities of this peptide have not been studied 
in detail, BMAP-27, another bovine cathelicidin, has demonstrated immunomodulatory 
activities (Mookherjee 2006). 
This investigation has demonstrated that the retro-inverso form of BMAP-28 
has maintained or improved function, as compared to the natural peptide, and 
significantly increased resistance to proteolytic degradation.  The expectation has been 
that systematic inversion of the stereochemistry at the backbone alpha-carbons, in 
combination with reversed amino acid sequence, would yield proteolytically stable retro-
inverso peptide isomers.  As a direct antimicrobial agent, RI-BMAP28 was 2-3 fold 
more potent than the natural isomer against a broad range of Gram-negative bacteria 
(Table 3.3).  That RI-BMAP28 is vastly superior to the natural isomer in terms of 
proteolytic stability, and protease secretion is a common theme amongst bacteria as a 
defensive response, suggests that this increase in direct antimicrobial activity is likely 
due to increased stability as opposed to enhanced activity (Figure 3.11).  Supporting this 
hypothesis, the RI-peptide had comparable increases in antimicrobial activity against all 
of the bacterial strains tested.  If the RI-modification indeed enhances antimicrobial 
activity it would be expected that a more diverse range of MICs would be found between 
the peptide isomers against different bacterial strains.  In direct contrast to the increased 
antimicrobial activity of the retro-inverso isomer, peptide cytotoxic activity was 
drastically reduced upon retro-inversion of BMAP28 (Figure 3.13).  The administration 
of the natural peptide resulted in nearly complete cell lysis at the highest concentration 
tested whereas RI-BMAP28 demonstrated no lytic activity.  Indeed, it is enticing to 
speculate that retro-inversion may in fact decrease cytoxicity concerns regarding HDP 
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administrations.  This must however be investigated with a broad-range of HDPs to see 
if it is a recurrent phenomenon amongst RI-modified HDPs.  Although no definitive 
conclusion regarding the nature of this phenomenon can be made it is speculated that the 
cytotoxic activity of BMAP28 is mediated through a specific interaction with a host cell 
component.  Indeed, the human cathelicidin LL-37 has been observed to modulate 
apoptotic pathways in human primary innate-immune effector cells and was proposed by 
the authors as an innate defense response to infected cells (Barlow 2006).  That the RI-
isomer results in decreased cytoxicity suggests that this interaction is sensitive to the 
change in hydrogen bonding pattern presented by the main chain of the peptide and may 
be a particularly desirable trait if the other non-host cell activities of the modified 
peptide are maintained.  Protein-peptide recognition is dominated by hydrophobic and 
electrostatic interactions where the latter, particularly dominated by hydrogen bonds, can 
involve the peptide backbone and side chains of polar and charged residues.  Upon RI-
modification, the amide bonds of a peptide are inverted with respect to the native ligand 
and may account for the observations that retro-inversion is not universally successful in 
mimicking native peptides as the result of decreased affinity for the receptor binding site 
(Fischer 2003).   
The results presented here lend support for the efficacy of HDPs, and in 
particular those that have undergone RI-modification, for therapeutic applications.  
Retro-inverso modification of BMAP28 results in conserved immunomodulatory 
activities to that of the natural peptide, on the basis of suppression of LPS-induced TNF-
α secretion (Figure 3.14).  In contrast to BMAP28 however, RI-BMA28 had improved 
proteolytic stability and antimicrobial activity with decreased cytotoxic activity.  As RI-
BMAP28 appears to meet the standards for safety and efficacy of HDPs as therapeutics, 
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with improved biological stability, RI peptide modification represents a potential 
mechanism for decreasing the prohibitive cost of HDP therapies due to a hypothesized 
reduction in dose frequency.   
Thus, the analyses presented here lend support for the manipulation of natural 
ligands of both prokaryotic and eukaryotic sensory systems in the development of novel 
therapeutics.  An increased understanding of the complexity of the interactions of these 
novel ligands with their biological targets will allow for a more calculated approach in 
therapeutic developments that offers minimal toxicity to the host while maximizing the 
biological activity of the ligand.
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